タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	臨床精神医学講座(全24巻) 第14巻精神科薬物療法
出版社	中山書店
発行日	1999-03-31
著者	村崎光邦(責任編集) 青葉安里(責任編集) 松下正明(総編集) 浅井昌弘(編集) 牛島定信(編集) 倉知正佳(編集) 小山司(編集) 中根允文(編集) 三好功峰(編集)
ISBN	4521491715
ページ数	623
版刷巻号	第1刷
分野	臨床医学：内科精神医学
シリーズ
閲覧制限	未契約

病棟から患者を解放したとされる精神科領域の薬物療法は、日進月歩の新薬開発と相伴って近年最も進歩した領域です。本巻では、分類、作用機序、適応、用法、用量、副作用、今後の展望等、最新知見をもとに解説します。

目次

表紙
閲覧
本巻の執筆者
閲覧
目次
閲覧
総論
P.1閲覧
- I. 精神科薬物療法の歴史と展望
各論
P.27閲覧
- I. 抗精神病薬
- II. 抗うつ薬
- III. 気分安定薬
- IV. 抗不安薬
- V. 睡眠薬
- VI. 抗痴呆薬
- VII. 抗てんかん薬
- VIII. 抗Parkinson病薬
- IX. 抗酒薬
- X. 精神刺激薬
- XI. β遮断薬
- XII. 漢方薬
- XIII. ベンゾジアゼピン拮抗薬
- XIV. 中枢作用を有するホルモン剤
- XV. 適応上の問題
索引
P.583閲覧
- 和文索引
- 欧文索引
奥付
閲覧

参考文献

総論

P.23 掲載の参考文献

1) 安西信雄:分裂病の再発防止と生活技能訓練(SST). 精神医学レビュー, 太田龍郎(編), No 12, pp 16-80, ライフ・サイエンス, 東京 (1994)

2) 浅井昌弘:軽症分裂病の診断. 臨床精神医学18:1199-1205 (1989)

3) Bachus SE, Kleinman JE:The neuropathology of schizophrenia. J Clin Psychiatry 57(S 11):72-83 (1996)

4) Ban T:Schizophrenia;A Psychopharmacological Approach. Charles C Thomas, Springfield (1972)-風祭元 (訳):精神分裂病と向精神療法. 国際医書出版, 東京 (1974)

5) Baxter LR Jr, Schwartz JM, Bergman KS, et al:Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 49:681-689 (1992)
pubmed

6) Bleuler M:Forschungen und Begriffswandlungen in der Schizophrenielehre 1941-1950. Fortschr Neurol Psychiatr 19:385-452 (1951)

7) Casey JF, et al:Drug therapy in schizophrenia. Arch Gen Psychiatry 2:210-220;Treatment of schizophrenia reactions with phenothiazine derivatives. Am J Psychiatry 117:97-105 (1960)

8) Davis JM, Bartlett E, Termini BA:Overdosage of psychotropic drug;A review, Part 1 & 2. Dis Nerv Syst 29:157-164;246-256 (1968)

9) Davis JM:Drugs used in the treatment of depression. Psychopharmacology;A review of progress 1957-1967, pp 719-747, Public Health Service Publication, USA (1968)

10) Davis JM:Overview;Maintenance therapy in psychiatry;II. Affective disorders. Am J Psychiatry 133:1-13 (1976)
pubmed

11) Davis JM:Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 11 (sec 2):18-21 (1985)

12) Delay J, Deniker P:Methodes chimiotherapiques en psychiatrie. Masson, Paris (1961)-秋元波留夫, 栗原雅直 (訳):臨床精神薬理学. 紀伊國屋書店, 東京 (1965)

13) Fink M (著), 清水信 (訳):電気けいれん療法. 星和書店, 東京 (1980)

14) Frank E, Kupfer DJ, Perel JM, et al:Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099 (1990)
pubmed

15) 藤縄昭:「病院内寛解」について. 精神医学 4:95-101 (1962)

16) 現代精神医学大系第23巻A 社会精神医学と精神衛生I. 中山書店, 東京 (1980)

17) 現代精神医学大系第23巻A 社会精神医学と精神衛生I. p 17, 中山書店, 東京 (1980)

18) 現代精神医学大系第23巻C 社会精神医学と精神衛生II. 中山書店, 東京 (1980)

19) 浜田秀伯:精神症候学. pp 10-18, 弘文堂, 東京 (1994)

20) 原田誠一:精神分裂病の精神療法の一側面. 精神科治療学 9:1105-1112 (1994)

21) 樋口輝彦:アルゴリズム. 臨床精神薬理 1:97-99 (1998)

22) Hogarty GE, et al:Family psychoeducation, social skills training, and maintenance chemotherapy in the after care treatment of schizophrenia, II. Arch Gen Psychiatry 48:340-347 (1991)
pubmed

23) Jeste DV, et al:Charging epidemiology of tardive dyskinesia;An overview. Am J Psychiatry 138:297-309 (1981)

24) 神庭重信:躁うつ病の神経解剖学的考察. Psychiatric Bulletin 10:10-11 (1998)

25) 上島国利, 津村哲彦:精神科外来薬物療法の問題点. 精神経誌 83:691-699 (1981)

26) 上島国利:躁うつ病の臨床. 金剛出版, 東京 (1983)

27) 神定守, 和木裕一, 中島誠一郎ほか:精神薬理学的観点からみた高齢分裂病者の特徴. 精神薬療基金研究年報18:283-293 (1987)

28) 加藤友之, 田島昭, 湯浅修一ほか:精神分裂病者の社会生活における特性 (精神分裂病の生活臨床第1報). 精神経誌 68:1076-1088 (1966)

29) 川上富美郎, 中嶋照夫, 小山司ほか:精神科薬物療法における多剤併用の実態調査. 精神科治療学 12:795-803 (1997)

30) 風祭元:精神分裂病治療における薬物併用の問題点. 臨床精神薬理 1:31-38 (1998)

31) Kennedy SH, Javanmard M, Vaccarino FJ:A review of functional neuroimaging in mood disorders;Positron emission tomography and depresssion. Can J Psychiatry 42:467-475 (1997)

32) 小林八郎, 小林清男:レクリエーション療法. 日医新報 1662:35-41 (1956)

33) 小林八郎:病院精神医学の課題. 精神医学 11:420-434 (1969)

34) Koreon AR, et al:Plasma home vanillic acid levels in first episode schizophrenia. Arch Gen Psychiatry 51:132-138 (1994)

35) 越川裕樹:慢性精神分裂病における陽性・陰性症状の薬物反応性. 慶応医学 73:365-374 (1996)

36) Kulhara P:Outcome of schizophrenia;Some transcultural observations with particular reference to developing countries. Eur Arch Psychiatry Clin Neurosci 244:227-235 (1994)
pubmed

37) 功刀弘:精神分裂病者の院内生活療法-破綻の原因. 精神医学 12:143-151 (1970)

38) 松浪克文, 布施木誠:精神分裂病の薬物療法と精神療法. 臨床精神医学 25:1049-1057 (1996)
Medical*Online

39) 三重野正彦:治療環境による欠陥分裂病の病像の変化. 九州神精医7:324-332 (1959)

40) 森山公夫:精神分裂病論の推移と精神医療の場の変化. 精神経誌78:21-41 (1976)

41) 森山公夫:狂気の軌跡. p 340, 岩崎学術出版社, 東京 (1988)

42) 村上圀也:薬物療法の導入による精神分裂病の経過と病像の変化. 精神経誌 73:635-649 (1971)

43) 永田俊彦:精神病院における治療状況と分裂病者の寛解過程について. 精神医学 18:951-957 (1976)

44) 永田俊彦, 水嶋節雄:東京下町の慢性分裂病者について. 精神医学 20:511-518 (1978)

45) 中井久夫:精神分裂病状態からの寛解過程-描画を併用する精神療法をとおしてみた縦断的観察. 分裂病の精神病理2, 宮本忠雄 (編), pp 157-217, 星和書店, 東京 (1974)

46) 中島啓:心をいやす薬の歴史. ファルマシアレビュー 10:1-6 (1983)

47) 岡上和雄:受療分裂病者のマクロ現状. 精神科 MOOK 22, pp 12-22, 金原出版, 東京 (1988)

48) 岡崎祐士, 太田敏男:精神分裂病の陽性症状と陰性症状. 臨床精神医学 11:1337-1350 (1982)

49) 岡崎祐士, 太田敏男, 中安信夫:抗精神病薬の大量療法の検討. 神経精神薬理 5:411-425 (1983)

50) 小此木啓吾, 延島信也:精神療法の治療機序および治癒機転-自然治癒における治癒機転との異同. 精神医学 9:263-269 (1967)

51) 大野裕:うつ病の薬物療法と精神療法. 臨床精神医学 25:1043-1048 (1996)
Medical*Online

52) 大島巌, 伊藤順一郎:精神分裂病の家族支援プログラムにおける問題点と留意点. 精神科診療の副作用・問題点・注意点, 八木剛平 (編), pp 389-401, 診療新社, 大阪 (1998)

53) 佐藤光源, 窪田恭彦, 伊藤千裕:合理的な薬物処方計画-精神薬理アルゴリズムの有用性. 臨床精神薬理 1:23-29 (1998)

54) Seeman P, Lee T, Chau-Wong M, et al:Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719 (1976)
pubmed

55) 柴原尭, 前田正典:精神病院における入院生活の様相について. 精神医学 7:322-326 (1965)

56) 新福尚隆:世界の精神医療と精神病院. こころの科学79:33 (1998)

57) 諏訪望:精神分裂病の症状構成-陰性および陽性症状をめぐって. 精神経誌 87:787-798 (1985)

58) 多田富雄:免疫の意味論. 新潮社, 東京 (1997)

59) 武正建一:精神分裂病治療の変遷. 日医新報 2343:136-137 (1969)

60) 武正建一, 保崎秀夫, 浅井昌弘ほか:精神分裂病の経過と転帰に与えた薬物療法の影響. 精神医学 15:617-625 (1973)

61) 高橋正和:在院患者調査中間報告. 日精協誌12:13 (1993)

62) 竹村堅次:精神分裂病の社会的治癒について. 精神医学 7:217-222 (1965)

63) 田辺英, 八木剛平:精神病 (分裂病)の治療史-江戸後期から明治時代まで. 臨床精神薬理 1:563-568 (1998)

64) 立山萬里, 越川裕樹, 徳野基晴:抗精神病薬処方の実態と問題点. 精神医学レビュー, 融道男 (編), No 6, pp 14-26, ライフ・サイエンス, 東京 (1993)

65) 特集:薬物と精神療法. 精神医学 8:442-476 (1966)

66) Torrey EF:Surviving Schizophrenia. 3rd ed, Harper Collins, New York (1995)-南光進一郎ほか (監):分裂病がわかる本. 日本評論社, 東京 (1997)

67) Tracy JI:Nonspecific abnormalities in psychiatry;Do they reflect an ordered pathway of brain dysfunction? Biol Psychiatry 38:207-209 (1995)
pubmed

68) 臺弘 (1955):精神分裂病の身体的治療の限界と作業療法 (再録). 病院精神医学 6:173-187 (1963)

69) 臺弘:精神療法と薬物療法の併用と統合. 精神療法 23:137-144 (1997)

70) Van Putten T, May PRA, 石井毅(訳):精神分裂病の環境療法. 精神分裂病の治療-その新しい動向, West LJ ほか(編), pp 236-264, 星和書店, 東京 (1978)

71) 渡辺昌祐, 江原嵩:躁病の診断と治療. 新興医学出版社, 東京 (1986)

72) Wilson WH, Ban TA, Guy W:Pharmacotherapy of chronic hospitalized schizophrenics;Prescription practices. Neuropsychobiology 14:75-82 (1985)
pubmed

73) 八木剛平:薬物療法の最近の進歩. 現代精神医学大系年刊版'87-A, pp 259-297, 中山書店, 東京 (1987)

74) 八木剛平, 白波瀬丈一郎:精神疾患における自然治癒力と自己治療行為 (COPING). 精神科MOOK増刊1, 精神科領域における薬物療法, pp 9-25, 金原出版, 東京 (1989)

75) 八木剛平:精神分裂病の薬物治療学-ネオヒポクラティズムの提唱. 金原出版, 東京 (1993)

76) 八木剛平, 神庭重信, 稲田俊也:薬物療法の視点から. 臨床精神医学 23:1305-1310 (1994)

77) 八木剛平, 田辺英:精神病の治療史-疾病観と治療法. 精神経誌 98:603-611 (1996)

78) 八木剛平, 稲垣中, 山田和男ほか:治療抵抗性精神分裂病の実態と至適薬物療法に関する研究. 厚生省精神科・神経疾患委託費;精神分裂病の病態・治療・リハビリテーションに関する研究, 総括報告書, pp 97-104 (1998)

79) 八木剛平:陰性症状の治療反応性-分裂病の脳病説に対する批判的考察. 精神病理 (印刷中)

80) 山田和男:漢方薬. 精神治療薬大系, 三浦貞則 (監), 第3巻, pp 284-309, 星和書店, 東京 (1996)

81) 山下格:わが国における薬物療法の歴史. 精神科MOOK No 9, pp 1-2, 金原出版, 東京 (1984)

82) 山内慶太, 馬場国博, 池上直己ほか:単科精神病院における処方の実態に関する研究. 精神経誌 100:51-68 (1998)

83) 山脇成人:悪性症候群. 新興医学出版社, 東京 (1989)

84) 養老猛:唯脳論. 青土社, 東京 (1989)

85) 湯浅修一:分裂病の治療過程について. 分裂病の精神病理5, pp 67-92, 星和書店, 東京 (1976)

86) 湯浅修一:分裂病の予後. こころの科学 10:29-37 (1981)

87) 湯浅修一:分裂病者の長期予後. 臨床精神医学 13:499-509 (1984)

88) 湯浅修一:分裂病者養生の抄. 精神科治療学 9:827-837 (1994)

89) 全家連 (編):みんなで歩けば道になる. p 141, 全家連, 東京 (1997)

各論

P.40 掲載の参考文献

1) Bernthsen A:Uber das Methylenblau. Ber Deutsch Chem Gesel 16:1025-1028 (1883)-Swazey JP:Chlorpromazine in Psychiatry. The MIT Press, Cambridge (1974) より.

2) Bersani G, Grispini A, Marini S, et al:Neuroleptic-induced extrapyramidal side effects;Clinical perspectives with ritanserin (R55 667);A new selective 5-HT2 receptor blocking agent. Curr Ther Res 40:492-499 (1986)

3) Charpentier P, Gaillot P, Jacob R, et al:Recherches sur les dimethylaminopropyl-N phenothiazines substituees. C R Acad Sci 235:59-60 (1952)

4) Delay J, Deniker P, Harl JM:Utilisation en therapeutique psychiatrique d'une phenothiazine d'action centrale elective (4560 RP). Ann Med Psychol 110:112-117 (1952)
pubmed

5) Huttunen M:The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacology 15(Supple 1):4S-10S (1995)

6) Janssen PAJ, Tollenaere Jp:The discovery of the butyrophenone-type neuroleptics. Discoveries in Pharmacology, Vol 1, Parnham MJ, Bruinvels J (ed), pp 181-196, Elsevier, Amsterdam (1983)

7) Kline NS:Use of, Rauwolfia serpentina Benth. in neuropsychiatric conditions. Ann NY Acad Sci 59:107-132 (1954)
pubmed

8) Laborit H, Leger L:Utilisation d'um antihistaminique de synthese en therapeutique pre, per, et post-operatoire. Presse Med 58:492 (1950)

9) Laborit H, Huguenard P, Alluaume R:Un nouveau stabilisateur vegetatif (le 4560 RP). Presse Med 60:206-208 (1952)
pubmed

10) Sen G, Bose KC:Rauwolfia serpentina, a new Indian drug for insanity and high blood pressure. Indian Med World 2:194-201 (1931)

11) Shore PA, Silver SL, Brodie BB:Interaction of reserpine, serotonin and lysergic acid diethylamide in brain. Science 122:284-285 (1955)
pubmed

12) Simpson GM:A brief history of depot neuroleptics. J Clin Psychiatry 45:3-4 (1984)
pubmed

13) Vakil RJ:A clinical trial of Rauwolfia serpentina in essential hypertension. Br Heart J 11:350-359 (1949)
pubmed

14) Wooley DW, Shaw E:A biochemical and pharmacological suggestion about certain mental disorders. Science 119:587-588 (1954)

15) Yale HL, Cohen AI, Sowinski F:Esters of 4-{3-[2-(trifluoromethyl) phenothiazin-10-yl] propyl}-1-piperazineethanol as long-acting tranquilizing agents. Synthesis of 4-{3-〔2-trifluormethyl)phenothiazin-10-yl〕propyl}-1-piperazine ethanol ethyl-C14 and its ester with heptanoic acid. III. J Med Chem 6:347-350 (1963)

P.52 掲載の参考文献

1) Banerjee SP, Zuck LG, Yablonsky-Alter E, et al:Glutamate agonist activity; Implications for antipsychotic drug action and schizophrenia. Neuroreport 6:2500-2504 (1995)
pubmed

2) Baldessarini RJ, Cohen BM, Teicher MH:Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 45:79-91 (1988)
pubmed

3) Benvenga MJ, Leander JD:Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 119:133-138 (1995)
pubmed

4) Bersani G, Grispini A, Marini S, et al:5-HT2 antagonist ritanserin in neuroleptic-induced Parkinsonism;A double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13:500-506 (1990)
pubmed

5) Bjork A, Bergman I, Gustavsson G:Amperozide in the treatment of schizophrenic patients;A preliminary report. Novel Antipsychotic Drugs, Meltzer HY (ed), pp 59-66, Raven Press, New York (1992)

6) Bowers MB Jr, Rezitis A:Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs. J Pharm Pharmacol 26:743-745 (1974)

7) Braum AR, Chase TN:Obligatory D-1/D-2 receptor interactions in the generation of dopamine agonist-related behaviors. Eur J Pharmacol 131:301-306 (1986)

8) Bunny BS, Grace AA:Acute and chronic haloperidol treatment;Comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1715-1728 (1978)

9) Butler B, Bech P:Neuroleptic profile of cipazoxapine (savoxepine), a new tetracyclic dopamine antagonist;Clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. Pharmacopsychiatry 20:122-126 (1987)
pubmed

10) Carlsson A, Lindqvist M:Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normethanephrine in mouse brain. Acta Pharmacol 20:140-144 (1963)

11) Carlsson A:The current status of dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186 (1988)
pubmed

12) Carlsson ML:The selective 5-HT2A receptor antagonist MDL100, 907 counter acts the psychomotor stimulation ensuing manipulation with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis. J Neural Transm (Gen Sect) 100:225-237 (1995)
pubmed

13) Cascella NG, Macciardi F, Cavallini C, et al:D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia;An open-label study. J Neural Transm (Gen Sect) 95:105-111 (1994)
pubmed

14) Corbett R, Camacho F, Woods AT, et al:Antipsychotic agents antagonize non-competitive N-methyl-D-asparate antagonist-induced behaviors. Psychopharmacology 120:67-74 (1995)

15) de Beaurepatier R, Labelle A, Naber D, et al:An open trial of the DI antagonist SCH39166 in six cases of acute psychotic states. Psychopharmacology 121:323-327 (1995)

16) Den Boer JA, van Megen HJGM, Fleischhacker WW, et al:Differential effects of the D-1 DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 121:317-322 (1995)

17) Deutch AY, Lee MC, Iadarola MJ:Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression;The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:332-341 (1992)
pubmed

18) Domeney AM, Arnt J, Costall B, et al:Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Dev Res 31:175-185 (1994)

19) Frieboes R-M, Murck H, Wiedemann K, et al:Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology (Berl) 132:82-88 (1997)
pubmed

20) Gerwitz GR, Gorman JM, Volavka J, et al:BMY14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37-40 (1994)

21) Gessa GL, Canu A, Zompo MD, et al:Lack of acute antipsychotic effect of Sch23390, a selective dopamine D, receptor antagonist. Lancet 337:854-855 (1991)

22) Goldstein JM, Litwin LC, Sutton EB, et al:SEROQUEL;Electrophysiological profile of a potent atypical antipsychotic. Psychopharmacology 112:293-298 (1993)

23) Grace AA:Phasic versus tonic dopamine release and the modulation of dopamine system responsivity;A hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24 (1991)
pubmed

24) Hartman DS, Civelli O:Dopamine receptor diversity;Molecular and pharmacological perspectives. Prog Drug Res 48:173-194 (1997)
pubmed

25) Heresco-Levy U, Javitt DC, Ermilov M, et al:Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Pharmacol 169:610-617 (1996)

26) Ishida K, Ohno Y, Ishibashi T, et al:Effects of SM-9018, a novel 5-HT2 and D2 antagonist, on the conditioned fear stress-induced immobility in rats. (Abstr). Jpn J Pharmacol 67(Suppl 1):221 (1995)

27) 石郷岡純:非定型抗精神病薬の衝撃-精神分裂病の治療にもたらす変化. 臨床精神薬理1:47-59 (1998)

28) Janssen PA, Niemegeers CJ, Schellekens KH:Is it possible to predict the clinical effects of neuroleptic drugs(major tranquilizers) from animal data? I. "Neuroleptic activity spectra" for rats. Arzneimittelforschung 15:104-117 (1965)
pubmed

29) Javitt DC, Zylberman I, Zukin SR, et al:Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236 (1994)
pubmed

30) Kahn RS, Davidson M:Serotonin receptor responsivity in schizophrenia. Int Clin Psychopharmacol 8(Suppl 2):47-51 (1993)

31) Kapur S, Remington G:Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476 (1996)-Murphy T (翻訳), 藤井康男, 宮田量治(監訳):セロトニン・ドパミン相互作用と精神分裂病に対するその重要性. 精神科治療学11:1105-1118 (1996)

32) Karlsson P, Smith L, Farde C, et al:Lack of apparent antipsychotic effect of D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121:309-316 (1995)

33) Kebabian JW, Calne DB:Multiple receptors for dopamine. Nature 277:93-96 (1979)
pubmed

34) 菊地哲朗:新規抗精神病薬aripiprazole (OPC-14597) -ドパミン自己受容体アゴニストの開発. 臨床精神薬理 1:105-110 (1998)

35) Klimke A, Klieser E:Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD49980 (Raxindol). Pharmacopsychiatry 24:107-112 (1988)

36) Kramer MS, Last B, Getson A, et al:The effect of a selective D, dopamine receptor antagonist (L-745, 870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54:567-572 (1997)
pubmed

37) Kuczenski R, Leith NJ:Chronic amphetamine;Is dopamine a link in or a mediator of the development of tolerance or reverse tolerance? Pharmacol Biochem Behav 15:405-413 (1981)

38) Kulagowski JJ, Patel S:Dopamine D, receptor antagonists. Curr Pharmaceut Design 3:355-366 (1997)

39) Leeson PD, Iversen LL:The glycine site on the NMDA receptor;Structure-activity relationships and therapeutic potential. J Med Chem 37:4503-4067 (1994)

40) Leiderman E, Zylberman I, Zukin SR, et al:Preliminary investigation of high-dose oral glycine on serum level and negative symptoms in schizophrenia;An open-label trial. Biol Psychiatry 39:213-215 (1996)
pubmed

41) Leonard BE:The pharmacology of the phenothiazines, butyrophenones, thioxanthines and diphenylbutylpiperidines. Antipsychotic Drugs and Their Side-effects, Barnes TRE (ed), pp 3-26, Academic Press, San Diego (1993)

42) Leysen D, Linders JTM, Ottenheijm CJ:5-HT2 antagonism;A concept for the treatment of schizophrenia. Curr Pharmaceut Design 3:367-390 (1997)

43) Lipka G, Wiedemann K, Benkert O, et al:Presynaptic dopamine receptor agonist (B-HT920);Treatment of schizophrenia. Psychopharmacology 96 (Suppl 33):96 (1988)

44) Martin P, Waters A, Carlsson A, et al:The apparent antipsychotic action of the 5-HT2A. receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104:561-564 (1997)

45) Mashurano M, Waddington JL:Stereotyped behavior in response to the selective D-2 dopamine receptor agonist RU24213 is enhanced by treatment with the selective D-1 agonist SK & F 38393. Neuropharmacology 25:947-949 (1986)

46) 松林弘明, 天野託, 笹征史:ドーパミン. "ニューロトランスミッター・トゥデイ". 神経精神薬理19(2月増刊号):114-130(1997)

47) 松井宏晃, 南雲智子, 大川義則ほか:セロトニン-セロトニン受容体および細胞内情報伝達系の多様性, その生理と病理. "ニューロトランスミッター・トゥデイ". 神経精神薬理19(2月増刊号):131-146(1997)

48) Maurel-Reiny S, Bervoets K, Millan MJ:Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL100, 907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280:R9-R11 (1995)

49) Meador-Woodruff JH:Update on dopamine receptors. Ann Clin Psychiatry 6:79-90 (1994)
pubmed

50) Modhaddam B:Preferential activation of cortical dopamine neurotransmission by clozapine;Functional significance. J Clin Psychiatry 55(Suppl B):27-29 (1994)

51) 鍋島俊隆, 奥山茂:シグマ受容体の機能-リガンドの中枢薬理作用. 日本神経精神薬理学雑誌14:51-76(1994)

52) Nanry KP, Pollard GT, Howard JL:Olanzapine moderately increases conflict responding but does not produce a benzodiazepine-like cue in rat. Drug Dev Res 34:317-319 (1995)

53) Nguyen TV, Kosofsky BE, Birnbaum R, et al:Differential expression of c-Fos and Zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 89:4270-4274 (1992)
pubmed

54) Noda Y, Yamada K, Furukawa H, et al:Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine;A new model of schizophrenia. Br J Pharmacol 116:2531-2537 (1995)
pubmed

55) Olbrich R, Schanz H:The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenia. Pharmacopsychiatry 21:389-390 (1988)
pubmed

56) Robertson GS, Fibiger HC:Neuroleptics increase c-fos expression in the forebrain; Contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328 (1992)
pubmed

57) Robertson GS, Fibiger HC:Effects of olanzapine in regional c-fos expression in rat forebrain. Neuropsychopharmacology 14:105-110 (1996)
pubmed

58) Robertson GS, Matsumura H, Fibiger HC:Induction patterns of Fos'like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066 (1994)
pubmed

59) Rosse RB, Fay-McCarthy M, Kendrick K, et al:D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol 19:444-450 (1996

60) Rosse RB, Theut SK, Banay-Schwartz M, et al:Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia. Clin Neuropharmacol 12:416-424 (1989)
pubmed

61) Roth BL:Multiple serotonin receptors;Clinical and experimental aspects. Ann Clin Psychiatry 6:67-77 (1994)
pubmed

62) Roth RH:Dopamine autoreceptors;Pharmacology, function and comparison with post-synaptic dopamine receptors. Commun Psychopharmacol 13:429-445 (1979)

63) Roth RH, Wolf ME, Deutch AY:Neurochemistry of midbrain dopamine system. Psychopharmacology;The third generation of progress, Meltaer HY (ed), pp 81-94, Raven Press, New York (1987)

64) Sanchez C, Arnt J, Costall B, et al:Sertindole;A limbic selective neuroleptic with potent anxiolytic effects. Drug Dev Res 34:19-29 (1995)

65) Schmauss C, Haroutunian V, Davis KL, et al:Selective loss of dopanline D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA 90:8942-8946 (1993)
pubmed

66) Sedavall GC:Neurobiological correlates of acute neuroleptic treatment. Int Clin Psychopharmacol 11(Suppl 2):41-46 (1996)

67) Seeger TF, Seymour PA, Schmidt AW, et al:Ziprasidone (CP-88, 059);A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113 (1995)
pubmed

68) Seeman P:Dopamine receptor sequences, therapeutic levels of neuroleptic occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284 (1992)
pubmed

69) Seeman P, Lee T, Chau-Wong M, et al:Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719 (1976)
pubmed

70) Seeman P, Van Tol HHM:Dopamine receptor pharmacology. TiPS 15:264-270 (1994)

71) Shaikh S, Makoff A, Collier D, et al:Dopamine D4 receptors;Potential therapeutic implications in the treatment of schizophrenia. CNS Drugs 8:1-11 (1997)

72) Skarsfeldt T:Electrophysiological profile of a new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats;Acute and repeated treatment. Synapse 10:25-33 (1992)
pubmed

73) Sokoloff P, Martres M-P, Giros B, et al:The third dopamine receptor(D3) as a novel target for antipsychotics. Biochem Pharmacol 43:659-666 (1992)
pubmed

74) Sokoloff P, Schwartz JC:Novel dopamine receptors half a decade later. TiPS 16:270-275 (1995)
pubmed

75) Sorensen SM, Kehne JH, Fadayel GM, et al:Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic;Behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691 (1993)
pubmed

76) Spealman RD, Katz JL:Some effects of clozapine on punished responding by mice and squirrel monkeys. J Pharmacol Exp Ther 212:435-440 (1980)
pubmed

77) Stathis P, Antoniou K, Papadopoulou-Daifotis Z, et al:Risperdone;A novel antipsychotic with many "atypical" properties? Psychopharmacology 127:181-186 (1996)

78) Stockton ME, Bymaster FP, Rausmussen K:Electrophysiological effects of olanzapine;A novel atypical antipsychotic, on A9 and A10 dopamine neurones. Neuropsychopharmacology 14:97-104 (1996)

79) Su T-P:Delineating biochemical and functional properties of sigma receptors; Emerging concepts. Crit Rev Neurobiol 7:187-203 (1993)
pubmed

80) Svenson TH, Mathe JM, Andersson JL, et al:Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia;Role of 5-HT2 receptor and α1-adrenoreceptor antagonism. J Clin Psychopharmacol 15 (Suppl 1):11S-18S (1995)

81) Tanaka T, Ishigooka J, Watanabe S, et al:Partial inhibition of reverse tolerance by a high dose of ritanserin or low dose of haloperidol in metham-phetamine-sensitized rat. Jpn J psychopharmacol 18:1-7 (1998)
pubmed

82) van Berckel BNH, Hijman R, van der Linden JA, et al:Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patient. Biol Psychiatry 40:1298-1300 (1996)

83) Walters JR, Bergstrom DA, Carlson JH, et al:D-1 dopamine receptor activation required for postsynaptic expression of D-2 agonist effects. Science 236:719-722 (1987)

84) Wang RY, Ashby CR Jr, Zhang JY:Modulation of the A10 dopamine system; Electrophysiological studies of the role of 5-HT3-like receptors. Behav Brain Res 73:7-10 (1996)
pubmed

85) White FJ, Wang RY:Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurones in the rat. Life Sci 32:983-993 (1983)
pubmed

86) Wiesel F-A, Farde L, Nordstrom A-L, et al:Central D1-and D2-receptor occupancy during antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 141759-767 (1990)

87) Wiesel F-A, Nordstrom A-L, Farde L, et al:An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 224:31-38 (1994)

P.77 掲載の参考文献

1) Baldessarini RJ, Frankenburg FR:Clozapine;A novel antipsychotic agent. N Engl J Med 324:746-754 (1991)
pubmed

2) Beasley CM, Tollefson GD, Tran P:Olanzapine versus placebo and haloperidol;Acute phase results of the North American double-blind olanzapine trial. Neuropsychophamacology 14:111-123 (1996)

3) France A, Docherty JP, Kahn DA:The Expert Consensus Guideline Series; Treatment of Bipolar Disorder. J Clin Psychiatry 57(Suppl 12A):1-88(1996)

4) France A, Docherty JP, Kahn DA:The Expert Consensus Guideline Series; Treatment of Schizophrenia. J Clin Psychiatry 57(Suppl 12B):1-58 (1996)

5) 藤井康男:分裂病治療におけるhaloperidol decanoateの位置付け. 精神科治療学 8:11-25 (1993)

6) Gilbert PL, Harris MJ, McAdams LA, et al:Neuroleptic withdrawal in schizophrenic patients;A review of the literature. Arch Gen Psychiatry 52:173-188 (1995)
pubmed

7) Haase H-J, Janssen PAJ:The Action of Neuroleptic Drugs. Elsevier, Amsterdam (1985)

8) 広兼元太, 染矢俊幸, 森田幸代ほか:Bromperidol血中濃度モニタリングの問題点と治療有効濃度域. 神経精神薬理19:39-49 (1997)

9) 伊藤千裕, 佐藤光源:実際処方における薬物選択の調査結果. 精神分裂病と気分障害の治療手順-薬物療法のアルゴリズム, 佐藤光源, 樋口輝彦, 山脇成人(編), pp 56-61, 星和書店, 東京 (1997)

10) 伊藤斉:向精神薬の臨床. A. 抗精神病薬. 現代精神医学大系, 懸田克躬(編), 第22巻 B II 精神薬理学, pp 49-72, 中山書店, 東京 (1979)

11) Joseph S:Symptom-focused Psychiatric Drug Therapy for Managed Care. Haworth Medical, New York (1997)

12) Joseph S:Personality disorders. New Symptom-focused Drug Therapy, Haworth Medical, New York (1997)

13) Kane JM, Lieberman JA:Maintenance pharmacotherapy in schizophrenia. Psychopharmacology;The Third Generation of Progress, Meltzer HY (ed), pp 1103-1109, Raven Press, New York (1987)

14) Kane J, Honigfeld G, Singer J, et al:Clozapine for the treatment-resistant schizophrenic;A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796 (1988)
pubmed

15) Kapur S, Remington G:Serotonin-dopamine interaction and its relevance to schizophrepia. Am J Psychiatry 153:466-476 (1996)
pubmed

16) 風祭元:分裂病の再発と薬物療法. 精神医学レビュー12, pp 50-56, ライフ・サイエンス, 東京 (1996)

17) 工藤義雄, 中嶋照夫, 西村健ほか:精神分裂病に対する抗精神病薬risperidoneの臨床評価-clocapramineを対照薬とした二重盲検比較試験. 臨床精神医学23:233-249 (1994)

18) Kramer MS, Last B, Getson A, et al:The effects of a selective D4 dopamine receptor antagonist (L-745, 870) in acutely psychotic inpatients with schizo-phrenia. Arch Gen Psychiatry 54:567-572 (1997)

19) Kurokawa K, Narita M, Koshiya K, et al:Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate-early gene expression in the rat forebrain. Neuropsychopharmacology 17:27-33 (1997)
pubmed

20) Lieberman JA:Understanding the mechanism of action of atypical antipsychotics. Br J Psychiatry 163(S-22):7-18 (1993)

21) Marder SR, Meibach RC:Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-825 (1994)
pubmed

22) Meltzer HY:The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287 (1991)
pubmed

23) 森田幸代, 染矢俊幸, 広兼元太ほか:Haloperidol 血中濃度に及ぼす加齢の影響. 精神科治療学12:423-428(1997)

24) 日本医薬品集(日本医薬情報センター編):1996年10月版. 薬業時報社, 東京 (1996)

25) Rifkin A, Siris S:Drug treatment of acute schizophrenia. Psychopharmacology;The Third Generation of Progress, Melter HY (ed), pp 1095-1101, Raven Press, New York (1987)

26) 坂西信彦, 大坪天平, 太田有光ほか:精神分裂病に対する塩酸sultoprideの長期投与試験. 薬理と臨床20:655-664(1992)

27) 佐藤啓二, Fibiger HC:ラット前脳における前早期遺伝子c-fos発現に対するhaloperidolとclozapineの影響-免疫組織化学的研究. 脳と精神の医学5:281-294 (1994)

28) 佐藤啓二, 成田実:新薬展望1997, 抗精神病薬と抗うつ薬. 医薬ジャーナル 33:35-42 (1997)

29) Satoh K, Someya T, Shibasaki M:A benzamide derivative, nemonapride, as a novel neuroleptic for treating schizophrenia(letter). Am J psychiatry 154:292 (1996)

30) Satoh K, Someya T, Shibasaki M:Effects of nemonapride on positive and negative symptoms of schizophrenia. Int Clin Psychopharmacol 11:279-281 (1996)
pubmed

31) Shader RI (ed):Manual of Psychiatric Therapeutics, 2nd ed, Little, Brown, Boston (1994) -井上令一, 四宮滋子(訳):精神科治療マニュアル27. 精神分裂病の治療, pp 381-411, メディカル・サイエンス・インターナショナル, 東京 (1994)

32) 下地恒毅(編):アトラス麻酔学. 金原出版, 東京(1989)

33) Small JG, Hirsch SR, Arvanitis LS, et al:Quetiapine in patients with schizophrenia;A high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54:549-557 (1997)

34) 祖父江逸郎, 加藤伸勝, 栗山欣弥:神経精神疾患の薬物療法. 医歯薬出版, 東京 (1983)

35) 染矢俊幸, 広兼元太, 尾関裕二ほか:ハロペリドール血中濃度モニタリングの現状と問題点. 精神医学38:835-842(1996)

36) Stimmel B:Pain and its Relief without Addiction. Haworth Medical Press, New York (1997)

37) 渡辺昌祐, 江原嵩:抗精神病薬の選び方と用い方. 新興医学出版社, 東京 (1984)

P.91 掲載の参考文献

1) 安部秀三, 鈴木利人, 堀孝文ほか:抗精神病薬投与中に著明な低γグロブリン血症を呈した非定型精神病の一例. 神経精神薬理18:659-662(1996)

2) Alvir JMJA, Lieberman JA:Agranulocytosis;Incidence and risk factors. J Clin Psychiatry 55(9):137-138 (1994)

3) American Psychiatric Association:Task Force Report #27;Sudden Death in Psychiatric Patients;The role of neuroleptic drugs. American Psychiatric Association, Washington DC (1988)

4) Aoba A, Murasaki M, Kamijima K, et al:A beta-adrenoceptor antagonist, carteolol, in the treatment of neuroleptic-induced akathisia. Eur Neuropsycho-pharmacol 5(3):391 (1995)

5) Bamrah JS:Neuroleptic-induced pyrexia;A benign variant. J Nerv Ment Dis 176:741-743 (1988)
pubmed

6) Bohacek N, Bolwing T, Banny WE, et al:Prophylactic use of anticholinergics in patients on longterm neuroleptic treatment. A consensus statement. Br J Psychiatry 156:412 (1990)

7) Borison RL:The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand 94:5-11 (1996)

8) Calne DB:Parkinsonism-physiology and pharmacology. Br Med J 3:693-697 (1971)
pubmed

9) Caroff SN, Mann SC:Neuroleptic malignant syndrome. Med Clin North Am 77:185-202 (1993)
pubmed

10) Casey DE:Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int Clin Psychopharmacol 12(Supple 1):19-27 (1997)

11) Chan J, Alldredge BK, Baskin LS:Perphenazine-induced priapism. DICP Ann Pharmacother 24:246-249 (1990)

12) Chiu HF, Lam LC, Chan CH, et al:Clinical and polygraphic characteristics of patients with respiratory dyskinesia. Acta Psychiatr Scand 83:494-495 (1991)

13) Chouinard G:Severe cases of neuroleptic-induced supersensitivity psychosis; Diagnostic criteria for the disorder and its treatment. Schizophr Res 5:21-33 (1990)

14) Crewe HK, Lennard MS, Tucker GT, et al:The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. Br J Clin Pharmacol 34:262-265 (1992)
pubmed

15) Decina P, Caracci G, Sandik R, et al:Cigarette smoking and neuroleptic induced parkinsonism. Biol Psychiatry 28:502-508 (1990)
pubmed

16) Delay J, Pichot P, Lemperiere T, et al:Un neuroleptique majeur non phnothiazinique et non reserpinique, haloperidol, dans le traitement des psychoses. Ann Med Psychol 118:145-152 (1960)

17) Dilsarer SC:Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 10:103-114 (1994)

18) Egan MF, Apud J, Wyatt RJ:Treatment of tardive dyskinesia. Schizophr Bull 23(4):583-606 (1997)
pubmed

19) 江原嵩, 渡辺昌祐, 福田賢司ほか:リチウム中毒と悪性症候群. 臨床精神医学 12:1045-1051 (1983)

20) Eitan N, Levin Y, Ben-Artzi E, et al:Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatr Scand 85:74-76 (1992)
pubmed

21) Ekbon K, Lindholm H, Ljungberg L:New dystonic syndrome associated with butyrophenone therapy. Z Neurol 202:94-103 (1972)

22) 藤井康男, 早馬俊, 稲垣中:Risperidoneによる分裂病治療-従来の抗精神病薬からの切り替えと経過追跡. 臨床精神薬理1:527-541 (1998)

23) 藤沢薬品工業株式会社:ロドピン発売後4年間の臨床集計成績の報告III (1986)

24) 藤原豊:抗精神病薬の副作用とドーパミンおよびシグマ(σ) 受容体. 精神医学レビュー, 融道男(編), No 6 抗精神病薬の副作用, pp 37-47, ライフ・サイエンス, 東京 (1993)

25) Fuller MA, Jurjus G, Kwon K, et al:Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia. J Clin Psychopharmacol 16(4):329-332 (1996)
pubmed

26) Gerlach J, Peacock L:Intolerance to neuroleptic drugs;The art of avoiding extrapyramidal syndromes. Eur Psychiatry 10(Suppl):27-31 (1995)

27) Greendyke RM, Bernhardt AJ, Tasbas HE, et al:Polydipsia in chronic psychiatric patients;Therapeutic trials of clonidine and enalapril. Neuropsychopharmacology 18(4):272-281 (1998)
pubmed

28) Haibreich U, Palter S:Accelerated osteoporosis in psychiatric patients;Possible pathophysiological processes. Schizophr Bill 22(3):447-454 (1996)

29) 原田俊樹:抗精神病薬の使い方. 大月三郎ほか(編), 日本アクセル・シュプリンガー出版, 東京 (1996)

30) 平山千里:薬物代謝産物と肝毒性. 肝疾患研究の進歩II, pp 218-228, メディカルレビュー社, 東京 (1986)

31) Hollister LE, Palo AC:Adverse reactions to phenothiazines. JAMA 189:331-313 (1964)

32) Huyse F, Van Schijndel RS:Haloperidol and cardiac arrest (letter). Lancet ii:568-569 (1988)

33) 生田孝:酢酸ブセリンの点鼻使用によりアカシジア, 抑うつ, 自殺念慮等を呈した1症例. 精神医学11(7):743-747 (1996)

34) 稲田俊也, 八木剛平:薬原性錐体外路症状の評価と診断. pp 25-43, 星和書店, 東京 (1996)

35) 稲田俊也, 八木剛平:抗精神病薬の錐体外路症状. 神経精神薬理11:5-6 (1989)

36) 井田能成:躁うつ病者の「知覚変容発作」. 新精神科選書精神科診療の副作用・問題点・注意点-患者・家族・治療者からのメッセージ, 八木剛平(編), pp 170-179, 診療新社, 大阪 (1998)

37) Jackson T, Ditmanson L, Phibbs B:Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157(17):2013-2015 (1997)
pubmed

38) 上島国利:抗精神病薬の副作用-うつ状態の誘発. 神経精神薬理11:25-35 (1989)

39) Kane JM:Schizophrenia. N Engl J Med 334:34-41 (1996)
pubmed

40) 風祭元:我が国の精神科医療における長期大量多剤投与とその副作用. 精神医学 38:1181-1187 (1997)

41) Kelly HG, Fay JE, Laverty SG:Thioridazine hydrochloride;Its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Canad Med Asst J 89:546-554(1963)

42) Klawans HL, Falk DK, Nausieda PA, et al:Gilles de la Tourette's syndrome after long term chlorpromazine therapy. Neurology 28:1064-1066(1978)

43) 金野滋, 大熊輝雄, 山下格ほか:精神分裂病に対するデカン酸フルフェナジンと経口バロペリドールの二重盲検比較試験. 臨床評価19:15-45(1991)

44) 久野貞子:抗パーキンソン病剤中止による悪性症候群. 臨床精神医学18:479-487 (1989)

45) Kutcher S, Williamson P, Mackenzie S, et al:Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults;A double-blind placebo controlled study. J Clin Psychopharmacol 9:403-406 (1989)

46) Lader M, the NIDS Working Group:Neuroleptic induced deficit syndrome (NIDS). J Clin Psychiatry 54:494-500 (1993)

47) Lai H, Carino MA, Horita A:Antiserotonin properties of neuroleptic drugs. Psychopharmacology and Biochemistry of Neurotransmitter Receptors, Yamamura, Olsen, Olsen (ed), pp 347-353, Elsevier, North Holland (1980)

48) Leadbetter RA, Shutty MS:Differential effects of neuroleptics and clozapine on polydipsia and intermittent hyponatremia. J Clin Psychiatry 55(Supple B):110-113 (1994)

49) Lenard AA, Eric P, John R, et al:Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 150 (9):1405-1407 (1993)

50) Lewander T:Neurolepties and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 89(Supple):8-13 (1994)

51) Malhotra AK, Litman RE, Picker D:Adverse effects of antipsychotics. Drug Saf 9:429-436 (1993)

52) Marken PA, Wells BG, Brown CS:Treatment of psychosis in pregnancy. Drug Intelligence Clin Pharmacy 23:595-599(1989)

53) May RH:Catatonic-like states following phenothiazine therapy. Am J Psychiatry 115:1119-1120 (1959)
pubmed

54) 松浦雅人, 大倉勇史, 吉野誠ほか:抗精神病薬服用中の慢性分裂病患者の脳波にみられる棘徐波複合について. 精神科治療学8(9):1113-1118 (1993)

55) Nishijima K, Ishiguro T:Neuroleptic malignant syndrome;A study of CSF monoamine metabolism. Biol Psychiatry 27:280-288 (1990)

56) 西村秀雄:催奇形性等発生毒性に関する薬品情報第2版. 清藤英一(編), 東洋書店, 東京(1986)

57) 大曲清, 緒方良, 森山成彬ほか:抗精神病薬投与中にみられた開眼困難-開眼失行およびMeige症候群との関連. 精神医学27:315-322 (1997)

58) 大野健樹:妊娠中における抗精神病薬の新生児への影響. 臨床精神医学23:219-225 (1994)

59) Oshika T:Ocular adverse effects of neuropsychiatric agents;Incidence and management. Drug Saf (New Zealand) 12(4):256-263 (1995)

60) 小山田静枝, 上島国利:向精神薬の副作用. 医学と薬学38(2):293-301 (1997)

61) Pavlidakey GP, Hashimoto K, Heller GL, et al:Chlorpromazine-induced lupus like disease;Case report and review of the literature. J Am Acad Dermatol 13:109-115(1985)

62) Pons G, Rey E, Matheson I:Exertion of psychoactic drugs into breast milk. Clin Pharmacokinet 27:270-289(1994)

63) Sullivan G, Lukoff D:Sexual side effects of antipsychotic medication;Evaluation and interventions. Hospital and Community Psychiatry 41:1238-1241(1990)

64) Tominaga T, Fukuzako H, Izumi K, et al:Tardive myoclonus. Lancet i:322(1978)

65) Toth P, Frankenburg FR:Clozapine and seizures;A review. Can J Psychiatry 39(4):236-238 (1994)
pubmed

66) Trixler M, Teny T:Antipsychotic use in pregnancy;What are the best treatment opinions? Drug Saf 16(6):403-410(1997)

67) Umbricht D, Kane JM:Medical complication of new antipsychotic drugs. Schizophr Bull 22(3):475-483(1996)

68) Villeneve A:Rabbit syndrome;A peculiar extrapyramidal reaction. Can Psychiatr Assoc J 17(Supple 2):69-72(1972)

69) Wagstaff AJ, Bryson HM:Clozapine;A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 4:370-400(1995)

70) Walker JM, Matsumoto RR, Bowen WD, et al:Evidence for a role of haloperidol-sensitive σ-opiate receptor in the motor effects of antipsychotic drug. Neurology 38:961-965(1988)

71) Webster P, Wijeratne C:Risperidone-induced neuroleptic malignant syndrome (letter). Lancet 344:1228-1229(1994)

72) Weiner WJ, Goetz CG, Nausieda PA, et al:Respiratory dyskinesia;Extrapyramidal dysfunction and dyspnea. Ann Intern Med 88:327-331(1978)

73) Whitten JR, Ruehter VL:Risperidone and hyponatremia;A case report. Ann Clin Psychiatry 9(3):181-183(1997)

74) Wilson IC, Garbutt JC, Lanier CF, et al:Is there a tardive dysmentia? Schizophr Bull 9:187-192(1983)

75) 八木剛平, 黄野博勝:悪性症候群-その歴史と症候学. 臨床精神医学18:453-464 (1989)

76) 八木剛平, 山下格, 加藤伸勝ほか:精神分裂病に対するリスペリドンの後期第二相試験. 臨床精神医学22:1059-1074(1993)

77) 山口直彦, 中井久夫:分裂病における「知覚潰乱発作」について一般に「発作」「頭痛」などさまざまな俗称で呼ばれて軽視されがちなものを中心として. 分裂病の精神病理, 14, 内沼幸雄(編), pp 295-314, 東京大学出版会, 東京 (1985)

78) 山脇成人:悪性症候群の病態に関する考察-dantroleneが有効であった3症例から. 精神科治療学1:413-422(1986)

79) Zito JM, Sofaia JB, Jaeger J:Self-reported neuroendocrine effects of antipsychotics in women;A pilot study. DICP Ann Pharmacother 24:176-180(1990)

P.105 掲載の参考文献

1) Amsler HA, Teerenhovi L, Barth E, et al:A granulocytosis in patients treated with clozapine;A study of the Finish epidemic. Acta Psychiatr Scand 56:214-248 (1977)

2) Anderman B, Griffth RWR:Clozapine-induced agranulocytosis;A situation report up to August 1976. Eur J Clin Pharmacol 11:199-201(1977)

3) Arnt J, Skarsfeldt T:Do novel antipsychotics have similar pharmacological characterics? A review of the evidence. Neuropsychopharmacology 18:63-101(1998)

4) Arvanov VL, Wang RY:M100907, a selective 5-HT2 receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209(1998)

5) Bench CJ, Lammertsma AA, Grasby PM, et al:The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone(CP-88, 159-01)determined by positron emission tomograpy. Psychopharmacology 124:141-147(1996)

6) Bristow LJ, Kramer MS, Kulagowski J, et al:Schizophrenia and L-745, 870, a novel dopamine D, receptor antagonist. Trends Pharmacol Sci 18:186-188(1997)

7) Bymaster FP, Calliaro DO, Falcone JF, et al:Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96(1996)

8) Carlsson A:Antipsychotic agents;Elucidation of their mode of action, Discoveries in Pharmacology, Vol 1, Psycho-and Neuro-pharmacology, Parnham MJ, Bruinvels J(ed), pp 197-206, Elsevier, Amsterdam(1983)

9) Carlsson A, Lindqvist M:Effect of chlorpromazine or haloperidol on formation of 3 methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol 20:140-144 (1963)

10) Deutch AY, Duman RS:The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex;Cellular localization and pharmacological characterization. Neuroscience 70:377-389(1996)

11) Fischman AJ, Bonab AA, Babich JW, et al:Positron emission tomographicanalysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J pharmacol Exp Ther 279:939-947(1996)

12) Hirose A, Kato T, Ohno Y, et al:Pharmacological actions of SM-9018, a new neuroleptic drug both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 53:321-329(1990)

13) 稲垣中, 藤井康男, 稲田俊也ほか:日本にはclozapineが必要ないのか? 臨床精神薬理1:315-319(1998)

14) Janssen PAJ:The development of new antipsychotic drugs;Towards a new strategy in the management of chronic psychoses. J Drug Ther Res 12:324-328 (1987)

15) Janssen PAJ, Niemegeers CJE, Awouters FHL, et al:Pharmacology of risperidone(R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685-693(1988)

16) Javitt DC, Zukin SR:Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308(1991)
pubmed

17) Kane J, Honigfeld G, Singer J, et al:Clozapine for the treatment-resistent schizophrenic;A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796 (1988)
pubmed

18) Kato T, Hirose A, Ohno Y, et al:Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 54:478-481(1990)

19) Kehne JH, Baron BM, Carr AA, et al:Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100, 907 as a potent 5-HT2 antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981 (1996)

20) 菊地哲朗:新規抗精神病薬 aripiprazole (OPC-14597)-ドパミン自己受容体アゴニストの開発. 臨床精神薬理1:105-110(1998)

21) Kikuchi T, Tottori K, Uwahodo Y, et al:7-{4-7〔4-(2, 3-chlorophenyl)1-piperazinyl〕 butyloxy}-3, 4-dihydro-2(1H)-quinolinone (OPC-14597);A unique antipsychotic drug candidate with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Neuropsychopharmacology 10(Suppl Part2):194S(1994)

22) Kramer MS, Last B, Getson A, et al:The effects of a selective D4, dopamine receptor antagonist(L-745, 870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54:567-572(1997)

23) Kulagowski JJ, Patel S:Dopamine D, receptor antagonists. Curr Pharmaceut Design 3:355-366(1997)

24) Leysen D, Joannes TM, Ottenheijm CJ:5-HT2 antagonists;A concept for the treatment of schizophrenia. Curr Pharmaceut Design 3:367-390(1997)

25) Leysen JE, Janssen PMF, Schotte A, et al:Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects;Role of 5-HT receptors. Psychopharmacology 112:S40-S54 (1993)

26) McAllister G, Knoweles MR, Ward-Booth SM, et al:Fundamental coupling of human D2, D3 and D4 dopamine receptors in HEK 293 cells. J Recept Signal Trans Res 15:267-281(1995)

27) Meltzer HY, Burnett S, Bastani B, et al:Effects of six months of clozapine treatment of the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 41:892-897(1990)

28) Merchant KM, Gill GS, Harris DW, et al:Pharmacological characterization of U-101387, adopamine D4 receptor selective antagonist. J Pharmacol Exp Ther 279:1392-1403(1996)

29) Migler BM, Warawa EJ, Malick JB:Seroquel;Behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112:299-307(1993)

30) Moor NA, Calligaro DO, Wong DT, et al:The pharmacology of olanzapine and other new antipsychotics. Curr Opinion Invest Drugs 2:281-293(1993)

31) Moor NA, Tupper DE, Hotten TM:Olanzapine. Drugs Future 19:114-117(1994)

32) 村崎光邦:向精神薬開発の最近の動向(2)-抗精神病薬. 日本神精薬理誌15:191-210 (1995)

33) 村崎光邦:これからの抗精神病薬の開発. 神奈川精神薬理8:35-62(1996)

34) Murasaki M:Phase 2 study results of AD-5423, a newly synthesized SDA neuroleptic in Japan. 37th NCDEU, Boca Raton(1997)

35) Murasaki M:An open-label, Japanese phase 2 clinical trial of ziprasidone in the treatment of schizophrenia. Eur Neuropsychopharmacol 7(Suppl 2):S220(1997)

36) 村崎光邦, 小山司, 町山幸輝ほか:新規抗精神病薬 perospironeの精神分裂病に対する臨床評価-haloperidolを対照薬とした第III相試験. 臨床評価24:159-205 (1997)

37) Murasaki M, Koyama T, Yagi G, et al:Pharmacokinetic investigations of clozapine in Japanese patients. 36th ACNP, Hawaii(1997)

38) Murasaki M, Kudo Y:Late phase 2 study of quetiapine(ICI 204, 636), a novel neuroleptic agent, in schizophrenic patients. CINP CMNP Regional Meeting, Acapulco(1997)

39) Murasaki M, Miura S, Ishigooka J, et al:Phase 1 study of a new antipsychotic drug, OPC-4392. Prog Neuro-psycho-pharmacol Biol Psychiatry 12:793-802(1988)

40) Noda Y, Kuriyama S, Miura Y, et al:Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5, 6, 7, 8, 9, 10-hexahydro-cycloocta(b) pyridine(AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 265:745-751 (1993)
pubmed

41) Oka M, Noda Y, Ochi Y:Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin S2 antagonist properties. J Pharmacol Exp Ther 264:158-165(1993)

42) Okuyama S, Chaki S, Kawashima N, et al:The atypical profile of NRAOO45, a novel dopamine D4 and 5-hydroxy-tryptamine2 receptor antagonist, in rats. Br J Pharmacol 121:515-525(1997)

43) Okuyama S, Chaki S, Yoshikawa R, et al:In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-TH2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-〔1-〔4-(4-fluorophenyl)-4-oxobutyl〕pyrrolidin-3-yl〕thiazole(NRAOO45). J Pharmacol Exp Ther 282:56-63(1997)

44) Okuyama S, Imagawa Y, Sakagawa T, et al:NE-100, a novel sigma receptor ligand;Effect on phencyclidine-induced behaviors in rats, dogs and monkeys. Life Sci 55:131-138(1994)

45) 奥山茂, 中里篤郎, 永峰政志ほか:ドーパミンD4 受容体拮抗物質の創薬-精神分裂病治療薬としての可能性. 第14回薬効薬理シンポジウム-よりすぐれた新薬の開発をめざして, pp 10-15, 大阪(1998)

46) Olney LW, Farber NB:Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007(1995)

47) Reeves K:The efficacy and safety of two fixed doses of ziprasidone in schizophrenia. Eur Neuropsychopharmacol 6(Suppl 3):201(1996)

48) Reynolds GP:The importance of dopamine D4 receptor in the action and development of antipsychotic agents. Drugs 51:7-11(1996)

49) Reynolds GP, Mason SL:Are striatal dopamine D4 receptors increased inschizophrenia? J Neurochem 63:1576-1577(1994)

50) Reyntjens A, Gelders YG, Hoppenbrouwers MJA, et al:Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8:205-211(1986)

51) Saller CF, Salam Al:Seroquel;Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292(1993)

52) Schmidt CJ, Fadayel GM:The selective 5-HT2A receptor antagonist, MDL100, 907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273-279(1995)

53) Seeger TF, Seymour PA, Schmidt AW, et al:Ziprasidone(CP-88, 059);A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-123(1995)

54) Seeman P:Dopamine receptor sequences, therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284 (1992)
pubmed

55) Seeman P:Therapeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 10(Suppl 3):5-13(1995)

56) Seeman P, Guan HC, Van Tol HHM:Dopamine D4 receptors elevated inschizophrenia. Nature 365:441-445(1993)

57) Sorensen SM, Kehne JH, Fadayel GM, et al:Characterization of the 5-HT2 receptor antagonist MDL 100, 907 as a putative atypical antipsychotic; Behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691(1993)

58) Toru M, Miura S, Kudo Y:Clinical experience of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology 10(Suppl Part 1):122S(1994)

59) Van Tol HHM, Bunzow JR, Guan HC, et al:Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614 (1991)

60) Weinberger DR:Schizophrenia and the frontal lobe. Trends Neurosci 11:367-370 (1988)
pubmed

61) Zarate CA Jr, Daniel DG, Kinon BJ, et al:Algorthythm for the treatment of schizophrenia. Psychopharmacol Bull 31:461-467(1995)

P.119 掲載の参考文献

1) アンプリット医薬品インタビューフォーム:第一製薬, 東京(1981)

2) Bolden・Watson C, Richelson E:Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023-1029(1993)

3) Carboni E, Tanda GL, Frau R, et al:Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex; Evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070(1990)

4) Cusack B, Nelson A, Richelson E:Binding of antidepressants to human brain receptors;Focus on newer generation compounds. Psychopharmacology 114:559-565 (1994)
pubmed

5) Erikkson E, Humble M:Serotonin in psychiatric pathophysiology;A review of data from experimental and clinical research. Progress in Basic Clinical Pharmacology, Pohl R, Gershon S(ed), Vol 3 The Biological Basis of Psychiatric Treatment, pp 66-119, Karger, Basel(1990)

6) Fink M:Convulsive therapy. Theory and Practice, Raven Press, New York(1979)-清水信(訳):電気けいれん療法. 星和書店, 東京(1980)

7) Glowinski J, Axelrod J:Inhibition of uptake of tritiated noradrenaline in the intact rat brain by imipramine and structurally related compounds. Nature 204:1318-1319 (1964)
pubmed

8) 葉田裕:薬物療法とその歴史. 現代精神医学大系, 懸田克躬ほか(編), 第5巻 B 精神科治療学II, pp 117-141, 中山書店, 東京(1977)

9) Hyttel J, Larsen J-J:Serotonin-selective antidepressants. Acta Pharmacol Toxicol 56(Suppl):146-153(1985)

10) 井上猛, 泉剛, 本間裕士ほか:抗うつ薬に治療抵抗性のうつ病の実態とその治療戦略-自験例における調査結果と治療抵抗性うつ病の段階的治療に関する試案. 精神経誌98(5):329-342(1996)

11) 上島国利:実地医家が知っておきたい抗うつ薬の知識と使い方. ライフ・サイエンス, 東京(1993)

12) Kaplan HI, Sadock BJ:Pocket Handbook of Pychiatric Drug Treatment, 2nd ed, Williams & Wilkins, Baltimore(1996)-神庭重信, 八木剛平(監訳):精神科薬物ハンドブック第2版. 医学書院MYW, 東京(1997)

13) Kline NS:Clinical experience with iproniazide(Marsilid). J Clin Exp Psycho path 19(Suppl 1):72-78 (1958)

14) 小山司:抗うつ薬と脳内受容体. 臨床精神医学16:1261-1275(1987)

15) 小山司, 石金朋人:三環系抗うつ薬, その他. 精神医学36:17-21(1994)

16) Kuhn R:Uber die Behandlung depressiver Zustande mit einem iminobenzylderivat(G22355). Schweiz Med Wochenschr 87:1135-1140(1957)

17) Kuhn R:The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 115:459-464(1958)

18) Mann JJ, Aarons SF, Wilner PJ, et al:A controlled study of the antidepressant efficacy and side effects of(-)-deprenyl. Arch Gen Psychiatry 46:45-50(1989)
pubmed

19) 松原良次, 松原繁広, 小山司ほか:新抗うつ薬milnacipran(TN-912)慢性投与によるラット大脳皮質β-adrenaline 性受容体-adenylate cyclase系およびserotonin 2 受容体に対する影響. 神経精神薬理15:119-126(1993)

20) Meltzer HY, Matsubara S, Lee J-C:Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. J Pharmacol Exp Ther 251:238-246(1989)

21) Moret C, Charveron M, Finberg JPM, et al:Biochemical profile of midalcipran(F2207)1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane(Z)hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219(1985)

22) 村崎光邦:うつ病治療におけるMAO阻害薬の役割. 神経精神薬理 19:685-700(1997)

23) 森温理:第三世代の抗うつ薬. 新興医学出版社, 東京(1986)

24) Peroutka SJ, Snyder SH:Long-term antidepressant treatment decreasess piroperidol-labeled serotonin receptor binding. Science 210:88-90 (1980)

25) Richelson E, Pfenning M:Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes; Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277-286(1984)

26) Richelson E, Nelson A:Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230:94-102(1984)

27) Snyder SH:Drugs and The Brain. WH Freeman and Company, New York(1986)-佐久間昭(訳):脳と薬物. 東京化学同人, 東京(1990)

28) Sulser F:New perspectives on the mode of action of antidepressant drugs. Trends Pharmacol Sci 1:92-94(1979)

29) 竹村道夫, 服部峰子, 風祭元:Clomipramineの血中濃度-点滴と内服の比較. 精神薬療基金研究年報11:200-205(1979)

30) テシプール・医薬品インタビューフォーム:持田製薬, 東京(1989)

31) Thase ME, Rush AJ:Treatment-resistant depression. Psychopharmacology;The Fourth Generation of Progress, Bloom FE, Kupfer DJ(ed), pp 1081-1097, Raven Press, New York(1995)

32) van Praag HM:Psychotropic drugs. Van Gorcum, Assen(1978)-加藤信(訳):プラーク向精神薬. 星和書店, 東京(1979)

33) Wander TJ, Nelson A, Okazaki H, et al:Antagonism by antidepressants of serotonin SI and S2 receptors of normal human brain in vitro. Eur J pharmacol 132:115-121 (1986)

34) Wong DT, Bymaster FP, Mayle DA, et al:LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8:23-33(1993)

P.137 掲載の参考文献

1) Aprison MH, Takahashi R, Tachiki K:Hypersensitive serotonergic receptors involved in clinical depression;A theory. Neuropharmacology and Behavior, Haber B, Aprison MH (ed), pp 23-53, Plenum Press, New York(1978)

2) Baldessarini RJ:Current status of antideppressant;Clinical pharmacology and therapy. J Clin Psychiatry 50:117-126 (1989)

3) Blackely RD, Berson HE, Fremean RT Jr, et al:Cloning and expression of a functional serotonin transporter from rat brain. Nature 354:66-70(1991)

4) Coppen A:The biochemistry of affective disorders. Br J Psychiatry 113:1237-1264 (1967)
pubmed

5) Inoue T, Tsuchiya K, Miura J, et al:Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 40:151-153(1996)

6) Kanba S, Richelson E:Antidepressant interactions with neurotransmitter receptors in vitro;Prediction of potential side effects. Receptor Binding in Drug Research, O'Brien RA(ed), pp 429-447, Marcel Dekker, Inc, New York, Basel(1986)

7) Kaplan HI, Sadock BJ:Synopsis of Psychiatry. 8th ed, Williams & Wilkins, New York(1998)

8) 堅田利明:三量体GTP結合蛋白質. 蛋白質・核酸・酵素42(3):353-363(1997)

9) Mai J, Przegalinski E, Mogilnicka E:Hypothesis concerning the mechanism of action of antidepressants drugs. Rev Physiol Biochem Pharmacol 100:1-74(1984)

10) 野村総一郎:抗うつ薬の薬理作用とうつ病の病因論. 抗うつ薬の過去現在未来, 上島国利(編), pp 69-83, 星和書店, 東京(1992)

11) 小沢寛樹:G蛋白質と躁うつ病の成因と治療. 躁うつ病の脳科学, 神庭重信(編), pp 175-204, 星和書店, 東京(1995)

12) Pacholczyk T, Blackely RD, Amara SG:Expression cloning of a cocain-andantidepressant-sensitive human noradrenaline transporter. Nature 350:350-354 (1991)

13) Richelson E:Biological basis of depreesion and therapeutic relevance. J Clin Psychiatry 52:4 (1991)

14) Schildkraut JJ:The catecholamine hypothesis of affective disorders;A review of supportive evidence. Am J Psychiatry 122:509-522(1965)

15) Segal DS, et al:Theoretical implications of drug-induced adaptive regulationfor a biogenic amine hypothesis of affective disorders. Biol Psychiatry 9:147-159 (1974)

16) Shimada S, Kitayama S, Lin CL, et al:Cloning and expression of a cocain sensitive dopamine transporter complementary DNA. Science 254:576-578(1991)

17) 島田昌一:アミントランスポーター. 蛋白質・核酸・酵素42(3):244-252(1997)

18) Wang YM, Gainetdinov RR, Funnagalli F, et al:Knockout of the vesicular monoamine trasporter 2 gene results in neonatal death and supersensitivity to cocain and amphetamine. Neuron 19(6):1285-1296(1997)

P.148 掲載の参考文献

1) Abou-Saleh M, Coppen A:Classification of depression and response to antidepressant therapies. Br J Psychiatry 143:601-603(1983)

2) Akiskal HS:Factors associated with incomplete recovery in primary depressive illness. J Clin Psychiatry 43:266-271 (1982)
pubmed

3) Angst J:The course of affective disorders. Psychopathology 19(Suppl 2):47-52 (1986)

4) Anton RF, Burch EA:Response of psychotic depression subtypes to pharmacology. J Affect Disord 28:125-131(1993)

5) Brown RP, Sweeney J, Frances A, et al:Age as a predictor of treatment response in endogenous depression. J Clin Psychopharmacol 3:176-178(1983)

6) Chan CH, Janicak PG, Davis JM, et al:Response of psychotic and non-psychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 47:197-200(1987)

7) de Montigny C, Gruneberg F, Mayer A, et al:Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J psychiatry 138:252-256 (1981)

8) de Montigny C:Lithium addition in refractory depression. Refractory Depression, Nolen WA, Zohar J, Roose SP, et al(ed), P50, John Wiley & Sons, New York(1994)

9) Den Boer JA, Westernberg HGM, Kamerbeek WDJ, et al:Effect of serotonin uptake inhibitors in anxiety disorders, a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2:21-32(1987)

10) de Veaugh Ceiss J, Landon P, Katz D, et al:Treatment of obsessive compulsive disorders with clomipramine. Psychiatric Ann February 19:97(1989)

11) Downing RW, Rickels K:Predictors of response to amitriptyline and placebo in three outpatient treatment settings. J Nerv Ment Dis 156:109-129(1973)

12) European Algorithm Project(Supp Ed:Kasper S). Int J Psychiatry Clin Practice 1(Suppl 1):Sl-S12 (1997)

13) Flaherty JA, Gaviria FM, Black EM, et al:The role of social support in the functioning of patients with unipolar depression. Am J Psychiatry 140:473-476(1983)

14) Goff DC:The stimulant challenge test in depression. J Clin Psychiatry 47:538-543 (1986)
pubmed

15) 鳩谷龍, 野村純一:難治性うつ状態に対する甲状腺療法. 精神薬療基金年報4:538-543 (1983)

16) 樋口輝彦:難治性うつ病の臨床. pp 175, 診療新社, 大阪(1997)

17) International Psychopharmacology Algorithm Project Report:Algorithms for the Treatment of Bipolar, Manic-Depressive Illness (Suppes T;Rapporteur). Psychopharmacol Bull 31:469-474(1995)

18) 医療薬日本医薬品集:1997年10月版. 薬業時報社, 東京(1997)

19) Janicak PG, Davis JM, Preskorn SH, et al:Principles and Practice of Psychopharmacotherapy. p 229, Williams & Wilkins, Baltimore(1993)

20) 上島国利, 田所千代子, 田島治:抗うつ薬. 精神治療薬大系, 三浦貞則ほか(編), 第3巻, pp 30-35, 星和書店, 東京(1996)

21) Keller MB, Klerman GL, Lavori PW, et al:Long-term outcome of episode of major depression. JAMA 252:788-792(1984)

22) Kerr TA, Schapira K, Roth M, et al:The relationship between the Maudsley Personality Inventory and the course of affective disorders. Br J Psychiatry 116:11-19 (1970)
pubmed

23) Montgomery SA, Dufour H, Brion S, et al:The prophylactic efficacy of Huoxetinein unipolar depression. Br J Psychiatry 3:69-76(1988)

24) Miller SE, de Beurs P, Timmerman L, et al:Plasma tryptophan and tyrosineratios to competing amino acids in relation to antidepressant response to citalopram and maplotiline. Psychopharmacology 88:96-110(1986)

25) Nolen WA, Haffmans PMJ:Treatment of resistant depression. Int J Clin Psychopharmacol 4:217-228(1989)

26) Psykel ES, Prussoff BA, Klerman G, et al:Clinical response to amitriptyline among depressed women. J Nerv Ment Dis 156:149-165(1973)

27) Peselow ED, Stanley M, Filippi AM, et al:The predictive value of the dexamethasone suppression test;A placebo-controlled study. Br J Psychiatry 155:667-672 (1989)

28) Prange AJ Jr, Wilson IC, Rabon AM:Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 126:457-469(1969)

29) Prien RF, Kupfer DJ, Mansky PA, et al:Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 41:1096-1104 (1984)
pubmed

30) Prien RF, Kupfer DJ:Continuation drug therapy for major depressive episodes. Am J Psychiatry 143:18-23(1986)

31) Rosenbaum AH, Schatzberg AF, Maruta T, et al:MHPG as a predictor of antidepressant response to imipramine and maprotiline. Am J Psychiatry 137:1090-1092(1980)

32) 精神科薬物療法研究会(編):精神分裂病と気分障害の治療手順-薬物療法のアルゴリズム. 星和書店, 東京(1998)

33) 渡辺昌祐, 横山茂生:抗うつ薬の選び方と用い方. 改訂版, pp 80-94, 新興医学出版社, 東京(1993)

P.163 掲載の参考文献

1) Altshuler LL, Cohen L, Szuba MP, et al:Pharmacologic management of psychiatric illness during pregnancy;Dilemmas and guidelines. Am J Psychiatry 153:592-606 (1996)
pubmed

2) Andersen H, Kristiansen ES:Tofranil-treatment of endogenous depressions. Acta Psychiatr Neurol Scand 34:387-397(1959)

3) Bader TF, Newman K:Amitriptyline in human breast milk and the nursing infant's serum. Am J Psychiatry 137:855-856(1980)

4) Beasley CM Jr, Dornseif BE, Bosomworth JC, et al:Fluoxetine and suicide;A meta-analysis of controlled trials of treatment for depression. BMJ 303:685-692 (1991)
pubmed

5) Biggs JT, Spiker DG, Petit JM, et al:Tricyclic antidepressant overdose;Incidence of symptoms. JAMA 238:135-138(1977)

6) Bodner RA, Lynch T, Lewis L, et al:Serotonin syndrome. Neurology 45:219-223 (1995)
pubmed

7) Callaham M, Kassel D:Epidemiology of fatal tricyclic antidepressant ingestion;Implications for management, Ann Emerg Med 14:1-9(1985)

8) Cassidy S, Henry J:Fatal toxicity of antidepressant drugs in overdose. BMJ295:1021-1024 (1987)
pubmed

9) Coulter DM, Pillans PI:Fluoxetine and extrapyramidal side effects. Am J Psychiatry 152:122-125 (1995)
pubmed

10) Coupland NJ, Bell C, Potokar JP:Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16:356-362 (1996)
pubmed

11) Coupland N, Wilson S, Nutt D:Antidepressant drugs and the cardiovascular system;A comparison of tricyclics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patiente with cardiovascular problems. J Psychopharmacol 11:83-92(1997)

12) Cowe L, Lloyd DJ, Dawling S:Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ 284:1837-1838(1982)

13) De Jonghe F, Swinkels JA:The safety of antidepressants. Drugs 43(Suppl 2):40-47(1992)

14) Dessain EC, Schatzberg AF, Woods BT, et al:Maprotiline treatment in depression;A perspective on seizures. Arch Gen Psychiatry 43:86-90(1986)

15) Dilsaver SC, Kronfol Z, Sackellares JC, et al:Antidepressant withdrawal syndromes;Evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 3:157-164(1983)

16) Dilsaver SC, Greden JF, Snider RM:Antidepressant withdrawal syndromes;Phenomenology and pathophysiology. Int Clin Psychopharmacol 2:1-19(1987)

17) Edwards JG, Inman WHW, Wilton L, et al:Prescription-event monitoring of 10401 patients treated with Huvoxamine. Br J Psychiatry 164:387-395(1994)

18) Falterman CG, Richardson CJ:Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 97:308-310(1980)

19) Fernstrom MH, Kupfer DJ:Antidepressant-induced weight gain;A comparison study of four medications. Psychiatry Res 26:265-271(1988)

20) Frazer A:Antidepressants. J Clin Psychiatry 58(Suppl 6):9-25(1997)

21) Frommer DA, Kulig KW, Marx JA, et al:Tricyclic antidepressant overdose;A review. JAMA 257:521-526(1987)

22) 福西勇夫:抗うつ薬によるけいれん発作. 精神医学32:253-258(1990)

23) 古川壽亮:抗うつ剤は気分障害の経過を不安定化させるか?-急性期治療/継続治療/予防治療の観点から. 精神科治療学7:903-909(1992)

24) Gammon GD, Hansen C:A case of akinesia induced by amoxapine. Am J Psychiatry 141:283-284(1984)

25) Gartrell N:Increased libido in women receiving trazodone. Am J Psychiatry 143:781-782 (1986)
pubmed

26) Garvey MJ, Tollefson GD:Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 44:269-272(1987)

27) Geller B, Cooper TB, Carr LG, et al:Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. J Clin Psychopharmacol 7:252-254 (1987)
pubmed

28) Gitlin MJ:Psychotropic medications and their effects on sexual function;Diagnosis, biology, and treatment approaches. J Clin Psychiatry 55:406-413(1994)

29) Glassman AH, Bigger JT Jr:Cardiovascular effects of therapeutic doses of tricyclic antidepressants;A review. Arch Gen Psychiatry 38:815-820(1981)

30) Glassman AH, Johnson LL, Giardina EGV, et al:The use of imipramine in depressed patients with congestive heart failure. JAMA 250:1997-2001(1983)

31) Glassman AH, Roose SP, Giardina EGV, et al:Cardiovascular effects of tricyclic antidepressants. Psychopharmacology;The third generation of progress, Meltzer HY(ed), pp 1437-1442, Raven Press, New York(1987)

32) Glassman AH, Roose SP, Bigger JT Jr:The safety of tricyclic antidepressants in cardiac patients;Risk-benefit reconsidered. JAMA 269:2673-2675(1993)

33) Haddad P:Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 58(Suppl 7):17-22 (1997)

34) Halper Jp, Mann JJ:Cardiovascular effects of antidepressant medications. Br J Psychiatry 153(Suppl 3):87-98(1988)

35) Hamilton MS, Opler LA:Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 53:401-406 (1992)
pubmed

36) 林みゑ子:緑内障患者にアトロピンは禁忌か-なぜ眼圧が上がるのか. SCOPE 37:14-15 (1998)

37) Henry JA, Alexander CA, Sener EK:Relative mortality from overdose of antidepressants. BMJ 310:221-224(1995)

38) Henry JA:Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 16:374-390 (1997)
pubmed

39) 堀正士, 新井哲明, 嶋崎素吉ほか:Trazodone投与中性欲の異常亢進を呈した妄想性うつ病の1女性例. 精神医学39:97-99(1997)

40) Isacsson G, Holmgren P, Wasserman D, et al:Use of antidepressants among people committing suicide in Sweden. BMJ 308:506-509(1994)

41) Isacsson G, Holmgren P, Druid H, et al:The utilization of antidepressants;A key issue in the prevention of suicide;An analysis of 5281 suicides in Sweden during the period 1992～1994. Acta Psychiatr Scand 96:94-100(1997)

42) Jabbari B, Bryan GE, Marsh EE, et al:Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 42:480-481(1985)

43) Jick H, Dinan BJ, Hunter JR, et al:Tricyclic antidepressants and convulsions. J Clin Psychopharmacol 3:182-185(1983)

44) Jick SS, Dean AD, Jick H:Antidepressants and suicide. BMJ 310:215-218(1995)

45) Jones BD, Steinberg S, Chouinard G:Fast-cycling bipolar disorder induced by withdrawal from long-term treatment with a tricyclic antidepressant. Am J Psychiatry 141:108-109 (1984)
pubmed

46) 上島国利, 石福行人:抗うつ薬の循環機能障害. 精神医学32:245-251(1990)

47) 神庭重信:抗うつ薬による躁転あるいは病相の頻発化の問題. 精神科治療学7:911-917 (1992)

48) Kapur S, Mieczkowski T, Mann JJ:Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 268:3441-3445(1992)

49) Kathol RG, Henn FA:Tricyclics;The most common agent used in potentially lethal overdoses. J Nerv Ment Dis 171:250-252(1983)

50) 木下潤:妊産婦・胎児・新生児. 精神科MOOK増刊1, pp 325-349, 金原出版, 東京(1989)

51) Kojima H, Terao T, Yoshimura R:Serotonin syndrome during clomipramine and lithium treatment. Am J Psychiatry 150:1897(1993)
pubmed

52) 小瀧一, 鹿志村淳子, 伊賀立二:Imipramine, desipramineの副作用・相互作用-最近の報告. 精神科治療学12:1522-1524(1997)

53) Kramer JC, Klein DF, Fink M:Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 118:549-550(1961)

54) Kronfol Z, Greden JF, Zis AP:Imipramine-induced tremor;Effects of a beta-adrenergic blocking agent. J Clin Psychiatry 44:225-226 (1983)
pubmed

55) 工藤貴代美, 佐々木一郎, 穐吉條太郎ほか:セロトニン症候群-三環系抗うつ薬における調査. 精神医学39:757-759(1997)

56) Lader MH:Tolerability and safety;Essentials in antidepressant pharmacotherapy. J Clin Psychiatry 57(Suppl 2):39-44(1996)

57) Lane R, Baldwin D:Selective serotonin reuptake inhibitor-induced serotonin syndrome;Review. J Clin Psychopharmacol 17:208-221(1997)

58) Lapierre YD, Anderson K:Dyskinesia associated with amoxapine antidepressant therapy;A case report. Am J Psychiatry 140:493-494(1983)

59) Law W III, Petti TA, Kazdin AE:Withdrawal symptoms after graduated cessation of imipramine in children. Am J Psychiatry 138:647-650(1981)

60) Lejoyeux M, Rouillon F, Ades J, et al:Neural symptoms induced by tricyclic antidepressants;Phenomenology and pathophysiology. Acta Psychiatr Scand 85:249-256 (1992)
pubmed

61) Lejoyeux M, Rouillon F, Ades J:Prospective evaluation of the serotonin syndromein depressed inpatients treated with clomipramine. Acta Psychiatr Scand 88:369-371 (1993)

62) Lejoyeux M, Ades J:Antidepressant discontinuation;A review of the literature. J Clin Psychiatry 58(Suppl 7):11-16 (1997)

63) Lipinski JF, Mallya G, Zimmerman P, et al:Fluoxetine-induced akathisia;Clinical and theoretical implications. J Clin Psychiatry 50:339-342(1989)

64) Lippmann S, Moskovitz R, O'tuama L:Tricyclic-induced myoclonus. Am J Psychiatry 134:90-91(1977)

65) Livingston RL, Zucker DK, Isenberg K, et al:Tricyclic antidepressants and delirium. J Clin Psychiatry 44:173-176(1983)

66) 松田源一:多飲・水中毒・SIADH. 精神治療薬大系, 三浦貞則(監), 第5巻向精神薬の副作用とその対策, pp 257-272, 星和書店, 東京(1997)

67) Meador-Woodruff JH, Akil M, Wisner-Carlson R, et al:Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels. J Clin Psychopharmacol 8:28-32(1988)

68) Mills KC:Serotonin syndrome. Am Fam Physician 52:1475-1482(1995)

69) Mirin SM, Schatzberg AF, Creasey DE:Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatry 138:87-89(1981)

70) 宮田量治:泌尿器系副作用, 麻痺性イレウス. 精神治療薬大系, 三浦貞則(監), 第5巻向精神薬の副作用とその対策, pp 203-239, 星和書店, 東京(1997)

71) 水川六郎, 岸本朗, 国元憲文ほか:抗うつ薬の眼科的機能に及ぼす影響. 臨床精神医学15:1835-1841(1986)

72) Molcho A, Stanley M:Antidepressants and suicide risk;Issues of chemical and behavioral toxicity. J Clin Psychopharmacol 12(Suppl):13S-18S (1992)

73) Montgomery SA:Suicide and antidepressants. Drugs 43(Suppl 2):24-31(1992)

74) 長沼英俊, 藤井薫:抗うつ薬による薬疹. 臨床精神医学16:1199-1200(1987)

75) 長沼英俊, 藤井薫:抗うつ薬中毒. 日医師会誌115:689-693(1996)

76) 内藤裕史:悪性症候群-ドパミン・セロトニン症候群-病態・診断・治療. 精神経誌99:803-808(1997)

77) 中村純, 内村直尚, 山田茂人ほか:せん妄に対するmianserinの治療効果-oxypertine, haloperidolとの比較. 日神精薬理誌14:269-277(1994)

78) 中村純:抗うつ薬の薬物動態と相互作用. 精神科治療学10:735-741(1995)

79) 中村純, 小鳥居剛:うつ病の経過中に性欲亢進を呈した1例-trazodone投与による副作用か? 精神医学38:1083-1086(1996)

80) Nelson JC:Safety and tolerability of the new antidepressants. J Clin Psychiatry 58(Suppl 6):26-31 (1997)

81) 西嶋康一, 清水光恵, 阿部隆明ほか:セロトニン症候群と考えられた2症例-悪性症候群との鑑別を中心に. 精神医学38:1035-1041(1996)

82) 西嶋康一, 石黒健夫:セロトニン症候群. 臨床精神医学26:339-348(1997)

83) 大江康雄:造血系障害. 精神治療薬大系, 三浦貞則(監), 第5巻向精神薬の副作用とその対策, pp 175-186, 星和書店, 東京(1997)

84) Oehrberg S, Christiansen PE, Behnke K, et al:Paroxetine in the treatment of panic disorder;A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167:374-379 (1995)
pubmed

85) 岡本康昌, 末田耕一, 吉村靖司ほか:せん妄に対するトラゾドンの治療効果. 精神医学39:1103-1108(1997)

86) Otani K, Sasa H, Kaneko S, et al:Lack of withdrawal symptoms after discontinuation of mianserin. Lancet 337:673-674(1991)

87) 小山田静枝, 上島国利:セロトニン症候群. 新精神科選書(4), 八木剛平(編), 精神科診療の副作用・問題点・注意点-患者・家族・治療者からのメッセージ , pp 213-225, 診療新社, 大阪(1998)

88) Pastuszak A, Schick-Boschetto B, Zuber C, et al:Pregnancy outcome following first-trimester exposure to fluoxetine(Prozac). JAMA 269:2246-2248(1993)

89) Paykel ES, Meuller PS, De La Vergne PM:Amitriptyline, weight gain and carbohydrate craving;A side effect. Br J Psychiatry 123:501-507 (1973)

90) Peck AW, Stern WC, Watkinson C:Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 44:5(sec. 2)197-201 (1983)

91) Pescatori ES, Engelman JC, Davis G, et al:Priapism of the clitoris;A case report following trazodone use. J Urol 149:1557-1559(1993)

92) Pohl R, Yeragani VK, Balon R, et al:The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 49:100-104(1988)

93) Preskorn SH, Simpson S:Tricyclic-antidepressant-induced delirium and plasma drug concentration. Am J Psychiatry 139:822-823(1982)

94) Preskorn SH, Jerkovich GS:Central nervous system toxicity of tricyclic antidepressants;Phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 10:88-95(1990)

95) Purcell P, Ghurye R:Trazodone and spontaneous orgasms in an elderly postmenopausal woman;A case report. J Clin Psychopharmacol 15:293-295(1995)

96) Ranga Rama Krishnan K, France RD, Ellinwood EH Jr:Tricyclic-induced akathisia in patients taking conjugated estrogens. Am J Psychiatry 141:696-697 (1984)

97) Rechlin T:The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability. J Clin Psychopharmacol 14:392-395(1994)

98) Roose SP, Glassman AH, Giardina EGV, et al:Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 44:273-275 (1987)

99) Rosenbaum JF, Zajecka J:Clinical management of antidepressant discontinuation. J Clin Psychiatry 58(Suppl 7):37-40 (1997)

100) Rosenstein DL, Nelson JC, Jacobs SC:Seizures associated with antidepressants;A review. J Clin Psychiatry 54:289-299(1993)

101) Saenz de Tejada I, Ware JC, Blanco R, et al:Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 145:60-64(1991)

102) 坂井俊之, 上島国利:抗うつ薬の薬物相互作用. 臨床精神医学26:165-177(1997)

103) 佐々木一郎, 藤井薫:抗うつ薬と躁転. 臨床精神医学24:1675-1679(1995)

104) 佐々木一郎, 穐吉條太郎, 土山幸之助ほか:Clomipramine単一投与中のセロトニン症候群. 精神医学38:727-731(1996)

105) 佐藤耕一:肥満. 精神治療薬大系, 三浦貞則(監), 第5巻向精神薬の副作用とその対策, pp 241-256, 星和書店, 東京(1997)

106) 佐藤重仁, Baud F, Bismuth Cほか:急性三環系抗うつ薬中毒. 救急医学9:383-389 (1985)

107) 佐藤俊樹, 濱村貴史, 李陽明ほか:Trazodone 150mg投与中に生じたセロトニン症候群の1症例. 精神医学40:289-294(1998)

108) Schatzberg AF, Haddad P, Kaplan EM, et al:Serotonin reuptake inhibitor discontinuation syndrome;A hypothetical definition. J Clin Psychiatry 58(Suppl 7):5-10 (1997)

109) Shearer WT, Schreiner RL, Marshall RE:Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 81:570-572(1972)

110) 塩江邦彦, 假屋哲彦:抗うつ薬の副作用. 神経精神薬理11:37-48(1989)

111) 下田和孝, 染矢俊幸:選択的セロトニン再取り込み阻害薬(SSRI)の薬物相互作用について-SSRI時代の夜明け前に. 精神医学39:1329-1336(1997)

112) Skowron DM, Stimmel GL:Antidepressants and the risk of seizures. Pharmacotherapy 12:18-22(1992)

113) Sovner R, Orsulak PJ:Excretion of imipramine and desipramine in human breast milk. Am J Psychiatry 136:451-452(1979)

114) Sternbach H:The serotonin syndrome. Am J Psychiatry 148:705-713(1991)

115) Sullivan G:Increased libido in three men treated with trazodone. J Clin Psychiatry 49:202-203 (1988)
pubmed

116) 諏訪克行:うつ状態における口渇と多飲. 臨床精神医学18:1349-1354(1989)

117) 田島治:急性中毒. 精神治療薬大系, 三浦貞則(監), 第5巻向精神薬の副作用とその対策, pp 273-293, 星和書店, 東京(1997)

118) 田島治:抗うつ薬の副作用, 特にSSRIによる錐体外路症状. 新精神科選書(4), 八木剛平(編), 精神科診療の副作用・問題点・注意点, -患者・家族・治療者からのメッセージ, pp 226-235, 診療新社, 大阪(1998)

119) 高宮真樹:肝障害. 精神治療薬大系, 三浦貞則(監), 第5巻向精神薬の副作用とその対策, pp 187-201, 星和書店, 東京(1997)

120) 竹村道夫, 利田周太, 淵野和子:Clomipramineとdesmethylclomipramineの乳汁中への分泌. 精神医学24:749-753(1982)

121) Teicher MH, Glod C, Cole JO:Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207-210(1990)

122) Thompson JW, Ware MR, Blashfield RK:Psychotropic medication and priapism;A comprehensive review. J Clin Psychiatry 51:430-433(1990)

123) Tollefson GD:Antidepressant treatment and side effect considerations. J Clin Psychiatry 52(Suppl 5):4-13 (1991)

124) Tollefson GD:Adverse drug reactions/interactions in maintenance therapy. J Clin Psychiatry 54(Suppl 8):48-58 (1993)

125) 融道男:抗うつ薬の現在. 治療学31:666-669(1997)

126) Tueth MJ:Revisiting fluoxetine(Prozac)and suicidal preoccupations. J Emerg Med 12:685-687(1994)

127) Warner MD, Peabody CA, Whiteford HA, et al:Trazodone and priapism J Clin Psychiatry 48:244-245 (1987)
pubmed

128) Warnock JK, Knesevich JW:Adverse cutaneous reactions to antidepressants. Am J Psychiatry 145:425-430(1988)

129) Warrington SJ, Dana-Haeri J, Sinclair AJ:Cardiovascular and psychomotor effects of repeated doses of paroxetine;A comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand 80(Suppl 350):42-44(1989)

130) 渡辺昌祐, 横山茂生:抗うつ薬の選び方と用い方, 改訂版. 新興医学出版社, 東京(1993)

131) Webster PA:Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet ii:318-319 (1973)

132) Wehr TA, Goodwin FK:Can antidepressants cause mania and worsen the course of affective illness. Am J Psychiatry 144:1403-1411(1987)

133) 山田尚登, 青谷弘, 高橋三郎:抗うつ薬とせん妄. 精神医学36:1153-1158(1994)

134) 山本保博, 鵜飼卓, 岡田芳明ほか:全国アンケートによる急性中毒物質についての調査. 中毒研究1:193-196(1988)

135) Yassa R, Camille Y, Belzile L:Tardive dyskinesia in the course of antidepressant therapy;A prevalence study and review of the literature. J Clin Psychopharmacol 7:243-246(1987)

136) Yoshida K, Smith B, Craggs M, et al:Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breastmilk. J Affect Disord 43:225-237(1997)

137) Zubenko GS, Cohen BM, Lipinski JF:Antidepressant-related akathisia. J Clin Psychopharmacol 7:254-257(1987)

P.178 掲載の参考文献

1) Blazer DG, Kessler RC, McGonagle KA, et al:The prevalence and distribution of major depression in a national community sample;The national comorbidity survey. Am J Psychiatry 151:979-986(1994)

2) 上島国利:抗うつ薬-現状と課題. 精神医学35:916-928(1993)

3) 上島国利:選択的セロトニン再取り込み阻害薬(SSRI)と可逆的選択的MAO阻害薬. 精神経誌(1999)in press.

4) Lepine J-P, Gastpar M, Mendlewicz J, et al:Depression in the community;The first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19-29(1997)

5) NIMH/NIH Consensus Development Panel:Mood disorders;Pharmacologic prevention of recurrence. Am J Psychiatry 142:469-476(1985)

6) Sternback H:The serotonin syndrome. Am J Psychiatry 148:705-713(1991)

7) Warrington SJ:Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int Clin Psychopharmacol 7(S2):13-19(1992)

8) Weissman MM, Leaf PJ, Tischler GL, et al:Affective disorders in five United States communities. Psychol Med 18:141-153(1988)

9) Weissman MM, Bland RC, Canino GJ, et al:Cross-national epidemiology of major depression and bipolar disorder. JAMA 276:293-299(1996)

10) 山田光彦 , 上島国利:新しい抗うつ薬の可能性-特にSSRIを中心に. 臨床精神薬理1:355-363(1998)

P.200 掲載の参考文献

1) Abou-Saleh MT:Who responds to prophylactic lithium therapy? Br J Psychiatry 163(Suppl 21):20-26 (1993)

2) Avissar S, Schreiber G, Danon A, et al:Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 331:440-442(1998)

3) 馬場信二, 渡辺昌祐:うつ病に対する有用性. リチウム療法の実際, 渡辺昌祐ほか(編), pp 67-100, 医歯薬出版, 東京(1983)

4) Baldessarini R, Tondo L, Faedda GL, et al:Effect of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 57:441-448 (1996)
pubmed

5) Ballenger JC, Post RM:Therapeutic effects of carbamazepine in effective illness;A preliminary report. Communications Psychopharmacology 2:159(1978)

6) Bauer MS, Whybrow OC:Rapid cycling bipolar affective disorder, II;Treatment of refractory rapid cycling with high-dose levothyroxine;A preliminary study. Arch Gen Psychiatry 47:435-440(1990)

7) Cade JF:Lithium salts in the treatment of psychotic excitement. Med J Aust 36:349-352 (1949)

8) Calabrese JR, Delucchi GA:Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147:431-434(1990)

9) Calabrese HR, Marchovitz PJ, Kimmel SE, et al:Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 12(Suppl 1):53S-56S (1992)

10) Calabrese JR, Woyshville MJ:A medication algorithm for treatment of bipolar rapid cycling? J Clin Psychiatry 56(Suppl 3):11-18 (1995)

11) Chouinard G, Sternberg S, Steiner W:Estrogen-progesteron combination;Another mood stabilizer? Am J Psychiatry 144:826(1987)

12) Denicoff KD, Smith-Jackson EE, Disney ER, et al:Valproate prophylaxis on aprospective clinical trial of refractory bipolar disorder. Am J Psychiatry 154:1456-1458 (1997)

13) Denicoff KD, Smith-Jackson EE, Disney ER, et al:Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 58:470-478 (1997)
pubmed

14) Dubovsky SL, Busan RD:Novel alternative and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 58:224-242(1997)

15) Dubovsky SL, Christiand J, Daniell LC, et al:Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 46:632-638 (1989)

16) Dubovsky SL, Murphy J, Thomas M, et al:Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J psychiatry 149:118-120 (1992)

17) Emrich HMV, Zerssen D, Kissling W, et al:Effect of sodium valproate on mania;The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 229(1):1-16 (1980)

18) Fatemi SH, Rapport DJ, Calabrese JR, et al:Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 58:522-527 (1997)
pubmed

19) Frances A, Docherty Jp, Kahn DA:Treatment of bipolar disorder. J Clin Psychiatry 57(Suppl 12A):3-80(1995)

20) Freeman MP, Stoll AL:Mood stabilizer combinations;A review of safety and efficacy. Am J Psychiatry 155:12-22(1998)

21) Gegenberg AJ, Kane JM, Keller MB, et al:Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 321:1489-1493(1989)

22) 原俊夫:Depakene(DPA:Sodium valproate)開発の歴史と現況. Depakeneの基礎と臨床, pp 49-76, 協和発酵工業, 東京(1975)

23) Hirshfeld RMA, Clayton RJ, Cohen I, et al:Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 151(Suppl 12):1-36(1994)

24) 石田元男, 富永一, 折橋洋一郎ほか:リチウム製剤(腸溶錠)による躁状態の治験と予防効果. 精神経誌70:89-90(1968)

25) 神庭重信:リチウム非反応者に期待される気分安定薬-研究・開発をめぐる最近のトピックス. 神経精神薬理11:781-792(1989)

26) Kendall DA, Nahorski SR:Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. J Pharmacol Exp Ther 241:1023-1027(1987)

27) 岸本朗:気分安定薬. 臨床精神医学21(7):1234-1235(1992)

28) 岸本朗:気分安定薬. 脳と精神の医学6(3):273-282(1998)

29) 岸本朗:双極病における病相発現予防の臨床. 精神医学33:910-924(1991)

30) 岸本朗:Mood stabilizerの再発予防効果. 臨床精神薬理1:397-404(1998)

31) Kishimoto A:The treatment of affective disorder with carbamazepine;Prophylactic synergism of lithium and carbamazepine combination. Prog Psychopharmacol Biol Psychiatry 16:483-493(1991)

32) Kishimoto A:Os Antiepilepticos e o Litio no Tratamento das Perturbacoes do Humor. Hosp Julio de Matos 3:129-135(1991)

33) 岸本朗, 井上雄一:躁病の薬物療法. 臨床精神医学講座, 松下正明ほか(編), 第4巻気分障害, pp 126-140, 中山書店, 東京(1998)

34) 岸本朗, 福田吉顕, 福田武雄ほか:双極性障害に対するバルプロ酸の長期予防効果. 精神経誌7:491(1990)

35) 岸本朗:気分安定薬. 精神科治療の理論と技法, 岸本朗, 井上雄一(編), 星和書店, 東京(1999出版予定)

36) Kusumi I, Koyama T, Yamashita I:Serotonin-stimulated Ca2+ response is increased in the blood platelets of depressed patients. Biol Psychiatry 30:310-312 (1991)
pubmed

37) Lambert PAV, Enaud G:Utilisation duvalpromide en therapeutique psychiatrique. Encephale XIII:367-373(1987)

38) Leach MJ, Marden CM, Miller AA:Pharmacological studies on lamotrigine;A novel potential antiepileptic drug, II;Neurochemical studies on the mechanism of action. Epilepsia 27:490-497 (1986)
pubmed

39) Leverich GS, Post RM, Rosoff AS:Factors associated with relapse during maintenance treatment of affective disorders. Int Clin Pharmacol 5:135-156(1990)

40) Littlejohn R, Leslie F, Cookson J:Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 165:827-829 (1994)
pubmed

41) Mander AJ, Loudon JB:Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet ii:15-17(1988)

42) Marjerrison G, Jedlicki SM, Keogh RP, et al:Carbamazepine;Behavioural, anticonvulsant, and EEG effects in chronically hospitalized epileptics. Dis Nerv Syst 29:133-136 (1968)
pubmed

43) McElroy SL, Keck PE, Pope HG, et al:Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 8:275-279(1988)

44) Michell PBM, Manji HKAN, Chen G, et al:High level of Gsα in platelets of euthymic patients with bipolar disorder. Am J Psychiatry 154:218-223(1997)

45) 西原こずえ:精神科領域におけるリチウム療法の実際リチウム療法の実際, 渡辺昌裕ほか(編), pp 245-269, 医歯薬出版, 東京(1990)

46) Okuma T, Kishimoto A, Inoue K, et al:Antimanic and prophylactic effects of carbamazepine(Tegretol)on manic depressive psychosis;A preliminary report. Folia Psychiat Neurol Jpn 27:283-297(1973)

47) Okuma T, Inanaga K, Otsuki S, et al:A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology 73:95-96(1981)

48) Okuma T, Inanaga K, Otsuki S, et al:Comparison of the antimanic efficacy of carbamazepine and chlorpromazine;A double-blind controlled study. Psychopharmacology 66:211-217(1979)

49) 小村文明, 梅沢要一, 岸本朗ほか:躁うつ病相構造とカルバマゼピン(CBZ)の予防効果. 精神経誌94:87(1992)

50) 小沢寛樹:G蛋白質と躁うつ病の成因と治療. 躁うつ病の脳科学-方法論から臨床研究まで, 神庭重信(編), pp 175-204, 星和書店, 東京(1995)

51) Pope HG Jr, McElroy SL, Keck PE Jr, et al:Valproate in the treatment of acute mania;A placebo controlled study. Arch Gen Psychiatry 48:62-68(1991)

52) Post RM:Carbamazepine treatment of bipolar affective disorder. Directions Psychiatry 9(Lesson 3):1-11 (1989)

53) Post RM:Sensitization and kindling perspectives for the course of affective illness;Towards a new treatment with the anticonvulsant carbamazepine. Pharmacopsychiatry 23:3-17(1990)

54) Post RM, Leverich GS, Altshuler L, et al:Lithium-discontinuation-induced refractoriness;Preliminary observations. Am J Psychiatry 149:1727-1729(1992)

55) Post RM, Uhde TW, Roy-Byrne PP, et al:Efficacy and mechanisms of action of carbamazepine in affective disorder. Biological Psychiatry, Shagass C, et al(ed), pp 886-888, Elsevier Science Publishing, Amsterdam(1985)

56) Post RM, Uhde TW, Roy-Byrne PP, et al:Correlates of antimanic response to carbamazepine. Psychiatry Res 21(1):71-83(1987)

57) Prazzaglia PJ, Post RM, Kener TA, et al:Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 49:257-272 (1993)

58) 佐久間もと:躁状態に行った炭酸リチウムの治療経験. 精神医学10:317-321(1968)

59) Schou M, Juel-Nielsen N, Stromgern E, et al:The treatment of manic psychosis by the administration of lithium salts. J Neurol Neurosurg Psychiatry 17:250-260 (1954)

60) Schou M:Lithium in psychiatric therapy and prophylaxis. J Psychiatr Res 6:67-95 (1968)
pubmed

61) Shukula S, Godwin C, Long L, et al:Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 141:1604-1605(1984)

62) Solomon DA, Ryan CE, Keitner GI, et al:A pilot study of lithium carbonate plus diproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 58:95-99 (1997)
pubmed

63) Suppes T, Ruch AJ Jr, Kraemer HG, et al:Treatment algorithm use to optimize management of symptomatic patients with a history of mania. J Clin Psychiatry 59:89-96 (1998)

64) Suppes T, Carabrese JR, Michll PB, et al:Algorithm for the treatment of bipolar manic-depressive illness. Psychopharmacol Bull 31:469-474(1995)

65) Swann AC, Bowden CL, Morris D, et al:Depression during mania treatment response to lithium or diproex. Arch Gen Psychiatry 54:37-42(1997)

66) 田島治, 上島国利:リチウムおよびその他の抗躁薬. 精神治療薬大系, 上島国利ほか(編), 第3巻抗うつ薬, 抗躁薬, 抗パ薬, 漢方薬, pp 112-142, 星和書店, 東京(1997)

67) Takahashi R, Sakuma A, Itoh K, et al:Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Arch Gen Psychiatry 32:1310-1318(1975)

68) 竹崎治彦, 花岡正憲:躁うつ病および症候性うつ状態に対するCarbamazepine(Tegretol)の効果. 精神医学13(2):77-87(1971)

69) Watanabe S, Ishino H, Otsuki S:Double-blind comparison of lithium carbonateand imipramine in the treatment of depression. Arch Gen Psychiatry 32:659-668 (1975)
pubmed

70) 渡辺昌祐:リチウム-基礎と臨床. 医歯薬出版, 東京(1983)

P.214 掲載の参考文献

1) Allgulander C:Dependence on sedative and hypnotic drugs. Acta Psychiatr Scand 270(Suppl):1-102 (1978)
pubmed

2) Balter MB, Manheimer DI, Mellinger GD, et al:Across-national comparison of antianxiety/sedative drug use. Curr Med Res Opinion 8(Suppl 4):5-18(1984)

3) Berger FM:The pharmacological properties of 2-methyl-2-n-propyl-1, 3-propanediol dicarbamate(Miltown), a new interneuronal blocking agent. J Pharmacol Exp Ther 112:413-423(1954)

4) Berger FM, Bradley W:Pharmacological properties of α:B-dihydroxy-γ-(2-methyl-phenoxy)-propane(myanesin). Muscle-relaxing action of myanesin. Lancet i:97 (1947)

5) Danneberg P, Weber KH:Chemical structure and biological activity of diazepines. Br J Clin Pharmacol 16:231S-243S(1983)

6) Eison AS, Temple DL:Buspirone;Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 80(Suppl 33):1-9(1986)

7) English DC:Librium, a new nonsedative neuroleptic drugs;A clinical evaluation. Curr Ther Res 2:88-91(1960)

8) ファイザー製薬:医薬品インタビューフォーム(1996)

9) Harris TH:Methaminodiazepoxide. JAMA 172:1162-1163(1960)

10) Hendley CD, Lynes TE, Berger FM:Effect of 2-methyl, 2-n-propyl-1, 3-propanediol dicarbamate(Miltown)on central nervous system. Proc Soc Biol Med 87:608-610 (1955)

11) Kinross-Wright J, Cohen IM, Knight JA:The management of neurotic and psychotic states with Ro5-0690(Librium). Dis Nerv Syst 21(Suppl 3):23-26(1960)

12) Kletzkin M, Berger FM:Effect of meprobamate on limbic system of the brain. Proc Soc Exp Biol Med 100:681-683(1959)

13) 小林雅文:臨床精神薬理学. 南山堂, 東京(1997)

14) Lemere F:Habit-forming properties of meprobamate(Miltown or Equanil). Arch Neurol Psychiatry 76:205-206(1956)
pubmed

15) 村崎光邦:抗不安薬の臨床用量依存. 精神経誌98:612-621(1996)

16) 村崎光邦:抗不安薬. 抗不安薬, 睡眠薬, 上島国利ほか(編), ppl-268, 星和書店, 東京(1997)

17) 村崎光邦:Tandospironeの基礎と臨床. 臨床精神薬理1:81-92(1998)

18) 成瀬浩:トランキライザーの精神科領域における臨床的意義 . 1. いわゆる"central relazant"について. 日本臨牀 15:2078-2087(1957)

19) Rickels K:Use of anti-anxiety agents in anxious outpatients. Psychopharmacology 58:1-17(1978)

20) Rickels K:Are benzodiazepines over used and abused? Br J Clin Pharmacol 11(Suppl 1):71S-83S (1981)

21) Rickels K, Schweizer E, Case WG, et al:Long-term therapeutic use of benzodiazepines I. Effects of abrupt discontinuation. Arch Gen Psychiatry 47:899-907(1990)

22) Rickels K, Schweizer E, Csanalos I, et al:Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 45:444-450 (1988)
pubmed

23) Salzman C:The APA task force report on benzodiazepine dependence, toxicity, and abuse. Am J Psychiatry 148:151-152(1991)

24) 澤温:抗不安薬. 向精神薬の歴史・基礎・臨床, 上島国利, 村崎光邦, 八木剛平(編), pp 145-167, 星和書店, 東京(1996)

25) Schweizer E, Rickels K, Case WG, et al:Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 47:908-915(1990)

26) 清水宏志, 加藤照文, 荒木美乃ほか:Tandospironeの中枢神経系に対する作用. 基礎と臨床26:1681-1695(1992)

27) Shimizu H, Tatsumoto T, Tanaka H, et al:Serotonergic mechanism in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J pharmacol 59:105-112 (1992)

28) Snyder SH:Drugs and the Brain. WH Freeman and Company, New York(1986)-佐久間照(訳):脳と薬物. 東京化学同人, 東京(1990)

29) Sternbach LH:Benzodiazepine story. J Med Chem 22:1-7(1979)

30) Tobin JM, Bird IF, Boyle DE:Preliminary evaluation of Librium(Ro5-0690)in the treatment of anxiety reactions. Dis Nerv Syst 21(Suppl 3):11-19(1960)

31) Williams M:Mollecular aspects of the action of benzodiazepine and nonbenzodiazepineanxiolytics;A hypothetical allosteric model of the benzodiazepine receptor complex. Prog Neuro-Psychopharmacol Biol Psychiaty 8:209-247(1984)

P.222 掲載の参考文献

1) Ballenger JC:Benzodiazepines. Textbook of Psychopharmacology, Schatberg AF, Nemeroff CB(ed), pp 215-243, American Psychiatric Press, Washington DC(1995)

2) Bellantuono C, Reggi V, Tognoni G, et al:Benzodiazepines;Clinical pharmacology and therapeutic use. Drugs 19:195-219 (1980)

3) Berstein JG:Handbook of Drug Therapy in Psychiatry. 2nd ed, PSG Publishing, Littleton, MA(1988)

4) Bond AJ, Hally DM, Lader MH:Plasma concentrations of benzodiazepines. Br J Clin Psychopharmacol 4:51-56(1977)

5) Cook L, Davidson AB:Effects of behaviorally active drugs in a conflict-punishment procedure in rats. The Benzodiazepines, pp 327-345, Raven, New York(1973)

6) Curry SH:Concentration-effect relationship with major and minor traquilizers. Clin Pharmacol Ther 16:192-197(1974)

7) Dantzer R:Behavioral effects of benzodiazepines;A review. Biobehav Rev 1:71-86 (1977)

8) Dasberg HH, van der Klijn E, Guelen PJR, et al:Plasma concentrations of diazepam and its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clin Pharmacol Ther 15:473-483(1974)

9) DeVane CL, Ware MR, Lydiard RB:Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines;Alprazolam, adinazolam, and clonazepam. Psychopharmacol Bull 27(4):463-473(1991)

10) Eison AS, Temple DL:Buspirone;Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 80(Suppl 33):1-9(1986)

11) File SE:Preclinical studies of the mechanisms of anxiety and its treatment. Neurobiology of Anxiety Disorders, Ballenger JC(ed), pp 31-48, Wiley-Liss, New York(1990)

12) Geller I, Seifter J:The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacology(Berl)1:482-492(1960)

13) Gozlan H, El Mestikawy S, Pichat L, et al:Identification of presynaptic serotonin autoreceptors using a new ligand;aH-PAT. Nature 305:140-142(1983)

14) Graeff FG, Silveria Filho NG:Behavioral inhibition induced by electrical stimulation of the median raphe nucleus of the rat. Physiol Behav 21:477-484(1978)

15) Gray JA:The Neuropsychology of Anxiety;An enquiry into the functions of the septo-hippocampal system. Clarendon, Oxford, England(1982)

16) Greenblatt DJ, Divoll M, Abernethy DR, et al:Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8:233-253(1983)

17) Greenblatt DJ, Shader RI:Benzodiazepines in Clinical Practice. Raven, New York(1974)

18) Haefely W:Behavioral and pharmacological aspects of drugs used in anxiety and related states. Psychopharmacology;A generation of progress, Lipton MA, DiMascio A, Killam KF(ed), pp 1359-1374, Raven, New York(1978)

19) Harvey SC:Hypnotics and Sedatives. Goodman and Gilman's the pharmacological basis of therapeutics, Gilman AC, Goodman LS, Rall TW(ed), 7thed, pp 339-371, Macmillan, New York(1985)

20) Hsiao JK, Potter WZ:Mechanism of action of antipanic drugs. Clinical Aspects of Panic Disorder, Ballenger JC(ed), pp 297-317, Wiley-Liss, New York(1990)

21) 石郷岡純:睡眠薬の薬理作用. 病態生理14(11):894-900(1995)

22) Kaneyuki H, Yokoo H, Tsuda A, et al:Psychological stress increases dopamine turnover selectivery in mesoprefrontal dopamine neurons of rats;Reversal bydiazepam. Brain Res 577:154-161(1991)

23) Kangas L, Kanto J, Lehtinen V, et al:Long-term nitrazepam treatment in psychiatric outpatients with insomnia. Psychopharmacology(Berl)63:63-66(1979)

24) 川北幸男, 古塚大介, 平山栄一:抗不安薬. 精神科領域における薬物療法, 精神科MOOK, 八木剛平(編), 増刊1, pp 122-134, 金原出版, 東京(1992)

25) Kilts CD, Commissaris RL, Rech RH:Comparison of anti-conflict drug effects in three experimental animal models of anxiety. Psychopharmacology(Berl)74:290-295 (1981)
pubmed

26) 栗山欣弥, 廣内雅明, 中安博司:GABA受容体の分子薬理学. 精神進歩37:377-384 (1993)

27) Mendelson WB, Gillin JC, Wyatt RJ:Human Sleep and its Disorders. Plenum, New York(1977)

28) 水野佳子, 射場一彦, 中塚巖ほか:SM-3997のラットにおける代謝. 基礎と臨床26(5):1885-1901(1992)

29) 村崎光邦:抗不安薬, 睡眠薬の薬物相互作用-特にbenzodiazepine系薬物を中心として. 精神科治療学10(7):743-756(1995)

30) 村崎光邦:BZの作用機序. 抗不安薬, 睡眠薬. 精神治療薬大系, 上島国利, 村崎光邦, 八木剛平(編), pp 114-129, 星和書店, 東京(1997)

31) 村崎光邦, 森温理, 遠藤俊吉ほか:各種神経症に対する新規向精神薬Tandospirone(SM-3997)の臨床評価-Diazepamを対照とした第III相試験 . 臨床評価2:295-329(1992)

32) 村崎光邦:セロトニン作動性抗不安薬の作用機序. 日病薬誌33(3):299-306(1997)

33) Nakamura K, Goto F, Ray WA, et al:Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402-408(1985)

34) 中島光好, 金丸光隆:新しい非Benzodiazepine系抗不安薬SM-3997の臨床第I相試験. 基礎と臨床26(10):4143-4165(1992)

35) Olsen RW, Tobin AJ:Molecular biology of GABAA receptors. FASEB J 4:1469-1480 (1990)
pubmed

36) Puia G, Santi M, Vicini S, et al:Neurosteroids act on recombinant human GABAA receptors. Neuron 4:759-765(1990)

37) Sepinwall J, Cook L:Behavioral pharmacology of anti-anxiety drugs. Handbook of Psychopharmacology, Iversen LL, Iversen SD, Snyder SH(ed), Vol 13, pp 345-393, Plenum, New York(1978)

38) Shimizu H, Tatsuno T, Tanaka H, et al:Serotnergic mechanism in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J pharmacol 59:105-112(1992)

39) 清水宏志, 加藤照文, 荒木美乃ほか:Tandospironeの中枢神経系に対する作用. 基礎と臨床26(5):1681-1695(1992)

40) Shimizu H, Kumasaka Y, Tanaka H, et al:Anticonflict action of tandospirone in a modified Geller-Seifter conflict test in rats. JPn J pharmacol 58:283-289(1992)

41) Shimizu H, Hirose A, Tatsuno T, et al:Pharmacological properties of SM-3997;A new anxioselective anxiolytic candidate. Jpn J Pharmacol 45:493-500(1987)

42) Simon P, Soubrie P:Behavioral studies to differenciate anxiolytic and sedative activity of the traquilizing drugs. Modern Problems in Pharmacopsychiatry, Boissier JR(ed), Vol 14, pp 99-142, Karger, Basel(1979)

43) Sohn DR, Musaka M, Ishizaki T, et al:Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences indiazepam pharmacokinetics. Clin Pharmacol Ther 52:160-169(1992)

44) Study RE, Barker JL:Diazepam and pentobarbital;Function analysis reveals different mechanisms for potenciation of gamma-aminobutyric acid responses incultured central neurons. Proc Natl Acad Sci USA 78(11):7180-7184(1981)

45) 田所作太郎:サルのsocially induced supressionに及ぼす薬物の影響. 日医師会誌58:1227-1232 (1967)

46) 田所作太郎:行動薬理学からみた病態モデル. 精神医学25:229-234(1983)

47) Tanaka H, Shimizu H, Kumasaka Y, et al:Autoradiographic localization and pharmacological characterization of tandospirone binding sites in the rat brain. Brain Res 546:181-189 (1991)
pubmed

48) 田中正敏, 吉田眞美, 横尾秀康ほか:不安と脳内ノルアドレナリン神経系. 臨床精神医学21(4):585-603(1992)

49) 田中正敏:ベンゾジアゼピン系抗不安薬. 精神医学36(1):43-48(1994)

50) Tatsuno T, Shimizu H, Hirose A, et al:Effects of putative anxiolytic SM-33970n central monoaminergic systems. Pharm Biochem Behav 32:1049-1055(1989)

51) Taylor DP:Serotonin agents in anxiety. Ann NY Acad Sci 600:545-556, discussion 556-557 (1990)

52) Thiebot MH, Soubrie P:Bihavioral pharmacology of the benzodiazepines. Benzodiazepines Molecular Biology to Clinical Practice, Costa E(ed), pp 67-92, Raven, New York(1983)

53) Thiebot MH, Soubrie P, Hamon M, et al:Evidence against the involvement of serotonergic neurons in the antipunishment activity of diazepam in the rat. Psychopharmacology 82:355-359(1984)

54) Vogel JR, Beer B, Clody DE:A simple and reliable conflict procedure for testing antiangiety agents. Psychopharmacologia 21:1-7(1971)

55) Zorumski CF, Isenberg KE:Insights into the structure and function of GABA benzodiazepine receptors;Ion channels and psychiatry. Am J Psychiatry 148:162-173 (1991)
pubmed

P.231 掲載の参考文献

1) Andersch S, Rosenberg NK, Kullingsjo H, et al:Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder;A Scandinavian multicenter study. Acta Psychiatr Scand 231(Suppl 365):18-27(1991)

2) Aronson TA, Shukla S, Hirschowitz J:Clonazepam treatment of five lithium-refractory patients with bipolar disorder. Am J Psychiatry 146:77-80(1989)

3) Bertilsson L, Henthorn TK, Sanz E, et al:Importance of genetic factors in the regulation of diazepam metabolism;Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355(1989)

4) Birkenhager TK, Moleman P, Nolen WA:Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol 10:181-195(1995)

5) Fleischhacker WW, Roth SD, Kane JM:The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 10:12-21(1990)

6) Furukori H, Otani K, Yasui N, et al:Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 18:364-369(1998)

7) Greenblatt DJ, Shader RI, Abernethy DR:Current status of benzodiazepines (first of two parts). N Engl J Med 309:354-358(1983)

8) Greenblatt DJ, Harmatz JS, Shader RI:Plasma alprazolam concentrations;Relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 50:715-722 (1993)
pubmed

9) Herman JB, Rosenbaum JF, Brotman AW:The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 7:175-178(1987)

10) Lingjaerde O:Benzodiazepines in the treatment of schizophrenia;An updated survey. Acta Psychiatr Scand 84:453-459(1991)

11) 村崎光邦:Tandospironeの基礎と臨床. 臨床精神薬理1:81-92(1998)

12) Otani K, Horiuchi M, Kondo T, et al:Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 158:850-853(1991)

13) Otani K, Yasui N, Kaneko S, et al:Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. Neuropsychopharmacology 16:8-14(1997)

14) Owen RT, Tyrer P:Benzodiazepine dependence;A review of the evidence. Drugs 25:385-398 (1983)
pubmed

15) Sachs GS, Rosenbaum JF, Jones L:Adjunctive clonazepam for maintenance treatment of bipolar disorder. J Clin Psychopharmacol 10:42-47(1990)

16) Sasa H, Otani K, Kondo T, et al:Alprazolam withdrawal symptoms. Br J Psychiatry 157:154-155 (1990)
pubmed

17) Sotaniemi EA, Arranto AJ, Pelkonen O, et al:Age and cytochrome P450-linked drug metabolism in humans;An analysis of 226 subjects with equal histopathological conditions. Clin Pharmacol Ther 61:331-339(1997)

18) Ungvari GS, Leung CM, Wong MK, et al:Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand 89:285-288(1994)

19) Yasui N, Otani K, Kaneko S, et al:A kinetic and dynamic study of oral diazepam with and without erythromycin in humans;In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59:514-519 (1996)

20) Yasumori T, Nagata K, Yang SK, et al:Cytochrome P450 mediated metabolism of diazepam in human and rat;Involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 3:291-301 (1993)

P.239 掲載の参考文献

1) Aarskog D:Association between maternal intake of diazepam and oral clefts. Lancet 2:921 (1975)
pubmed

2) Abbruzzese A, Swanson J:Jaundice aftre therapy with chlordiazepoxide hydrochloride. N Engl J Med 275:321-322(1965)

3) Abernethy DR, Greenblatt DJ, Shader RI:Treatment of diazepam withdrawal syndrome with propranolol. Ann Intern Med 94:354-355(1981)

4) Athinarayanan P, Pierog SH, Nigam SK, et al:Chlordiazepoxide withdrawal in the neonate. Am J Obstet Gynecol 124:212-213(1976)

5) Barrett JS, Hey EB Jr:Ventricular arrhythmias associated with the use of diazepam for cardioversion. JAMA 214:1323-1324(1970)

6) Barten WH:Toxic psychosis with transient dysmnestic syndrome following withdrawal from valium. Am J Psychiatry 121:1210-1211(1965)

7) Bracken MB, Holford TR:Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 58:336-344(1981)

8) Brandt R:Passage of diazepam and desmethyldiazepam into breast milk. Arzneimittelforschung 26:454-457(1976)

9) Celada A, Herreros V, Rudolf H:Thrombocytopenic purpura during treatment with Librax. Br Med J 1:268(1977)
pubmed

10) Cimo PL, Pisciotta AV, Desai RG, et al:Detection of drug-dependent antibodies by the 51Cr platelet lysis test;Documentation of immune thrombocytopenia induced by diphenylhydantoin, diazepam, and sulfisoxazole. Am J Hematol 2:65-72 (1977)
pubmed

11) Clarke PR, Eccersley PS, Frisby JP, et al:The amnesic effect of diazepam(Valium). Br J Anaesth 42:690-697(1970)

12) Clergue F, Desmonts JM, Duvaldestin P, et al:Depression of respiratory drive by diazepam as premedication. Br J Anaesth 53:1059-1063(1981)

13) Cohn MA:Hypnotics and the control of breathing;A review. Br J Clin Pharmacol 16(Suppl 2):245S-250S(1983)

14) Cole AP, Hailey DM:Diazepam and active metabolite in breast milk and their transfer to the neonate. Arch Dis Child 50:741-742(1975)

15) Cowen PJ, Nutt DJ:Abstinence symptoms after withdrawal of tranquillising drugs;Is there a common neurochemical mechanism? Lancet ii:360-362(1982)

16) Crombie DL, Pinsent RJ, Fleming DM, et al:Letter;Fetal effects of tranquilizers in pregnancy. N Engl J Med 293:198-199(1975)

17) Cunningham ML:Acute hepatic necrosis following treatment with ami-triptyline and diazepam. Br J Psychiatry 111:1107-1109(1965)

18) Czeizel A:Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod Toxicol 1:183-188(1987)

19) Czeizel A:Letter;Diazepam, phenytoin, and aetiology of cleft lip and/or cleft palate. Lancet i:810 (1976)
pubmed

20) Czeizel A, Lendvay A:In-utero exposure to benzodiazepines. Lancet i:628(1987)

21) Czeizel A, Metneki J:Evaluation of counselling for pregnant women exposed to potentially hazardous environmental factors. Acta Paediatr Hung 26:175-185(1985)

22) Czeizel A, Pazsy A, Pusztai J, et al:Aetiological monitor of congenital abnormalities;A case-control surveillance system. Acta Paediatr Hung 24:91-99(1983)

23) Czeizel A, Szentesi I, Szekeres I, et al:Pregnancy outcome and health conditions of offspring of self-poisoned pregnant women. Acta Paediatr Hung 25:209-236 (1984)
pubmed

24) Divoll M, Greenblatt DJ, Lacasse Y, et al:Benzodiazepine overdosage;Plasma concentrations and clinical outcome. Psychopharmacology(Berl)73:381-383(1981)

25) Erkkola R, Kanto J:Diazepam and breast-feeding. Lancet i:1235-1236(1972)

26) Fang MH, Ginsberg AL, Dobbins WO:Cholestatic jaundice associated with flurazepam hydrochloride. Ann Intern Med 89:363-364(1978)

27) Finkle BS, McCloskey KL, Goodman LS:Diazepam and drug-associated deaths;A survey in the United States and Canada. JAMA 242:429-434(1979)

28) Fontaine R, Annable L, Beaudry P, et al:Efficacy and withdrawal of two potent benzodiazepines;Bromazepam and lorazepam. Psychopharmacol Bull 21:91-92 (1985)
pubmed

29) Forster A, Gardaz JP, Suter PM, et al:Respiratory depression by midazolam and diazepam. Anesthesiology 53:494-497(1980)

30) Ghoneim MM, Mewaldt SP, Hinrichs JV:Behavioral effects of oral versus intravenous administration of diazepam. Pharmacol Biochem Behav 21:231-236 (1984)
pubmed

31) Gillberg C:"Floppy infant syndrome" and maternal diazepam. Lancet ii:244(1977)

32) Gitlin MJ:Psychotropic medications and their effects on sexual function;Diagnosis, biology, and treatment approaches. J Clin Psychiatry 55:406-413(1994)

33) Greenblatt DJ, Allen MD:Toxicity of nitrazepam in the elderly;A report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol 5:407-413 (1978)
pubmed

34) Haerten K, Poettgen W:Leukopenie nach Benzodiazepin-Derivaten. Med Welt 26:1712 (1975)

35) Hall RC, Joffe JR:Aberrant response to diazepam;A new syndrome. Am J Psychiatry 129:738-742 (1972)
pubmed

36) Hall RC, Zisook S:Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 11(Suppl 1):99S-104S(1981)

37) Haram K:"Floppy infant syndrome" and maternal diazepam. Lancet ii:612-613 (1977)

38) Hartz SC, Heinonen OP, Shapiro S, et al:Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 292:726-728(1975)

39) Hollister LE, Motzenbecker FP, Degan RO:Withdrawal reactions from chlordiazepoxide(Librium). Psychopharmacologia 2:63-68(1961)

40) Hughes J M:Failure to ejaculate with chlordiazepoxide. Am J psychiatry 121:610-611 (1964)
pubmed

41) Keshavan MS, Crammer JL:Clonidine in benzodiazepine withdrawal. Lancet i:1325-1326 (1985)
pubmed

42) Klein E, Uhde TW, Post RM:Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal. Am J Psychiatry 143:235-236(1986)

43) Kullander S, Kallen B:A prospective study of drugs and pregnancy I. Psychopharmaca. Acta Obstet Gynecol Scand 55:25-33(1976)

44) Lader M:Benzodiazepine dependence. Prog Neuropsychopharmacol Biol Psychiatry 8:85-95 (1984)
pubmed

45) Lader M, Petursson H:Long-term effects of benzodiazepines. Neuropharmacology 22:527-533 (1983)
pubmed

46) Lydiard RB, Howell EF, Laraia MT, et al:Sexual side effects of alprazolam. Am J Psychiatry 144:254-255(1987)

47) Mazzi E:Possible neonatal diazepam withdrawal;A case report. Am J Obstet Gynecol 129:586-587(1977)

48) McKay AC, Dundee JW:Effect of oral benzodiazepines on memory. Br J Anaesth 52:1247-1257(1980)

49) Milkovich L, van den Berg BJ:Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. N Engl J Med 291:1268-1271(1974)

50) Model DG:Nitrazepam induced respiratory depression in chronic obstructive lung disease. Br J Dis Chest 67:128-130(1973)

51) Model DG, Berry DJ:Effects of chlordiazepoxide in respiratory failure due tochronic bronchitis. Lancet ii:869-870 (1974)

52) Munjack DJ, Crocker B:Alprazolam-induced ejaculatory inhibition [letter]. J Clin Psychopharmacol 6:57-58(1986)

53) Munjack DJ, Kanno PH:Retarded ejaculation;A review. Arch Sex Behav 8:139-150 (1979)
pubmed

54) 村崎光邦:BZの副作用. 精神治療薬大系, 上島国利, 村崎光邦, 八木剛平(編), 第4巻, pp 146-238, 星和書店, 東京(1997)

55) Murphy SM, Owen RT, Tyrer PJ:Withdrawal symptoms after six weeks'treatment with diazepam. Lancet ii:1389(1984)

56) Nutt D, Hackman A, Hawton K:Increased sexual function in benzodiazepine withdrawal. Lancet ii:1101-1102(1986)

57) Patrick MJ, Tilstone WJ, Reavey P:Diazepam and breast-feeding. Lancet i:542-546 (1972)
pubmed

58) Petursson H, Lader MH:Withdrawal from long-term benzodiazepine treatment. Br Med J Clin Res Ed 283:643-645(1981)

59) Rementeria JL, Bhatt K:Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 90:123-126(1977)

60) Reynolds R, Lloyd DA, Slinger RP:Cholestatic jaundice induced by flurazepam hydrochloride. Can Med Assoc J 124:893-894(1981)

61) Riley AJ, Riley EJ:Cyproheptadine and antidepressant-induced anorgasmia. Br J Psychiatry 148:217-218 (1986)
pubmed

62) Risch SC, Groom GP, Janowsky DS:Interfaces of psychopharmacology and cardiology-Part two. J Clin Psychiatry 42:47-59(1981)

63) Rosenberg L, Mitchell AA, Parsells JL, et al:Lack of relation of oral clefts todiazepam use during pregnancy. N Engl J Med 309:1282-1285(1983)

64) Rowlatt RJ:Effect of maternal diazepam on the newborn. Br Med J 1:985(1978)
pubmed

65) Roy Byrne P, Vittone BJ, Uhde TW:Alprazolam-related hepatotoxicity. Lancet ii:786-787 (1983)

66) Safra MJ, Oakley GP Jr:Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet ii:478-480(1975)
pubmed

67) Sangal R:Inhibited female orgasm as a side effect of alprazolam. Am J Psychiatry 142:1223-1224 (1985)
pubmed

68) Saxen I:Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 4:37-44(1975)

69) Saxen I, Saxen L:Letter;Association between maternal intake of diazepam and oral clefts. Lancet ii:498 (1975)

70) Scharf MB, Khosla N, Brocker N, et al:Differential amnestic properties of short-and long-acting benzodiazepines. J Clin Psychiatry 45:51-53 (1984)

71) Segraves RT:Treatment of premature ejaculation with lorazepam. Am J Psychiatry 144:1240 (1987)
pubmed

72) Shimoda K, Jerling M, B6ttiger Y, et al:Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol (in press)

73) Speight AN:Floppy-infant syndrome and maternal diazepam and/or nitrazepam. Lancet ii:878(1977)
pubmed

74) Tobin JM, Lewis NDC:New psychotherapeutic agent, chlordiazepoxide. JAMA 174:1242-1249(1960)

75) Tyrer P, Owen R, Dawling S:Gradual withdrawal of diazepam after long-term therapy. Lancet i:1402-1406 (1983)
pubmed

76) Tyrer P, Rutherford D, Huggett T:Benzodiazepine withdrawal symptoms and propranolol. Lancet i:520-522 (1981)
pubmed

77) Tyrer PJ, Seivewright N:Identification and management of benzodiazepine dependence. Postgrad Med J 60(Suppl 2):41-46(1984)

78) Vyas I, Carney MW:Diazepam withdrawal fits. Br Med J 4:44(1975)
pubmed

79) Ward S, Meecham J:Reversible agranulocytosis due to meprobamate. Postgrad Med J 62:499-500(1986)

80) Winokur A, Rickels K, Greenblatt DJ, et al:Withdrawal reaction from longterm, low-dosage administration of diazepam. A double-blind, placebo-controlled case study. Arch Gen Psychiatry 37:101-105(1980)

81) Woods JH, Katz JL, Winger G:Abuse liability of benzodiazepines. Pharmacol Rev 39:251-413 (1987)
pubmed

P.250 掲載の参考文献

1) Adams JB, Pyke RE, Costa J, et al:A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 15:428-434(1995)

2) 赤池紀扶:GABAA 受容体. 生体の科学48:342-345(1997)

3) Britton KT, Morgan J, Rivier J, et al:Chlordiazepoxide attenuates response suppression induced by corticotropin releasing factor in the conflict test. Psychopharmacology 86:170-174(1985)

4) Chang CP, Pearse RV, O'Connell S, et al:Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 11:1187-1195(1993)

5) Chen YL, Mansbach RS, Winter SM, et al:Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolol 2, 3-d] ryrimidine;A centrally active corticotropin-releasing factor 1 receptor antagonist. J Med Chem 40:1749-1754(1997)

6) de Montigny C:Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 46:511-517(1989)

7) Dockray GJ:Immunochemical evidence of cholecystokinin-like peptide in brain. Nature 264:568-570(1976)

8) File SE:Anxiolitic action of a neurokinin 1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 58:747-752(1997)

9) Haefely W, Martin JR, Schoch P:Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 11:452-456(1990)

10) Harro J, Vasar E:Cholecystokinin-induced anxiety;How is it reflected in studies on exploratory behaviour? Neurosci Biobehav Rev 15:473-477(1991)

11) 工藤義雄, 工藤喬:向精神薬開発の最近の動向(1)-抗不安薬. Jpn J Psychopharmacol 15:75-86(1995)

12) Maggi CA:The mammalian tachykinin receptors. Gen Pharmacol 26:911-944(1995)

13) 松崎一葉, 諸治隆嗣:不安における脳内神経ペプチドの役割-特にCorticotropin releasing factor(CRF)について. 神経精神薬理10:677-685(1988)

14) Menzaghi F, Howard RL, Heinrichs SC, et al:Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J pharmacol Exp Ther 269:564-572 (1994)
pubmed

15) Ravard S, Dourish CT:Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271-273 (1990)
pubmed

16) Schulz DW, Mansbach RS, Sprouse J, et al:CP-154, 526;A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477-10482(1996)

17) Shader RI, Greenblatt DJ:The pharmacotherapy of acute anxiety;A miniupdate. Psychopharmacology;The fourth generation of progress, Bloom FE, Kupfer DJ(ed), pp 1341-1348, Raven Press, New York(1995)

18) Singh L, Field MJ, Hughes J, et al:The behavioural properties of CI-988, a selective cholecystokinin B receptor antagonist. Br J Pharmacol 104:239-245(1991)

19) Valentino RJ, Foote SL, Aston-Jones G:Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res 270:363-367(1983)

20) Vaughan J, Donaldson C, Bittencourt J, et al:Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287-292 (1995)
pubmed

21) Wank SA, Pisegna JR, de Weerth A:Brain and gastrointestinal cholecystokinin receptor family;Structure and functional expression. Proc Natl Acad Sci USA 89:8691-8695 (1992)
pubmed

22) Woodruff GN, Hughes J:Cholecystokinin antagonist. Annu Rev Pharmacol Toxicol 31:469-501(1991)

23) Yakushiji T, Fukuda T, Oyama Y, et al:Effects of benzodiazepine and nonbenzodiazepine compounds on the GABA-induced response in frog isolated sensory neurons. Br J Pharmacol 98:735-740(1989)

24) Yasumatsu H, Morimoto Y, Yamamoto Y, et al:The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Br J Pharmacol 111:1170-1178 (1994)
pubmed

P.262 掲載の参考文献

1) Breimer DD, Jochemsen R:Pharmacokinetics of hypnotic drugs. Pharmacologyof Sleep, Wheatley D(ed), pp 135-152, Raven Press, New York(1981)

2) Ford DE, Kamerow DB:Epidemiologic study of sleep disturbances and psychiatric disorders. JAMA 262:1479-1514(1989)

3) Hartmann E:The Sleeping Pill. Yale University Press, London(1978)

4) 菱川泰夫(編・著):睡眠の病態. 精神科MOOK 21, 金原出版, 東京(1988)

5) 石崎高志:チトクローム450(cytochromes P450)の遺伝的多型性と向精神薬の代謝. 臨床精神医学26(2):137-152(1997)

6) Kales A, Vgontzas AN, Bixler EO:Hypnotic drugs. Pharmacology of Sleep, Kales A(ed), pp 345-385, Springer, Berlin(1995)

7) 菅野道:新しい睡眠薬の臨床. 臨床神経医学19:197-205(1990)

8) Kay DC, Blackburn AB, Buckingham JA, et al:Human pharmacology of sleep. Pharmacology of Sleep, William RL, Karacan I(ed), pp 83-210, John Wiley & Sons, New York(1976)

9) Lugaresi E, Cirignotta F, Zucconi M, et al:Good and poor sleepers;An epidemiological survey of the San Marino population. Sleep/Wake Disorders, Guilleminault C, Lugaresi E(ed), pp 1-12, Raven Press, New York(1993)

10) 村崎光邦:睡眠薬. 精神治療薬大系, 上村国利, 村崎光邦, 八木剛平(編), 第4巻抗不安薬・睡眠薬, pp 269-338, 星和書店, 東京(1997)

11) 中沢洋一, 内村直尚, 坂本哲郎ほか;高齢者の睡眠障害の実態調査と病態の解明. 厚生省精神・神経疾患委託研究:睡眠障害の診断・治療および疫学に関する研究. 平成7年度研究報告書, pp 53-62(1996)

12) NCSDR:National Commission of Sleep Disorders Research:Wake Up America;A National Sleep Alert, NIMH, USA(1993)

13) 日本睡眠学会(編):睡眠学ハンドブック. 朝倉書店, 東京(1994)

14) 白川修一郎, 石郷岡純, 石束嘉和ほか:全国総合病院外来における睡眠障害と睡眠習慣の実態調査. 厚生省精神・神経疾患委託研究;睡眠障害の診断・治療および疫学に関する研究, 平成7年度研究報告書, pp 7-23(1996)

15) WPA:World Psychiatric Association-大熊輝雄・監訳):不眠症の診断と治療Pergamon, Chicago(The Up John Co)(1992)

P.271 掲載の参考文献

1) Bartholini G:Growing aspects of hypnotic drugs. Imidazopyridine and Sleep Disorders, Langer SZ, Moreselli PL(ed), pp 1-9, Raven Press, New York(1988)

2) Benavides J, Peny B, Dubois A, et al:In vivo interaction of zolpidem with central benzodiazepine (BZD) binding site. As labelled by [3H]Ro15 in therat brain. Preferential affinity of zolpidem for the ω1(BZD1)subtype. J Pharmacol Exp Ther 245:1033-1041(1988)

3) Besnard F, Avenet P, Itier V, et al:GABA-A receptor subtypies and mechanism of action of zolpidem. Zolpidem;An update of its pharmacological properties and therapeutic place in the management of insomnia, Freeman H(ed), pp 21-31, Elesevier, New York(1996)

4) Bowery NG, Knott C, Moratalla R, et al:GABA-B receptor and their heterogeneity. GABA and Benzodiazepine Receptor, Biggio G, Costa E(ed), Vol 146, pp 127-139, Raven Press, New York(1990)

5) Braestrup C, Nielsen M:[3H]Propyl-β-carboline-3-carboxylate([3H]-PrCC)as a selective radio-ligand for the BZ-1 benzodiazepine receptor subclass. J Neurochem 37:333-341(1981)

6) Burn JP:Zopiclolle, a cyclopyrrolone hypnotic;Review of properties. Pharmacol Biochem Behav 28:831-832 (1988)

7) Costa E, Guidotti A:Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol Toxicol 19:531-545(1981)

8) Costa E, Guidotti A:Diazepam binding inhibitor(DBI);A peptide with multiple biological actions. Life Sci 49:325-344 (1991)
pubmed

9) Depoortere H, Zivkovic B, Lioyd K, et al:Zolpidem, a novel nonbenzodiazepine hypnotic I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649-658(1986)

10) Enna SJ, Karbon EW:GABA receptor. An Over-view;Receptor biochemistry and methodology, Oslen RW, Venter JC(ed), Vol 5, pp 41-56, Alan R Liss, New York(1986)

11) Enna SJ, Mohler H:GABA receptors and their association with benzodiazepines recognition site. Psycopharmacology;The third generation of progress, Meltzer HY(ed), pp 265-272, Raven Press, New York(1987)

12) Gee KW, Bolger MB, Brinton RE, et al:Steroid modulation of the chlorideionophore in rat brain. J Pharmacol Exp Ther 246:803-812(1988)

13) Graham DF, Bernard C, Faure SZ, et al:GABA-A receptor subtype diversity;Implication for new generation hypnotic drug. Sleep 19:43-45(1996)

14) Haefly W, Kyburt E, Gerecke M, et al:Recent advances in the molecular pharmacology of benzodiazepine receptors and in the stracture-activity relationship of their agonists and antagonists. Adv Drug Res 14:165-322(1985)

15) Haefely W:Benzodiazepine receptor and ligands;Structural and functional differences. Benzodiazepines;Current concept, Hindmarch I, Beaumont G, Brondon S, et al(ed), pp 1-18, John Wiely & Sons, New York(1990)

16) Haefely WE, Martin JR, Richards JG, et al:The multiplicity of action of benzodiazepine receptor ligands. Can J psychiatry 38:102-108 (1993)

17) Hamill OP:Activation of multiple conductance state chloride channels in spinal neurons by glicine and GABA. Nature 305:805-808(1983)

18) Harrison NL, Majewska MD, Harrington JW, et al:Structure activity relationships for steroid interaction with GABA receptor complex. J Pharmacol Exp Ther 241:346-353(1987)

19) Ito Y, Kuriyama K:Some properties solubilized GABA receptor. Brain Res 236:351-356 (1982)
pubmed

20) Javanovic UJ, Dreyfus JF:Polygraphical sleep recording in insomniac patient sunder zopiclone or nitrazepam. Pharmacology 27(Suppl 2):136-145(1983)

21) 菅野道, 渡辺洋文, 中込和之ほか:健康成人の夜間睡眠及び翌日の精神機能に及ぼすZolpidemとTriazolamの影響. I 終夜睡眠ポリグラフによる検討. 神経精神薬理15:589-602(1993)

22) 小林利男, 木内祐二, 清水浩光ほか:ヒト死後脳のベンゾジアゼピン受容体に関する研究. 精薬療基金研年報20:113-120(1989)

23) Langer SZ, Arbilla S:Imidazopyridine as a tool for the characterization of benzodiazepines;A proposal classification as omega receptor subtypes. Pharmacol Biochem Behav 29:763-769(1988)

24) McGeer PF, McGeer EG:Amino acid neurotransmitters. Basic Neurochemistry, Sigel GJ, Albert RW, Agranoff BW, et al(ed), pp 233-252, Raven Press, New York(1981)

25) Mendelson WB, Martin JV, Perlis M, et al:Sleep and benzodiazepine receptor subtypes. J Neural Trans 70:329-336(1987)

26) Mo1er H, Okada T:Benzodiazepine receptor;Demonstration in the central nervous system. Science 198:848-851(1977)

27) Moler WE:New trend in benzodiazepine research. Drug Today 9:649-663(1988)

28) Muller WE:Pharmacology of the GABAergic/benzodiazepine system. Pharmacology of Sleep, Kales A(ed), pp 211-242, Springer, Berlin(1995)

29) Nicholson AN, Marks J:Insomnia. MTP Press, Boston(1983)

30) Oslen RW:GABA-drug interactions. Prog Drug Res 31:224-238(1987)

31) Oslen RW, Tobin AJ:Molecular biology of GABA-A receptors. FASEB J 4:1469-1480 (1990)

32) Paul SM:GABA and glycine. Psychopharmacology;The fourth generation of progress, Bloom FE, Kupher DJ(ed), pp 87-94, Raven Press, New York(1995)

33) Polc P, Laurent JP, Schershlicht, et al:Electorophysiological studies on the specific benzodiazepine antagonist Ro 15-1788. Naunyn Schmiedebergs Arch Pharmacol 316:317-325(1981)

34) Polc P, Bonetti EP, Schaffner R, et al:A three-state model of the benzodiazepine receptor explains the interaction between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizer, β-carbolines and phenobarbitone. Naunyn Schmiedebergs Arch Pharmacol 321:260-264(1982)

35) Pritchett DB, Luddens H, Seeburg P:Type-I and type-II GABA-A benzodiazepine receptors produced in transfected cells. Science 245:1389-1392 (1989)

36) Puia G, Santi M, Vicini S, et al:Neurosteroid acts on recombinant human GABA-A receptors. Neuron 4:759-765(1990)

37) Rall TW:Hypnotics and sedatives. Ethanol;The pharmacological basis of therapeutics, 8th edition, Gilman AG, Rall TW, Nies AS, et al(ed), pp 345-382, Pergamon Press, New York(1990)

38) Robert E, Freankel S:γ-Aminobutyric acid in brain;Its formation from gulutamic acid. J Biolumin Chemilumin 187:55-63(1950)

39) Sieghart W:Benzodiazepine receptors;Multiple receptors or multiple conformations. J Neural Transm 63:191-208(1985)

40) Simmonds MA:Physiological and pharmacological characterization of the action of GABA. Actions and Interactions of GABA and Benzodiazepines, Bowery NG(ed), pp 27-43, Raven Press, New York(1984)

41) 白川修一郎, 石郷岡純, 石束嘉和ほか:全国総合病院外来における睡眠障害と睡眠習慣の実態調査. 厚生省精神・神経疾患研究委託費睡眠障害の診断・治療および疫学に関する研究, 平成7年度研究報告書, pp 7-19(1996)

42) Skeritti JH, Willow M, Johnston GAR:Diazepam enhancement of low affinity GABA binding to rat brain membranes. Neurosci Lett 29:63-67(1982)

43) Speth RC, Wastek GJ, Yamamura HI:Benzodiazepine receptors;Temperature dependence 3H-flunitrazepam binding. Life Sci 24:351-358(1978)

44) Squires RF, Brasetrup C:Benzodiazepine receptors in rat brain. Nature 266:732-734 (1977)

45) Ticku MK, Maksay G:Minireview. Convulsant/depressant site of action at the allosteric benzodiazepine-GABA receptor-ionophore complex. Life Sci 33:2363-2375 (1983)

46) Ueno E, Kuriyama K:Phospholipid and benzodiazepine recognition site of brain synaptic membranes. Neuropharmacology 20:1169-1176(1981)

47) 山口成良, 清田吉和, 久保田陽介ほか:ベンゾジアゼピン系とシクロピロロン系睡眠薬のネコの海馬律動ならびに睡眠覚醒周期に及ぼす影響についての比較研究. 精薬療基金研年報22:27-33(1991)

P.280 掲載の参考文献

1) Boivin DB, Montplaisir J, Lambert C:Effects of bromocriptine in human narcolepsy. Clin Neurophamacol 16(2):120-126(1993)

2) Bonnet MH, Arand DL:Chronic use of triazolam in patients with periodic leg movements, fragmented sleep and daytime sleepiness. Aging(Milano)3(4):313-324 (1991)
pubmed

3) Brodeur C, Montplaisir J, Marinier R:Treatment of restless legs syndrome and periodic movements during sleep with L-dopa;A double-blind controlled study. Neurology 38(12):1845-1848(1988)

4) Callaghan N:Restless legs syndrome in uremic neuropathy. Neurology 16(4):359-361 (1966)
pubmed

5) Coleman RM, Miles LE, Guilleminault C, et al:Sleep-wake disorders in the elderly;Polysomnographic analysis. J Am Geriatr Soc 29(7):289-296(1981)

6) Coleman RM:Periodic movements in sleep(nocturnal myoclonus)and restless legs syndrome. Sleeping and Waking Disorders;Indications and techniques. Guilleminault C(ed), pp 265-295, Addison-Wesley, Menlo-Park(1982)

7) Dahlitz M, Alvarez B, Vignau J, et al:Delayed sleep phase syndrome response to melatonin. Lancet 337(8750):1121-1124(1991)

8) Diagnostic Classification Steering Comittee, Thorpy MJ(Chairman):International Classification of Sleep Disorders;Diagnostic and coding manual. American Sleep Disorders Association, Rochester, Minesota(1990)-日本睡眠学会診断分類委員会(訳):睡眠障害国際分類. 診断とコードの手引, 日本睡眠学会, 東京(1994)

9) 遠藤四郎:神経質性不眠の精神生理学的研究. 精神経誌64(7):673-707(1962)

10) Guilleminault C, Flagg W:Effect of baclofen on sleep-related periodic leg movements. Ann Neurol 15(3):234-239(1984)

11) 菱川泰夫, 増田豊, 湊浩一郎ほか:高齢者の睡眠障害に対するTriazolam 0. 125mg 錠の有用性の検討. 医学と薬学29(1):295-304(1993)

12) Humpel M, Illi V, Milius W, et al:The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C. Eur J Drug Metabolism Pharmacokinet 4(4):237-243(1979)

13) Kales A, Soldatos CR, Bixler EO, et al:Rebound insomnia and rebound anxiety;A review. Pharmacology 26(3):121-137(1983)

14) Matthews WB:Iron deficiency and restless legs. Br Med J 1(6014):898(1976)
pubmed

15) Moldofsky H, Tullis C, Quance G, et al:Nitrazepam for periodic movements in sleep(sleep-related myoclonus). Can J Neurol Sci 13(1):52-54(1986)

16) Montplaisir J, Godbout R, Pelletier G:Restless legs syndrome and periodic limb movements during sleep. Principles and Practice of Sleep Medicine, Kryger MH, Roth T, Dement WC(ed), pp 589-597, WB Saunders Company, Philadelphia(1994)

17) 村崎光邦:短時間作用型睡眠薬の動向-triazolam storyを通して. 精神医学レビュー, 太田龍朗(編), No 4睡眠・覚醒とその障害 , pp 80-92 , ライフ・サイエンス, 東京(1992)

18) 中沢洋一, 野中健作, 大島正親ほか:ヒトの睡眠に及ぼすVegetaminの影響-終夜睡眠ポリグラフィーと睡眠内省による検討. 薬理と治療7(9):2719-2724(1979)

19) Ozaki N, Iwata T, Itoh A, et al:A treatment trial of delayed sleep phase syndrome with triazolam. Jpn J Psychiatry Neurol 43(1):51-55(1989)

20) Peled R, Lavie P:Double-blind evaluation of clonazepam on periodic leg movements in sleep. J Neurol Neurosurg Psychiatry 50(12):1679-1681(1988)

21) Reynolds G, Blake DR, Pall HS, et al:Restless leg syndrome and rheumatoid arthritis. Br Med J(Clin Res)292(6521):659-660(1986)

22) 坂本哲郎, 中沢洋一:ミオクローヌスを伴う不眠症. 臨床科学21(3):295-300(1985)

23) 坂本哲郎, 中沢洋一:睡眠薬の使い方. 精神医学レビュー, 太田龍朗(編), No 4睡眠・覚醒とその障害, pp 59-67, ライフ・サイエンス, 東京(1992)

24) 佐藤重一:不眠症治療薬剤と多剤との相互作用. 薬局46(4):545-551(1995)

25) 白川修一郎, 石郷岡純, 石束嘉和ほか:全国総合病院外来における睡眠障害と睡眠習慣の実態調査. 平成7年度厚生省精神神経疾患研究委託費「睡眠障害の診断・治療および疫学に関する研究(主任研究者:大川匡子)」研究報告書, pp 7-23 (1996)

26) 高橋清久, 森田伸行, 三島和夫ほか:わが国における睡眠覚醒リズム障害の多施設共同研究. 第2報;ビタミンB12および光療法の効果. 精神医学36(3):275-284(1994)

27) 融道男:IC50と受容体占拠率. KEY WORD 1997-98精神, 松下正明, 倉知正佳, 樋口輝彦(編), pp 10-11, 先端医学社, 東京(1997)

28) Trzepacz PT, Violette EJ, Sateia MJ:Response to opioids in three patients with restless legs syndrome. Am J Psychiatry 141(8):993-995(1984)

29) Weitzman ED, Czeisler CA, Coleman RM, et al:Delayed sleep phase syndrome;A chronobiological disorder with sleep-onset insomnia. Arch Gen Psychiatry 38(7):737-746 (1981)
pubmed

30) Wittig R, Zorich F, Piccone P, et al:Narcolepsy and disturbed nocturnal sleep. Clin Electroencephalogr 14(3):130-134 (1983)

P.295 掲載の参考文献

1) Arendt RM, Greenblatt DJ, Liebisch DC, et al:Determinants of benzodiazepine brain uptake;Lipophilicity versus binding affinity. Psychopharmacology 93:72-76 (1987)
pubmed

2) Ashton H:Brain System Disorders and Psychotropic Drugs. Oxford University Press, Oxford (1987)

3) Bixler EO, Kales A, Manfredi RL, et al:Next-day memory impairment with triazolam use. Lancet 337:827-831(1991)

4) Bonnet MH, Dexter JR, Arand DL:The effect of triazolam on arousal and respiration in central sleep apnea patients. Sleep 13:31-41 (1990)
pubmed

5) Brosen K:Isozyme specific drug oxidation;Genetic polymorphism and drug-drug interations. Nord J Psychiatry 47(Suppl 30):21-26(1993)

6) Chaudoir PJ, Bodkin NL, O'Donnel J, et al:A comparative study of zopiclone and triazolam in patients with insomnia. Int Clin Psychopharmacol 5(Suppl 2):21-27 (1990)

7) Clark TJH, Collins JV, Tong D:Respiratory depression caused by nitrazepamin patient with respiratory failure. Lancet 2:737-738(1971)

8) Clarke PRF, Eccesley PS, Frisby JP, et al:The amnesic effect of diazepam(Valium). Br J Anaesth 42:690-697(1970)

9) Curran HV:Tranquilizing memories;A review of the effects of benzodiazepines on human memory. Biol Psychol 23:179-213(1986)

10) Dolly FR, Block AJ:Effect of fiurazepam on sleep-disordered breathning and nocturnal oxygen desaturation in asymptomatic subjects. Am J Med 73:239-243 (1982)
pubmed

11) Erkkola R, Kanto J:Diazepam and breast feeding. Lancet l:1235-1236(1972)

12) 古田寿一, 山口成良:老年期の睡眠障害-睡眠ポリグラフィによる検討. 老年精神医学雑誌1:179-189(1990)

13) 古田壽一:高齢者における睡眠障害. Progress Medicine 17:75-82(1997)

14) Gaillot J, Le Roux Y, Houghton GW, et al:Critical factors for pharmacokinetisc of zopiclone in the elderly and in patients with liver and renal-insufficiency. Sleep 10(Suppl 1):7-21 (1987)

15) Guilleminault C, Cummiskey J, Silvestri R:Benzodiazepines and respiration during sleep. Pharmacology of Benzodiazepines, Udsin E, Clarke P, Tellmen D, et al(ed), pp 229-236, Macmillan, London(1978)

16) Guilleminault C:Benzodiazepines, breathing, and sleep. Am J Med 88(Suppl 3A):25S-28S(1990)

17) Hall RCW, Zisook SP:Paradoxical response to benzo diazepines. Br J Clin Pharmacol 11:99S-104S(1981)

18) Haram K:"Floppy infant syndrome" and maternal diazepam. Lancet 2:612-613 (1977)
pubmed

19) Harris RA, Allan AM:Alcohol intoxication;Ion channels and genetics. FASEB J 3:1689-1695(1989)

20) 挟間秀文, 川原隆造:新benzodiazepine製剤(triazolam)による短期記憶の障害. 精神医学23:361-365(1981)

21) 井上雄一, 高田耕吉, 星野映治ほか:高齢者の睡眠時無呼吸に対する睡眠薬の影響ゾピクロンとフルラゼパムの比較. 精神医学37:959-966(1995)

22) Kales A, Bixler EO, Tan TL, et al:Chronic hypnotic use;In effectiveness, drug withdrawal insomnia, and dependence. JAMA 247:513-517(1974)

23) Kales A, Scharf MB, Kales JD:Rebound insomnia;A new clinical syndrome. Science 201:1039-1041 (1978)
pubmed

24) Kales A, Bixler EO, Soldatos CR, et al:Dose-response studies of lormetazepam;Efficary, side effect, and rebound insomnia. J Clin Pharmacol 22:520-53()(1982)

25) Kales A, Kales JD:Sleep laboratory studies of hypnotic drugs;Efficacy and withdrawal effects. J Clin Psychopharmacol 3:140-150(1983)

26) Kales A, Kales JD:Evaluation and Treatment of Insomnia. Oxford University Press, New York(1984)

27) Lader M, File S:The biological basis of benzodiazepine dependence. Psychol Med 17:539-547(1987)

28) Laegreid L, Olegard R, Wahlstrom J, et al:Benzodiazepine over consumption in pregnancy. Lancet 2:1405-1406 (1987)

29) Lieber CS:Mechanisms of ethanol-drug-nutrition interactions. Clin Toxicol 32:631-681 (1994)
pubmed

30) Lister RG:The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 9:87-94 (1985)
pubmed

31) Mehta AS, Ticku MK:Ethanol potentiation of GABAergic transmission incultured spinal cord neurons involves y-aminobutyric acids A-gated chloride channels. J Pharmacol Exp Ther 246:558-564(1988)

32) Mendelson WB, Garnett D, Gillin JC:Flurazepam-induced sleep apnea syndromein a patient with insomnia and mild sleep-related respiratory changes. J Nerv Ment Dis 169:261-264(1981)

33) Morgan K, Oswald I:Anxiety caused by a short-life hypnotic. BMJ 284:942(1982)

34) 森川恵一, 松原六郎, 村田哲人ほか:Brotizolam投与後出現した健忘を主症状とする異常行動の2症例. 精神医学34:265-268(1992)

35) 村崎光邦:睡眠薬と反跳性不眠. 日濁医報37:31-43(1992)

36) 村崎光邦:ベンゾジアゼピン系睡眠薬の副作用. 睡眠学ハンドブック, 日本睡眠学会(編), pp 379-389, 朝倉書店, 東京(1994)

37) 村崎光邦:不眠症の診断と治療. 北里医学24:1-14(1994)

38) 村崎光邦:睡眠薬の使い方. 臨床精神医学24:975-984(1995)

39) 村崎光邦:抗不安薬, 睡眠薬. 精神治療薬大系, 三浦貞則(監), 第4巻, pp 146-338, 星和書店, 東京(1997)

40) Murray N:Methaminodiazepoxide. JAMA 173:1760-1761(1960)

41) Nierenberg AA, Adler LA, Peselow E, et al:Trazodone for anti-depressant associated insomnia. Am J Psychiatry 155:1069-1072(1994)

42) 日医新報3426:103(1989)(古河宏一ほか:高齢の外来患者に対する薬物療法に関する調査表)

43) O'Hanlon JF, Volkers ER:Hypnotics and actual driving performance. Act Psychiatr Scand 74(Suppl 332):95-104 (1986)

44) 大熊輝雄:老年者の不眠の薬物療法. 老化と疾患2:1909-1916(1989)

45) Peck AW, Bye CE, Claridge R:Differences between light and sound sleepers in the residual effects of nitrazepam. Br J Clin Pharmacol 4:101-108(1977)

46) Poldinger W:Compendium of Psychopharmacotherapy. Third revised edition, Roche, Basel(1975)

47) Roehrs T, Zornick EJ, Sicklesteel JM, et al:Effects of hypnotics on memory. J Clin Psychopharmacol 3:310-313(1983)

48) Scharf MB, Sarkin P, Fletcher K:Benzodiazepine-induced amnesia;Clinical laboratry findings. J Clin Psychiatry 5:14-17 (1987)

49) Somogi A, Gugler R:Drug interaction with cimetidine. Clin Pharmacokinet 7:23-41 (1982)

50) Subhan Z, Harrison C, Hindmarch I:Alprazolam and lorazepam single and multiple dose effects on psychomotor skills and sleep. Eur J Clin Pharmacol 29:709-712 (1986)
pubmed

51) 炭谷信行, 金英道, 小山善子ほか:老人の睡眠障害に対するHydroxyzinepamoate(Atarax-P)の臨床効果. 医学と薬学10:2092-2100(1983)

52) Summerfield RJ, Nielsen MS:Excretion of Iorazepam into breast milk. Br J Anaesth 57:1042-1043(1982)

53) Varhe A, Olkkola KT, Neuvonen PL:Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607(1994)

54) Wildschiodtz G, Jennum P, Gynning B:Effect of zopiclone in sleep related respiratory disorders. Presented at the 5th International Congress of Sleep Research, Copenhagen, June 28-July 3 (1987)

55) Woods JH, Katz JL, Winger G:Abuse liability of benzodiazepines. Pharmacol Rev 39:251-413 (1987)
pubmed

56) 山口成良, 伊崎公徳:睡眠導入剤の神経生理学的機構. 臨床精神医学98:417-423(1980)

57) 山口成良, 浜原昭仁:睡眠時無呼吸不眠症候群(SAIS). 精神科MOOK 21, 菱川泰夫(編), 睡眠の病態, pp 177-186, 金原出版, 東京(1988)

P.302 掲載の参考文献

1) Arendt J, Aldhous M, Marks V:Alleviation of jet-lag by melatonin;Preliminary results of controled double-blind trial. Br Med J 292:1170(1986)

2) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, IVth ed(DSM-IV). American Psychiatric Association, Washington DC (1994)

3) Cirgnotta F, Mondini S, Zucconi M, et al:Zolpidem-polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharmacol Biochem Behav 29:807-809 (1988)

4) Diagnostic Classification Steering Committee. Thorpy MJ(Chairmen):International Classification of Sleep Disorders;Diagnostic and coding manual, American Sleep Disorders Association, Rochester(1990)

5) Dietrich B, Farr I:Zaleplon;Dose-response evaluation in primary insomnia. Sleep Res 24A:116(1995)

6) FK-199(酒石酸ゾルピデム)の概要. 藤沢薬品工業(株), 藤沢サンテラボ(株), サンテラボ薬品(株)(1995)

7) Graham D, Besnard C, Faure C, et al:GABAA receptor subtype diversity;Implications for new generation hypnotic drug discovery. Sleep 19:S43-S45(1996)

8) 伊藤洋, 小曽根基裕, 松永直樹ほか:ビタミンB12の睡眠及び血中メラトニン濃度に与える影響に関する研究. 臨床精神医学26:1327-1334(1997)

9) Kales A, Vgontzas AN, Bixler EO:Hypnotic drugs. Handbook of Experimental Pharmacology, Kales A(ed), Vol 116, The Pharmacology of Sleep, pp 345-385, Springer-Verlag, Berlin, Heidelberg(1995)

10) 菅野道:睡眠薬の開発. 治療学28:1045-1050(1994)

11) 菅野道, 渡辺洋文, 中込和幸ほか:健康成人の夜間睡眠及び翌日の精神機能に及ぼすZolpidemとTriazolamの影響-I. 終夜ポリグラフィによる検討. 神経精神薬理15:589-602(1993)

12) Kashorek G, Roehrs T, Sicklesteel J, et al:Dose effects of zolpidem on transient insomnia. Sleep Res 17:47(1988)

13) 風祭元, 金野滋, 山下格ほか:精神神経科領域における睡眠障害に対するzolpidemの臨床効果. 臨床医薬9(Suppl 2):23-39(1993)

14) 風祭元, 菅野道, 山下格ほか:精神神経科領域における不眠に対するzolpidemの臨床効果. 臨床医薬9(Suppl 2):81-100(1993)

15) 風祭元, 山下格, 佐藤光源ほか:精神分裂病, 躁うつ病に伴う不眠に対するzolpidemの臨床効果-Nitrazepamを対照群とした二重盲検比較試験. 臨床医薬9:109-136(1993)

16) Kramgar-Parsi B, Wehr TA, Gillin C:Successful treatment of human non-24-hour sleep wake syndrome. Sleep 6:257-264(1983)

17) 工藤義雄, 島田修, 黒河内寛ほか:zolpidemの第一相試験-単回及び連続投与試験. 臨床医薬6:651-675(1990)

18) 工藤義雄, 川北幸男, 斉藤正巳ほか:不眠症に対するゾルピデムの有効性と安全性-ニトラゼパムを対照とする二重盲検比較試験. 臨床医薬9:81-105(1993)

19) L-846の概要. 日本レダリー(株)(1995)

20) Langer SZ, Arbilla S, Scatton B, et al:Receptors involved in the mechanisms of action of zolpidem. Imidazopyridines in Sleep Disorders, Sauvanet JP, Langer SZ, Morselli, PL(ed), pp 55-70, Raven Press, New York(1990)

21) Maggioni M, Frattola L, Cesana B, et al:Double-blind comparison of zolpidem 20mg versus flunitrazepam 2mg in insomniac inpatients. Drugs Exp Drug Res 15:371-376 (1990)

22) Merlotti L, Rochrs T, Koshorek G, et al:The dose effects of zolpidem on the sleep of healthy normals. J Clin Psychopharmacol 9:9-14(1989)

23) 村崎光邦:新規睡眠薬の開発. 神経精神薬理18:123-133(1996)

24) 村崎光邦:新しい精神科薬物治療の展開-新規向精神薬の開発を通して. 臨床精神薬理1:5-22(1998)

25) 中沢洋一:睡眠薬の種類と使い方のアドバイス. 睡眠・覚醒障害, 中沢洋一(編), pp 267-283, メディカルレビュー社, 大阪(1991)

26) National Institutes of Health Consensus Development Conference:Drugs and insomnia. JAMA 251:2410-2414(1984)

27) Nicholson AN, Pascoe PA:Hypnotic activity of imidazopyridine(zolpidem). Br J Clin Pharmacol 9:223-227(1980)

28) 延原健二, 磯谷俊明, 岡島詳泰ほか:Zolpidemの終夜睡眠に及ぼす影響について-健常被験者の終夜睡眠ポリグラフィ的研究. 神経精神薬理14:137-143(1992)

29) 野口秀晃, 北角和洗, 森恵ほか:新規非ベンゾジアゼピン系睡眠導入剤CL284, 846の作用機序に関する研究. 日神精薬理誌15:602(1995)

30) 太田龍朗:向精神薬開発の最近の動向(5)-睡眠導入薬. 日神精薬理誌16:161-170 (1996)

31) 坂本哲郎, 内村直尚, 向井正樹ほか:超短時間作用型非ベンゾジアゼピン系睡眠薬L-846の睡眠障害に対する効果-ポリソムノグラフィーによる評価. 神経精神薬理19:935-945 (1997)

32) Sch161治験用資料. エスエス製剤(株)(1986)

33) 白川修一郎, 高橋清久:睡眠障害に関する疫学的事項. 日本臨牀56:475-481(1998)

34) Stephen IA, Goa KL:Quazepam;A preliminary review of its pharmaco-dynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. Drugs 35:42-62 (1988)

35) 高橋清久, 田中総一郎:メラトニンの臨床応用-特に生体リズム・睡眠障害に関連して. 神経精神薬理19:185-195(1997)

36) 高橋清久, 森田伸行, 三島和夫ほか:我が国における睡眠覚醒リズム障害の多施設共同研究第2報-ビタミンB12および光療法の効果. 精神医学36:275-284(1994)

37) 田中正敏, 桑原啓朗, 磯崎宏ほか:Benzodiazepine系睡眠薬と終夜睡眠パターンー新しいbenzodiazepine系睡眠薬, quazepam(Sch161)の健康人終夜睡眠パターンに及ぼす影響. 臨床と研究67:561-570(1990)

38) 筒井末春, 桂戴作, 河野友信ほか:Sch161の心療内科領域における用量設定試験-Placeboとの二重盲検比較試験. 臨床医薬8:335-356(1992)

39) 筒井末春, 桂戴作, 河野友信ほか:Sch161の睡眠障害に対する第III相比較試験-Nitrazepamを対照薬とした二重盲検比較試験. 臨床医薬8:357-374(1992)

40) 筒井末春, 桂戴作, 河野友信ほか:内科・心療内科領域における睡眠導入剤zolpidemの臨床的研究. 臨床医薬9(Suppl 2):387-413(1993)

41) 内海光朝, 杉山健志, 鈴木牧彦ほか:Imidazopyridine系睡眠薬とbenzodiaze-pine系睡眠薬triazolamおよびnitrazepamのdaytime sleepinessに及ぼす影響-Placeboを対照とした二重盲検交叉試験. 神経精神薬理16:45-56(1994)

42) 内海光朝, 杉山健志, 鈴木牧彦ほか:Benzodiazepine受容体作動性新規睡眠薬L-846の第一相試験-単回投与・反復投与試験. 神経精神薬理17:185-202(1995)

43) World Health Organization:The ICD-10 Classification of Mental and Behavioral Disorders;Clinical descriptions and diagnostic guidelines. WHO, Geneva(1992)

44) 山寺博史:開発中の睡眠薬. 日本臨牀56:515-520(1998)

45) 山寺亘, 佐々木三男, 伊藤洋ほか:睡眠覚醒障害を主訴とした外来患者の臨床的研究. 精神医学38:363-370(1996)

46) 山村秀夫, 芦沢直文, 川島康男ほか:手術前夜睡眠に対するSch161(Quaze-pam)の第III相比較試験-塩酸フルラゼパムとの二重盲検交叉試験. 薬理と臨床19:4957-4973 (1991)

47) Zhdanova IV, Lynch HJ, Wurtman RJ:Melatonin;A sleep-promoting hormone. Sleep 20:899-907 (1997)
pubmed

P.312 掲載の参考文献

1) Bowen DA, Smith CB, White P:Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99:459-496(1976)

2) Davies P, Malony AJF:Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet ii:1403(1976)

3) Frostl W, Mairtre L:The families of cognition enhancers. Pharmacopsychiatry 22:54-100 (1989)

4) Giurgea C, Salama M:Nootropic drugs. Progress in Neuro-psycho-pharmacology, Vol 1, pp 235-247, Pergamon, London(1977)

5) 平井俊策:抗痴呆薬の対象選択と標的症状-神経学的観点. 抗痴呆薬開発のストラテジー, 神経精神薬理編集委員会(編), pp 69-79, 星和書店, 東京(1988)

6) 平井俊策:抗痴呆薬の将来. 老年精神医学雑誌5(6):683-688(1994)

7) 平井俊策:Alzheimer病の薬物療法-最近の試みと将来の展望. 医学のあゆみ174(6):632-636 (1995)

8) 平井俊策:ラセタム系薬剤(2-ピロリジノン系薬剤)の発見の経緯とその薬剤特性. Clin Pharmacother 3(1):52-59(1997)

9) 本間昭:抗痴呆薬の評価のあり方. 老年期痴呆8(1):39-47(1994)

10) 大友英一:抗痴呆薬とは. 老年期痴呆8(1):33-37(1994)

11) Perry EK, Perry PH, Blessed G, et al:Necropsy evidence of central cholinergic deficits in senile dementia. Lancet i:189(1977)
pubmed

12) 田所作太郎:行動薬理学的にみた抗痴呆薬の考え方. 抗痴呆薬の探究, 田所作太郎(編), pp 1-13, 星和書店, 東京(1985)

13) Whitehouse PJ, Price DL, Clark AW, et al:Alzheimer's disease;Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122-126 (1981)
pubmed

14) Whitehouse PJ:The international working group on harmonization of dementia drug guidelines;Past, present, and future. Alzheimer disease and associated disorders. Intern J 11(Suppl 13):2-5 (1997)

P.320 掲載の参考文献

1) Alvarez XA, Laredo M, Corzo D, et al:Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol 19:201-210(1997)

2) Deckert J, Gleiter C:Adenosine-an endogenous neuroprotective metabolite and neuromodulator. J Neural Transm 43(Suppl):23-31(1994)

3) Garcia-Mas A, Rossinol A, Roca M, et al:Effects of citicholine in subcorticaldementia associated with Parkinson's disease assessed by quantified electroen-cephalography. Clin Ther 14:718-729(1992)

4) Green RC, Goldstein FC, Auchus AP, et al:Treatment trial of oxiracetam in Alzheimer's disease. Arch Neurol 49:1135-1136(1992)

5) Herrmann WM, Stephan K, Gaede K, et al:A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 8:9-17(1997)

6) 平井俊策:脳循環代謝改善薬. 臨牀と研究67:19-25(1992)

7) Imperato A, Obinu MC, Dazzi L, et al:Co-dergocrine(Hydergine)regulates striatal and hippocampal acetylcholine release through D2 receptors. Neuroreport 5:674-676 (1994)
pubmed

8) Kittner B, Rossner M, Rother M:Clinical trials in dementia with propentofyl-line. Ann NY Acad Sci 826:307-316(1997)

9) Kondo Y, Ogawa N, Asanuma M, et al:Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion. Neurosci Res 24:409-414 (1996)

10) 三好功峰:痴呆の薬物療法はどうするか. 老年期痴呆診療マニュアル. 日医師会誌114:110-118 (1995)

11) Molto JM, Falip R, Martin R, et al:Estudio comparativo de nicardipina frentea placebo en la prevencion del deterioro cognitivoen los pacientes con accidentes isquemicos transitorios. Rev Neurol 23:54-58(1995)

12) 鍋島俊隆:抗痴呆薬の現状と展望. Therapeutic Res 18:3172-3177(1997)

13) Ogawa N, Asanuma M, Mizukawa K, et al:Post-ischemic administration of bifemelane hydrochloride prohibits ischemia-induced depletion of the muscarinic M1-receptor and its mRNA in the gerbil hippocampus. Brain Res 591:171-175 (1992)
pubmed

14) Posner J-D, Landsberg L:Lack of efficacy of hydergine in Alzheimer's disease. N Engl J Med324:197-198(1991)

15) Parnetti L, Senin U, Carosi M, et al:Mental deterioration in old age;Results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group. Clin Ther 15:394-406(1993)

16) Parsons CG, Quack G, Bresink I, et al:Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258(1995)

17) Rozzini R, Zanetti O, Bianchetti A:Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. Acta Neurol(Napoli)15:44-52(1993)

18) Saletu B, Moller HJ, Grunberger J, et al:Propentofylline in adult-onset cognitive disorders;double-blind, placebo-contolled, clinical, psychometric and brain mapping studies. Neuropsychobiology 24:173-184(1990)

19) Saletu B, Paulus E, Linzmayer L, et al:Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia;adouble-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology(Berl)117:385-395 (1995)

20) Schneider LS, Olin JT:Overview of clinical trials of hydergine in dementia. Arch Neurol 51:787-798(1994)

21) Semlitsch HV, Anderer P, Saletu B:Topographic mapping of long latency "cognitive" event-related potentials(P300):A double-blind, placebo-controlled study with amantadine in mild dementia. J Neural Transm Park Dis Dement Sect 4:319-336 (1992)
pubmed

22) Spiers PA, Myers D, Hochanadel GS, et al:Citicoline improves verbal memory in aging. Arch Neurol 53:441-448(1996)

23) Thal LJ, Salmon DP, Lasker B, et al:The safety and lack of efficacy of vinpocetine in Alzheimer's disease. J Am Geriatr Soc 37:515-520(1989)

24) Thompson TL 2, Filley CM, Mitchell WD, et al:Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med 323:445-448(1990)

25) Weyer G, Babej-Dolle RM, Hadler D, et al:A controlled study of 2 dose of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 36:7382 (1997)

26) Yamada K, Nitta A, Hasegawa T, et al:Orally active NGF synthesis stimulators;Potential therapeutic agents in Alzheimer's disease. Behav Brain Res 83:117-122 (1997)
pubmed

P.326 掲載の参考文献

1) Guilleminault C, Tharp BP, Cousin D:HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements. J Neurol Sci 18:435-441 (1973)

2) Ichinose H, Ohye T, Takahashi E, et al:Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase Igene. Nature Genet 8:236-241(1994)

3) Manin't Veld AJ, Boomsma F, Van den Meicker AH, et al:Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet ii:1172-1175(1987)

4) 中村重信, 亀山正邦:Norepinephrineとserotonin. 神経進歩25(1):130-141(1981)

5) Rogers SL, Doody R, Mohs R, et al:E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease. Results of a 30-week phase III. Neurology 46:A217(1996)

6) Rothman JE:Mechanism of intracellular protein transport. Nature 372:55-63(1994)

7) 佐野勇:錐体外路系の生化学. 神経進歩5:42-48(1960)

8) 笹征史:神経伝達物質遊離機構. 神経伝達物質update, 中村重信(編), pp 48-53, 中外医学社, 東京(1998)

9) Takahashi T, Yamashita H, Zhang YX, et al:Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 41:363-367 (1996)
pubmed

10) Udaka F, Yamao S, Nagata H, et al:Pathologic laughing and crying treated with levodopa. Arch Neurol 41:1095-1096(1984)

11) Walker M:Treatment of myasthenia gravis with physostigmine. Lancet i:1200-1201 (1934)

P.336 掲載の参考文献

1) 青葉安里:新しい臨床試験のあり方-患者エントリーを迅速にするために . 臨床精神薬理1:243-249(1998)

2) 赤池昭紀:大脳皮質グルタミン酸誘発神経細胞死に対するアセチルコリン系の保護作用と新規抗痴呆薬としての可能性に関する研究. 医科学応用研究財団研究報告(0914-5117) 14:171-177 (1996)

3) 朝倉幹雄, 宮本聖也, 貴家康男ほか:軸索輸送と抗痴呆薬-Sabelzoleについて. 神経精神薬理16(12):783-794(1994)

4) Cheng B, Mattson MP:NGF and bFGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron 7:1031-1041(1991)

5) Emmerling MR, Moor CJ, Doyle PD, et al:Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein. Biochem Biophys Res Commun 197:292-297(1993)

6) Fujiyoshi K, Suga H, Okamoto K, et al:Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia. J Neurol Neurosurg Psychiatry 50:929-932 (1987)
pubmed

7) 平井俊策:痴呆の薬物療法の最前線-向知性薬の臨床と基礎. アルツハイマー型痴呆を中心として. 精神医学38(12):1309-1314(1996)

8) 平井俊策:治療法-2. アルツハイマー型痴呆. Annual Review神経1996:75-82(1996)

9) 広津千尋:臨床試験への統計解析手法の応用について. 臨床試験の統計解析をめぐって, 日本抗生物質学術協議会(編), pp 10-41, 株式会社ミクス, 東京(1992)

10) 本間昭, 新名利恵 , 石井徹郎ほか:老年期痴呆を対象とした精神機能障害評価表の作成. 老年精神医学雑誌2(10):1217-1222(1991)

11) ICH Steering Committee:Guideline for good clinical practice. Draft ICH Tripartitie Guideline Released for Consultation. 9 MAY 1995 at step 2 of the ICH process. ICH-GCP はどう変わるのか-ICH-GCPとインフォームド・コンセント, pp 275-320, 株式会社ミクス, 東京(1996)

12) 飯塚友道, 東海林幹夫:アルツハイマー型痴呆に関する知見. アミロイドβ蛋白およびその前駆体に関する研究. 老年痴呆9(1):29-38(1995)

13) Inuzuka T, Tamura A, Sato S, et al:Suppressive effect of E-64c on ischemic degradation of cerebral proteins following occlusion of the middle cerebralartery in rats. Brain Res 526:177-179 (1990)

14) 兼行浩史, 山田通夫:抗痴呆薬開発の現状-コリン系以外の薬物について. 老年痴呆8(1):97-102(1994)

15) 北口哉, 伊東平隆:アルツハイマー病治療薬のターゲットとしてのアミロイドβ蛋白(Aβ)とその前駆体βAPP. 神経精神薬理16(12):747-764(1994)

16) 小林真一:改定GCPに対応したモデル病院のチャレンジ-聖マリアンナ医科大学病院の試み. 臨床精神薬理1:271-276(1998)

17) Kovacs GL, Bohus B, Versteeg DHG:The effects of vasopression on memory processes;The role of noradrenergic neurotransmission. Neuroscience 4:15291537 (1979)

18) 九穂泰三:「抗痴呆薬」開発の展望. 日大医誌56(4):187-191(1997)

19) 松下亮:ベンゾジアゼピンインバースアゴニスト. 神経精神薬理16(12):775-782 (1994)

20) 三浦貞則:わが国における向精神薬の治験をめぐる諸問題. 臨床精神薬理1:227-234 (1998)

21) 三好功峰:アルツハイマー型痴呆の薬物療法. 老年痴呆6:62-68(1992)

22) 中村重信, 渡邊千種:アセチルコリン系と知的機能. Dementia 9:246-253(1995)

23) 鍋島俊隆:抗痴呆薬の開発の現状. ファルマシア33(11):1228-1234(1997)

24) 内藤周幸:統計解析を考慮した臨床試験の進め方について. 臨床試験の統計解析をめぐって, 日本抗生物質学術協議会(編), pp 42-70, 株式会社ミクス, 東京(1992)

25) Nisch RM, Slack BE, Wurtman RJ:Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Scinece 258:304-307 (1992)

26) 太田共夫, 青葉安里:高齢者人口に占める痴呆性老人の割合と今後の推移-痴呆性老人ケアに求められる独自性. 在宅医療3(4):5-8(1997)

27) 大谷義夫:ACh-M1受容体作動薬(M1アゴニスト)とACh放出促進薬. 神経精神薬理16(12):739-745(1994)

28) Rogers J, Kirby LC, Hempelman SR, et al:Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609-1611(1993)

29) 阪田千種, 中村重信:抗痴呆薬開発の現状-アセチルコリン賦活薬. 老年痴呆8(1):91-96 (1994)

30) 砥出勝男, 岩本陽子, 藤原教子:老年痴呆治療薬を目指す新規prolyl endopepti-dase阻害薬, JTP-4819の生化学的性質及び薬理活性. 神経化学33:400-401(1995)

31) 遠山育夫, 木村宏:アルツハイマー病と塩基性線維芽細胞成長因子. Dementia9:183-190(1995)

32) Umegaki H, Yamada K, Naito M, et al:Protective effect of interleukin-6 against the death of PC12 cells caused by serum deprivation or by the additionof a calcium ionophore. Biochem Pharmacol 52:911-916(1996)
pubmed

33) 吉田維志, 長谷川雅哉, 野田幸裕ほか:アルツハイマー型痴呆治療薬の開発状況. Dementia 9:233-245(1995)

P.348 掲載の参考文献

1) Everett GM, Richards RK:Comparative anticonvulsive action of 3, 5, 5-trimethy-loxazolidine-2, 4-dione(Tridione), Dilantin and phenobarbital J Pharmacol Exp Ther 81:402-407(1944)

2) Friedlander WJ:Who was "the father of bromide treatment of epilepsy"? Arch Neurol 43:505-507(1986)

3) Friedlander WJ:Putnam, Merritt, and the discovery of Dilantin(R). Epilepsia 27(Suppl 3):S1-S21 (1986)

4) 福島裕:薬物療法. てんかんの臨床と理論, 原俊夫, 平井富雄, 福山幸夫(編), pp 479-527, 医学書院, 東京(1974)

5) Hauptmann A:Luminal bei Epilepsie. MUnch Med Wochenschr 59:1907-1909(1912)

6) 君島健次郎:抗てんかん薬の薬理学. てんかん学, 秋元波留夫, 山内俊雄(編), pp 262-272, 岩崎学術出版社, 東京(1984)

7) Lennox WG:The petit mal epilepsies;Their treatment with Tridione. JAMA129:1069-1074 (1945)
pubmed

8) Lennox WG, Lennox MA:Epilepsie and Related Disorders. Vol 2, p 868, Little, Brown and Company, Boston(1960)

9) Merritt HH, Putnam TJ:A new series of anticonvulsant drugs tested by expriments on animals. Arch Neurol Psychiatry 39:1003-1005(1938)

10) Merritt HH, Putnam TJ:Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 111:1068-1073(1938)

11) Merritt HH, Putnam TJ:Sodium diphenyl hydantoinate in treatment of convulsive seizures;Toxic symptoms and their prevention. Arch Neurol Psychiatry 42:1053-1058 (1939)

12) Merritt HH, Putnam TJ:Further experiences with the use of sodium diphenyl hydantoinate in the treatment of convulsive disorders. Am J Psychiatry 96:1023-1027 (1940)

13) Perlstein MA:Tridione;A new experimental drug for treatment of convulsive and related disorders. II. Clinical investigations. Arch Neurol Psychiatry 55:16+165 (1946)

14) Putnam TJ, Merritt HH:Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 85:525-526(1937)

15) Rogawski MA, Porter RJ:Antiepileptic drugs;Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42:223-286(1990)

16) Rowland LP:Introduction. Epilepsia 23(Suppl 1):S1-S4(1982)

17) 清野昌一:てんかん薬物治療の歴史. 新版てんかん, 秋元波留夫(監), pp 90-99, 日本文化科学社, 東京(1995)

18) 田橡修治, 関場一恵, 後藤蓉子:てんかん薬剤治療. てんかん学-臨床・基礎, 和田豊治(編) , pp 172-200, 医学書院, 東京(1964)

19) The Editor of Epilepsia:O缶cial names of antiepileptic drugs. Epilepsia 27(3):311 (1986)

20) 山田了士, 森本清, 大月健郎:向精神薬開発の最近の動向(4)-抗てんかん薬;作用機序と最近の開発動向. 日神精薬理誌16:151-159(1996)

21) 八木和一:てんかんの薬物療法の歴史と最近の動向. 臨床精神薬理1:575-582(1998)

P.358 掲載の参考文献

1) Ayala GF, Matsumoto H, Gumnit RJ:Excitability changes and inhibitory mechanisms in neocortical neurons during seizures. J Neurophysiol 33:73-85(1970)

2) Ben-Menachem E:Topiramate. Antiepileptic Drugs, 4th ed, Levy RH, Mattson RH, Meldrum BS(ed), pp 1063-1070, Raven Press, New York(1995)

3) Biggs CS, Pearce BR, Fowler LJ, et al:The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus;An in vivo microdyalysis study. Brain Res 594:138-142(1992)

4) Braestrup C, Nielsen EB, Sonnewald U, et al:NO-328 binds with high affinity to the brain GABA uptake carrier. J Neurochem 54:639-645(1990)

5) Cheung H, Kamp D, Harris E:An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 13:107-112 (1992)

6) Chiba S, Omori N, Kamata S, et al:Kindling of the mesencephalic reticular formation and its infuence on subsequent amygdala kindling in rats. Epilepsia 37(Suppl 3):116-117 (1996)

7) Chiba S, Wada JA:Kindling of the interpeduncular nucleus and its influence on subsequent amygdala kindling in rats. Epilepsia 36:410-415(1995)

8) Commission on Classification and Terminology of the International League Against Epilepsy;Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489-501 (1981)
pubmed

9) Coulter DA, Hugenard JR, Prince DA:Characterization of ethosuximide reduction of low threshold calcium current in thalamic neurons. Ann Neurol 25:582593 (1989)

10) Coulter DA, Sombati S, DeLorenzo RJ:Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 34(Suppl 2):123 (1993)

11) During MJ, Spencer DD:Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341:1607-1610(1993)

12) Glass M, Dragunow M:Neurochemical and morphological changes associated with human epilepsy. Brain Res Rev 21:29-41(1995)

13) Hosford DA, Clark S, Cao Z, et al:The role of GABAB receptor activator in absence seizures of lethargic(lh/lh)mice. Science 257:398-401(1992)

14) 平松緑, 小松真紀子, 石紅朕:抗てんかん薬のフリーラジカル消去作用について-鉄塩誘導てんかん焦点形成におけるフリーラジカルのin vivoによる検討. てんかん治療研究振興財団研究年報9:91-96(1997)

15) 日吉俊雄:ネコ扁桃核キンドリングでの観察てんかんの神経機構-キンドリングによる研究, Wada JA, 佐藤光源, 森本清(編), pp 242-256, 世界保健通信社, 大阪(1993)

16) Jung MJ, Palfreyman MG:Vigabatrin mechanisms of action. Antiepileptic Drugs, 4th ed, Levy RH, Mattson RH, Meldrum BS(ed), pp 903-913, Raven Press, New York(1995)

17) 加藤進昌, 石田展弥:キンドリング研究からみた発作発現機序. てんかん学の進歩3, 秋元波留夫, 山内俊雄(編), pp 389-401, 岩崎学術出版社, 東京(1996)

18) Kelly KM, Gross RA, MacDonald RL:Valproic acid selectively reduces the low-threshold(T)calcium in rat nodose neurons. Neurosci Lett 116:233-238(1990)

19) Lang DG, Wang CM, Casper BR:Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TGI mouse neuroblastoma cells. J Pharmacol Exp Ther 266:829-835(1993)

20) Leach MJ, Baxter MG, Critchley MAE:Neurochemical and behavioral aspects of lamotrigine. Epilepsia 12(Suppl 2):S4-S8(1991)

21) Liu Z, Vergnes M, Depaulis A, et al:Involvement of intrathalamic GABAB neurotransmission in the control of absence seizures in the rat. Neuroscience 48:87-93 (1992)
pubmed

22) Lloyd KG, Arbilla S, Beaument K, et al:γ-Aminobutyric acid(GABA)receptor stimulation. I. Specificity of progabide(SL 76002)and SL 75102 for the GABA receptor. J Pharmacol Exp Ther 220:672-677(1982)

23) Loscher W:Comparative study of the inhibition of GABA amino transferase by different anticonvulsant drugs. Arch Int Pharmacodyn Ther 243:48-55(1980)

24) L6scher W, Honack D, Taylor CP:Gabapentin increases amino oxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett 128:150-154 (1991)

25) L6scher W, Nau H:Valproic acid;Metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Arch Int Pharmacodyn Ther 257:20-31(1982)

26) MacDonald RL:Antiepileptic drug actions on neurotransmitter receptors andion channels. Neurotransmitters and Epilepsy, Fisher RS, Coyle JT(ed), pp 231-245, Wiley-Liss, New York(1991)

27) MacDonald RL, Kelly KM:Antiepileptic drug mechanisms of action. Epilepsia 34(Suppl 5):S1-S8 (1993)

28) MacDonald RL, Kelly KM:Antiepileptic drug mechanisms of action. Epilepsia 36(Suppl 2):S2-S12 (1995)

29) McCabe RT, Wasterlain RG, Kucharczyk N, et al:Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 264:1248-1252(1993)

30) McLean MJ, MacDonald RL:Multiple actions of phenytoin on mouse spinalcord neurons in cell culture. J Pharmacol Exp Ther 227:779-789(1983)

31) McLean MJ, MacDonald RL:Sodium valproate, but not ethosuximide, producesuse-and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J pharmacol Exp Ther 237:1001-1011(1986)

32) McLean MJ, MacDonald RL:Benzodiazepines, but not beta carbolines, limithigh frequency of action potentials of spinal cord neurons in cell culture. J Pharmacol Exp Ther 244:789-795(1988)

33) Meldrum BS:Update on the mechanism of action of antiepileptic drugs. Epilepsia 37:S4-S11 (1996)
pubmed

34) Merritt HH, Putnam TJ:Sodium diphenyl hydantoinate in treatment of convulsive disorders. JAMA 111:1068-1073(1938)

35) Miller AA, Wheatley P, Sawyer DA, et al:Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. I;Anticonvulsant profile in mice and rats. Epilepsia 27:483-489(1986)

36) 森本清, 難波多鶴子:発作発現に関わる脳内抑制系と促進系. てんかん-けいれん準備性と発作発現の神経機構, 佐藤光源, 加藤進昌(編), pp 85-98, 学会出版センター, 東京(1995)

37) Morimoto K, Sanei T, Sato K:Comparative study of the anticonvulsant effect of γ-aminobutyric acid agonists in the feline kindling model of epilepsy. Epilepsia 34:1123-1129 (1993)

38) Nakamura F, Suzuki S, Nishimura S, et al:Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 37:728-735 (1996)
pubmed

39) Nakamura J, Tamura S, Kanda T, et al:Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 254:83-89(1994)

40) Nielsen EB, Suzdak PD, Andersen KE, et al:Characterization of tiagabine(NO-328);A new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196:257-272 (1991)
pubmed

41) Ono M, Akiyama K, Tsutsuji K, et al:Differential changes in the activities of multiple protein kinase C subspecies in the hippocampal-kindled rat. Brain Res 660:27-33 (1994)

42) 大月健郎, 佐藤佳子, 山田了士ほか:新しい抗てんかん薬lamotrigineのラット扁桃核および海馬焦点キンドリング発作に対する抗てんかん効果. 神経精神薬理17:35-42 (1995)

43) Petroff OAC, Rothman DL, Behar KL, et al:The effect of gabapentin on brain GABA in patients with epilepsy. Ann Neurol 39:95-99(1996)

44) Pranzatelli MR, Nadi NS:Mechanism of action of antiepileptic and antimyoclonic drugs. Negative Motor Phenomena;Advances in neurology, Vol 67, Hallet M, Luders HO, Marsden CD(ed), pp 329-360, Lippincott-Raven Publishers, Philadelphia (1995)

45) Purpura DP, Penry JK, Tower D, et al(ed):Experimental Models of Epilepsy;A manual for the laboratory worker. Raven Press, New York(1972)

46) Rho JM, Donevan SD, Rogawski MA:Mechanism of action of the anticonvulsant felbamate;Opposing effect on N-methyl-D-aspartate and gamma-amino-butyric acidA receptors. Ann Neurol 35:229-234(1994)

47) Rock DM, MacDonald RL, Taylor CP:Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 3:138-143 (1989)
pubmed

48) Rogawski MA, Porter RJ:Antiepileptic drugs;Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42:223-286(1990)

49) Rogers CJ, Twyman RE, MacDonald RL:Benzodiazepine and β-carboline regulation of single GABAA receptor channels of mouse spinal neurones inculture. J physiol 475:69-82 (1994)

50) Sato H, Morimoto K, Yamamoto Y, et al:Anticonvulsant effects of tiagabine;AGABA uptake inhibitor, in the rat kindling model of epilepsy. Epilepsia 36(Suppl 3):S34 (1995)

51) Sato K, Kashihara K, Morimoto K, et al:Regional increase in brain-derived neutrophic factor and nerve growth factor mRNAs during amygdaloid kindling, but not in acidic and basic fibroblast growth factor mRNAs. Epilepsia 37:6-14(1996)

52) 佐藤光源:キンドリング-定義と概説. てんかんの神経機構-キンドリングによる研究, Wada JA, 佐藤光源, 森本清(編), pp 1-9, 世界保健通信社, 大阪(1993)

53) Sayin U, Timmerman W, Westerink BHC:The significance of extracellular GABA in the substantia nigra of the rat during seizures and anticonvulsants. Brain Res 669:67-72 (1995)

54) Schmutz M, Klebs K:Kindling and antiepileptic drugs. The Clinical Relevance of Kindling, Blowing TG, Trimble MR(ed), pp 55-68, John Wiley & Sons, New York (1989)

55) 清野昌一:てんかんの新治療. 精神経誌93:759-767(1991)

56) Seino M, Naruto S, Ito T, et al:Zonisamide. Antiepileptic Drugs, 4th ed, Levy RH, Mattson RH, Meldrum BS(ed), pp 1011-1023, Raven Press, New York(1995)

57) Severt L, Coulter DA, Sombati S, et al:Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia 36(Suppl 4):38(1995)

58) Shank RP, Gardock Jp, Vaught JL, et al:Topiramate;Preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 35:450-460 (1994)

59) Shovron SD:Benzodiazepines;Clobazam. Antiepileptic Drugs, 4th ed, Levy RH, Mattson RH, Meldrum BS(ed), pp 763-777, Raven Press, New York(1995)

60) Snead OC:Evidence for GABAB-mediated mechanisms in experimental absence seizures. Eur J Pharmacol 213:343-349(1992)

61) Snead OC III:Basic mechanisms of generalized absence seizures. Ann Neurol 37:146-157 (1995)

62) Staley KJ, Soldo BL, Proctor WR:Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 269:977-981(1995)

63) Suman-Chauhan N, Webdale L, Hill DR, et al:Characteristics of[3H]-gabapent in binding to a novel site in rat brain;Homogenate binding studies. Eur J Pharmacol 244:293-301(1993)

64) Suzdak PD, Jansen JA:A review of the preclinical pharmacology of tiagabine;A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36:612-626 (1995)
pubmed

65) Suzuki S, Kawakami K, Nishimura S, et al:Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 12:21-27(1992)

66) Sypert GW, Reynols AF:Single pyramidal-tract fiber analysis of neocortical propagated seizures with reference to inactivation responses. Exp Neurol 45:228-240 (1974)

67) 田中達也, 藤田力, 田中滋也ほか:抗てんかん薬の辺縁系発作重積に対する効果と局所脳血流量への影響について. 脳神経44:234-240(1992)

68) Taylor CP:Gabapentin. Antiepileptic Drugs, 4th ed, Levy RH, Mattson RH, Meldrum BS(ed), pp 829-842, Raven Press, New York(1995)

69) Thurlow RJ, Brown Jp, Gee NS, et al:[3H]-Gabapentin binding may label a system-L like neutral amino acid carrier in brain. Eur J pharmacol 247:341-345 (1993)

70) 鶴紀子:キンドリング研究からみた発作発現機序. てんかん学の進歩3, 秋元波留夫, 山内俊雄(編), pp 389-401, 岩崎学術出版社, 東京(1996)

71) Tunnicliff G:Basis of the antiseizure action of phenytoin. Gen Pharmacol 27:1091-1097 (1996)
pubmed

72) Twyman RE, Rogers CJ, MacDonald RL:Differential regulation of γ-amino-butyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 25:213-220 (1989)

73) 植村秀治, 北村吉宏, 木村宏:側頭葉てんかんにおける歯状回苔状線維発芽とシナプス再構成の意義脳と神の医7:337-344(1996)

74) Upton N:Mechanisms of action of new antiepileptic drugs;Rational design and serendipitous findings. Trens Pharmacol Sci 15:456-463(1994)

75) van der Laan JW, de Boer T, Bruinvels J:Di-N-propylacetate and GABA degradation. ;Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA transaminase. J Neurochem 32:1769-1780(1979)

76) Van Dongen AMJ, Van Erp MG, Voskuyl RA:Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia 27:177-182(1986)

77) Wada JA:Kindling, antiepileptic drugs, seizure susceptibility and a warning. Epilepsy Updated;Causes and treatment, Robb P(ed), pp 51-69, Year Book Medical Publishers, Chicago(1980)

78) Wada Y, Nakamura M, Hasegawa H, et al:Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett 141:2L24(1992)

79) Wada Y, Nakamura M, Hasegawa H, et al:Intra-hippocampal injection of 8-hydroxy-2-(di-N-propylamino)tetralin(8-HO-DPAT)inhibits partial and generalized seizures induced by kindling stimulation in cats. Neurosci Lett 159:179-182 (1993)

80) Wamil AW, McLean MJ:Use-, concentration-and voltage-dependent limitation by MK-8010f action potential firing frequency in mouse central neurons in cellculture. J Pharmacol Exp Ther 260:376-383(1992)

81) Wamil AW, McLean MJ:Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res 17:1-11(1994)
pubmed

82) Warmsley JK, Sophia RD, Faull RLM, et al:Interaction of felbamate with[3H]DCKA-labeled strychnine-insensitive glycine receptors in human postmortembrain. Exp Neurol 129:244-250(1994)

83) Wauquier A, Zhou S:Topiramate;A potent anticonvulsant in the amygdalakindled rat. Epilepsy Res 24:73-77 (1996)
pubmed

84) White HS:Clinical significance of animal seizure models and mechanism of action studies of potential drugs. Epilepsia 38(Suppl 1):S9-S17 (1997)

85) White HS, Brown SD, Skeen GA, et al:The anticonvulsant topiramate displaysa unique ability to potentiate GABA-evoked currents. Epilepsia 36(Suppl 3):39(1995)

86) White HS, Wolf HH, Swinyard EA, et al:A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 33:564-572(1992)

87) White HS, Woodhead JH, Franklin MR, et al:General principles;Experimental selection, quantification, and evaluation of antiepileptic drugs. Antiepileptic Drugs, 4th ed, Levy RH, Mattson RH, Meldrum BS(ed), pp 99-110, Raven Press, New York(1995)

88) 山田了士, 森本清, 大月健郎ほか, 向精神薬開発の動向(4)-抗てんかん薬;作用機序と最近の開発動向. 神経精神薬理16:151-159(1996)

89) 山内俊雄:けいれんの神経生理学. Clin Neurosci 12:257-262(1994)

90) 山内俊雄:抗てんかん薬の選択と新しい抗てんかん薬. 臨床精神医学26:847-855(1997)

91) Zona C, Avoli M:Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp Brain Res 81:313-317 (1990)
pubmed

P.373 掲載の参考文献

1) Bourgeois BFD:Problems of combination drug therapy in children. Epilepsia 29(Suppl 3):S20-S24 (1988)

2) Bourgeois BFD:Antiepileptic drugs in pediatric practice. Epilepsia 36(Suppl 2):S34-S45 (1995)

3) Comission on Classification and Terminology of the International League Against Epilepsy;Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489-501 (1981)

4) Dean JC, Penry JK:General principles discontinuation antiepileptic drugs. Antiepileptic Drugs, Levy FE, Mattson RH, Meldrum BS, et al(ed), 3rd ed, pp 133-142, Raven Press, New York(1989)

5) Devinski O:Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 36(Suppl 2):S46-S65 (1995)

6) Dodson WE:Special pharmacokinetic considerations in children. Epilepsia 28(Supp11):S65-S70 (1987)

7) Eadia MJ:Place of antiepileptic drug combinations. J Clin Neurosci 4(4):432438 (1997)

8) Fujii T, Okuno T, Go T, et al:Clorazepate therapy for intractable epilepsy. Brain Dev 9:288-291 (1987)
pubmed

9) Graves NM:Neuropharmacology and drug interactions in clinical practice. Epilepsia 36(Suppl 2):S27-S33 (1995)

10) Genton P, Roger J:Antiepileptic drug monotherapy versus polytherapy;A historical perspective. Epilepsia 38(Suppl 5):S2-S5 (1997)

11) 原實:てんかん診療と脳波診断-外来てんかん診療にまつわる諸問題. 臨床精神医学26(8):1063-1072(1997)

12) Hart YM, Sander JWAS, Johonson AL, et al:National general practice study of epilepsy;Recurrence after a first siezure. Lancet 336:1271-1274 (1990)

13) 細川清:てんかんに対する合理的薬物療法. 医学のあゆみ156(5):310-315(1991)

14) 金子直, Nau H:バルプロ酸の臨床薬理. pp 146-155, ライフ・サイエンス, 東京(1996)

15) Kraemer G:The limitations of antiepileptic drug monotherapy. Epilepsia 38(Suppl 5):S9-S13 (1997)

16) Mattson RH, Cramer JA, Collins JF, et al:Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalizedtonic-clonic seizures. N Engl J Med 313:145-151(1985)

17) Mattson RH, Cramer JA, Collins JF:A comparison of valproate with carbamazepine for the treatment of complex partial seizure and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No 264 group. N Engl J Med 327(11):765-771(1992)

18) Mattson RH:Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 36(Suppl 2):S13-S26 (1995)

19) Marescaux C, Hirsh E, Finck S, et al:A pharmacologic study of five cases. Epilepsia 31:768-777 (1990)

20) 中山和彦:向精神薬の科学. その6;抗てんかん薬. こころの臨床ア・ラ・カルト3:43-49(1989)

21) Okuno T, Ito M, Nakao S, et al:Carbamazepine therapy and long term prognosis in epilepsy of childhood. Epilepsia 30:57-61 (1989)

22) 奥野武彦, 浜田泰, 服部春生:てんかん薬物療法の新しい展開-小児. Medico24(4):12-14 (1993)

23) 清野昌一:抗てんかん薬. 臨床精神医学増刊号(今日の精神科治療1995):84-89(1995)

24) Siemes H:West syndrome;New therapeutic strategies. Epileptic Seizures and Syndromes, Wolf P(ed), pp 619-629, John Libbey, London(1994)

25) 扇谷明:てんかん薬物療法の新しい展開-成人. Medico 24(4):9-11(1993)

26) Wilensky AJ, Friel PN, Ojemann LM, et al:Zonisamide in epilepsy;A pilot study. Epilepsia 26(3):212-220 (1985)
pubmed

27) 八木和一, 福島克之:抗てんかん薬の長期投与とその減量. 神経内科38:543-551(1993)

28) 八木和一, 清野昌一, 三原忠紘ほか:新抗てんかん薬ゾニサミド(zonisamide, ZNA)の臨床第二相試験. 精神医学29(1):111-119(1987)

29) Yukawa E:Optimisation of antiepileptic drug therapy;The importance of serum drug concentration monitoring. Clin Pharmacokinet 31(2):120-130(1996)

30) Yerby MS:Risks of pregnancy in woman with epilepsy. Epilepsia 33(Suppl 1):S23-S27 (1992)

P.385 掲載の参考文献

1) Andrewes DG, Bullen JG, Tomlinson L, et al:A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 27:128-134 (1986)

2) Bentsen KD, Gram L, Veje A:Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate. Acta Neurol Scand 67:235-241 (1983)
pubmed

3) Bossi L:Fetal effects of anticonvulsants. Antiepileptic Drug Therapy in Pediatrics, Morselli PL, Pippenger CR, Penry JK(ed), pp 37-64, Raven Press, New York(1983)

4) Camfield PR, Camfield CS, Smith EC, et al:Newly treated childhood epilepsy;A prospective study of recurrences and side effects. Neurology 35:722-725(1985)

5) Collaborative Group for Epidemiology of Epilepsy:Adverse reactions to anti-epileptic drugs;A multicenter survey of clinical practice. Epilepsia 27:323-330(1986)

6) Committee on Drugs:Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics 76:644-647 (1985)
pubmed

7) Dreifuss FE, Langer DH:Hepatic considerations in the use of antiepileptic drugs. Epilepsia 28(Suppl 2):S23-S 29 (1987)

8) Green ST:Two episodes of erythema multiforme affecting one individual; Sequential causation by phenytoin and carbamazepine. Clin Neuropharmacol 9:561-562 (1986)
pubmed

9) Herranz JL, Armijo JA, Arteaga R:Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 29:794-804 (1998)

10) 市川一男:向精神薬の薬物相互作用-総説. 精神科治療の副作用・問題点・注意点, 八木剛平(編), pp 283-309, 診療新社, 大阪(1998)

11) 稲本淳子, 西島久雄, 藤元ますみほか:血液. 骨に対する抗てんかん薬の副作用の特性. 臨床精神医学21:1085-1093(1992)

12) 井上哲郎, 串田一博, 宮本繁仁ほか:X線像による骨萎縮度判定の試み. 骨代謝13:187-195 (1980)

13) Kaneko S:Antiepleptic drug therapy and reproductive consequences;Functional and morphologic effects. Reprod Toxicol 5:179-198(1991)

14) 兼子直, 大谷浩一, 平野敬之ほか:各種抗てんかん薬の催奇性の強さ. てんかんと妊娠出産, 福島裕, 兼子直(編), pp 187-197, 岩崎学術出版社, 東京(1993)

15) 兼子直:妊娠, 挙子, 催奇性の問題点. 精神医学レビュー10, 清野昌一(編), 難治てんかん, pp 45-54, ライフ・サイエンス, 東京(1994)

16) 兼子直, 河田祐子:抗てんかん薬の薬物相互作用. 臨床精神医学26:191-199(1997)

17) 川崎淳, 扇谷明, 兼本浩裕ほか:てんかんの急性幻覚妄想状態の発現について-抗てんかん薬との関連. 精神医学33:595-600(1991)

18) 北原尊義:てんかんの血清葉酸の研究-葉酸の治療効果を中心に. 臨床精神医学7:577-585 (1978)

19) Klipstein FA:Subnormal serum folate and macrocytosis associated with anticonvulsant drug therapy. Blood 23:68-86 (1964)
pubmed

20) 久郷敏明, 山本光利, 細川清:抗てんかん剤治療下にみられる骨萎縮性病変-マイクロデンシトメトリー法による検討. 臨床精神医学12:333-339(1983)

21) 久郷敏明, 細川清:抗てんかん薬治療下にみられる骨軟化症. Pharma Medica3:75-80 (1985)

22) Kugoh T, Yamamoto M, Hosokawa K:Blood ammonia level during valproic acid therapy. Jpn J Psychiatr Neurol 40:655-662(1986)

23) 久郷敏明:抗てんかん薬に特徴的な副作用. てんかん学の臨床, pp 347-355, 星和書店, 東京(1996)

24) 松浦雅人:抗てんかん薬A. 抗てんかん薬投与中の幻覚妄想状態. 精神科診療の副作用・問題点・注意点, 八木剛平(編), pp 256-264, 診療新社, 大阪(1998)

25) 松浦雅人, 先崎章, 大久保喜朗ほか:Zonisamide投与中に幻覚妄想状態を呈したてんかんの8例. 精神医学35:413-419(1993)

26) Nakane Y, Okuma T, Takahashi R, et al:Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs;A report of a collaborative study group in Japan. Eplepsia 21:663-680 (1980)

27) 日本てんかん協会(編):4副作用の種類. てんかんの薬物療法, p71, ぶどう社, 東京(1987)

28) Pellock JM, Willmore LJ:A rational guide to routine blood monitoring inpatients receiving antiepleptic drugs. Neurology 41:961-964(1991)

29) Ralston AJ, Snaith RP, Hinley JB:Effects of folic acid on fit-frequency and behaviour in epileptics on anticonvulsants. Lancet 1:867-868 (1970)
pubmed

30) 連理貴司, 植田清一郎, 安楽武彦ほか:抗てんかん薬と骨萎縮病変-3年間追跡調査. てんかん研究9:14-23(1991)

31) Reynolds EH:Effects of folic acid on the mental state and fit frequency of drug-treated epileptic patients. Lancet 1:1086-1088 (1967)
pubmed

32) Smith MC, Bleck TP:Convulsive disorders;Toxicity of anticonvulsants. Clin Neuropharmacol 14:97-115(1991)

33) Trimble MR:Cognitive hazards of seizure disorders. Epilepsia 29(Suppl 1):S19-S24 (1988)

34) Trimble MR, Cull C:Children of school age;The influence of antiepileptic drugs on behavior and intellect. Epilepsia 29(Suppl 3):S15-S19 (1988)

35) Ueda S, Shirakawa T, Nakazawa Y, et al:Epilepsy and folic acid. Folia Psychiatrica et Neurologia Jpn 31:327-337(1977)

P.395 掲載の参考文献

1) Brodie MJ, Richens A, Yuen AWC:Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345:476-479(1995)

2) Commission on Antiepileptic Drugs of the International League Against Epilepsy:Guideline for clinical evaluation of antiepileptic drugs. Epilepsia 30:400-408 (1989)

3) Gram L:Pharmacokinetics of new antiepileptic drugs. Epilepsia 37(Suppl 6):S12-S16 (1996)

4) Johannessen SI:New drugs for intractable epilepsy. Intractable Epilepsy, Johannessen SI, Gram L, Sillnpaa M, et al(ed), pp 191-210, Wrightson Biomedical Publ, Petersfield, UK and Bristol, PA, USA(1995)

5) Macdonald RL, Kelly KM:Mechanisms of action of new anticonvulsant drugs. New Anticonvulsants;Advances in the treatment of epilepsy, Trimble MR(ed), pp 35-50, Jone Wiley & Sons Ltd, Chichester, New York, Brisbane, Toronto, Singapore(1994)

6) Mattson RH:Introduction and symposium overview. Epilepsia 37(Suppl 6):S1-S3 (1996)

7) Meldrum BS:Update on the mechanism of action of antiepileptic drugs. Epilepsia 37(Suppl 6):S4-Sll (1996)

8) Meldrum BS, Porter RJ:New anticonvulsant drugs. Current Problems in Epilepsy 4, John Libbey, London, Paris (1986)

9) 大田原俊輔:共同調査研究-小児難治性てんかんの実態. 「難治性てんかんの成因と治療に関する研究」厚生省神経疾患研究委託費昭和60年度報告, pp 13-21(1986)

10) 清野昌一:共同調査研究-成人の難治性てんかんの実態. 「難治性てんかんの成因と治療に関する研究」厚生省神経疾患研究委託費昭和60年度報告, pp 23-28(1986)

11) Shorvon SD:Worldwide Topics in Epilepsy, Interview series Issue 1, 1-8, adis International Ltd, Osaka (1996)

12) Smith D, Baker G, Dewey M, et al:Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34:213-222(1993)

13) Smith D, Chadwick D, Baker G, et al:Seizure severity and the quality of life. Epilepsia 34(Suppl 5):S33-S35 (1993)

14) Trimble MR(ed):New Anticonvulsants;Advances in the treatment of epilepsy. John Wiley & Sons Ltd, Chichester, New York, Brisbane, Toronto, Singapore (1994)

P.406 掲載の参考文献

1) Arai N, Isaji M, Miyata H, et al:Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. J Neural Transm Park Dis Dement Sect 10:55-62 (1995)
pubmed

2) Balk JB, Picetti R, Saiardi A, et al:Parkinsonian-like locomotor impairement in mice lacking dopamine D2 receptors. Nature 377:424-428(1995)

3) Birkmayer W, Mentasti M:The potentiation of antiakinetic effects after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36:303-326 (1975)

4) Brannan T, Martinez J, Melvin D, et al:Methyltransferase inhibition increases striatal L-dopa and dopamine;An in vivo study in rats. Neurology 42:683-685(1992)

5) Civelli O, Bunzow JR, Grandy DK, et al:Molecular biology of the dopamine receptors. Eur J Pharmacol 207:177-184(1991)

6) Date I, Ohmoto T, et al:Cografting with polymer-encapsulated human nerve growth factor-secreting cells and chromaffin cell survival and behavioral recovery in hemiparkinsonian rats. J Neurosurg 84:1006-1012(1996)

7) Dexter DT, Carter CJ, Wells FR, et al:Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389(1989)

8) Dogali M, Sterio D, Fazzini E, et al:Effects of poseroventral pallidotomy on Parkinson's disease. Adv Neurol 69:585-590(1996)

9) Dupont E, Mikkelsen B, Wermuth L, et al:The levodopa-sparing capacity of pergolide compared with that of bromocriptine. Eur J Neurol 3(Suppl):9-12 (1996)

10) Fowler JS, Volkow ND, Wang GJ, et al:Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733-736(1996)

11) Guttman M, Legar G, Cedarbaoum JM, et al:3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 31:638-643(1992)

12) Haefely WE, Arnett CD:Ro19-6327, A Reversible and Highly Selective Mono-amineoxydase B Inhibitor;A novel tool to explore the MAO-B function in humans. I, Streiffer MB, et al(ed), Vol 53, pp 127-135, Raven Press, New York(1990)

13) Heikkila RE, Manzino L, Cabbat FS, et al:Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine by monoamineoxidase inhibitors. Nature 311:467-469(1984)

14) 平井俊策:フリーラジカルの基礎と臨床. 脳変性疾患-アルツハイマー病とパーキンソン病. 日本臨牀46:2184-2189(1988)

15) Kakkola S:Effects of a novel catechol-O-methyl-transferase inhibitor, nitecapone, on the metabolism of L-DOPA in healthy volunteers. Clin Neuropharmacol 13:436-440 (1990)

16) Kakkola S, Teravainen H, Ahtila S, et al:Effect of entakapone, a COMT inhibitor as adjuncts in parkinsonism patients. Neurology 44:77-80(1994)

17) 金沢一郎:モノアミン酸化酵素B阻害薬. 神経治療11:253-259(1994)

18) Koller WC, Silver DE, Lieberman A:An algorithm for the management of Parkinson disease. Neurology 44(Suppl 10):S5-S52(1994)

19) Lees AJ:Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. BMJ 311:1602-1607(1995)

20) Lera G, Vaamonde J, Rodriguez M, et al:Carbegoline in Parkinson's disease;Long-term follow-up. Neurology 43:2587-2590(1993)

21) Mayeux R, Tang MX, Marder K, et al:Smoking and Parkinson's disease. Mov Dis 92:207-212(1994)

22) 中西孝雄, 古和久幸, 水野美邦ほか:BH-T920(塩酸タリペキソール)のパーキンソン病に対する臨床評価-メシル酸ブロモクリプチンを対照とした第3相多施設二重盲検比較試験. 臨床評価21:59-110(1993)

23) 楢林博太郎:パーキンソン病におけるL-DOPSの治療効果-レボドーパ基礎治療例におけるプラセボを対照薬とした二重盲検比較法による検討. 臨床評価15:423457 (1987)

24) 楢林博太郎, 安藤一也, 中西孝雄ほか:パーキンソン病に対するpergolidemesilate(LY127809)の臨床的有用性の検討-bromocriptine mesilateを対照薬とした2重盲検比較試験. 医学と薬学27:147-168(1992)

25) 小川紀雄:Parkinson病の診断と治療-抗Parkinson病薬の種類と特徴-薬理作用と適応病態. 日本臨牀55:43-51(1997)

26) 大江千廣:振戦に対する視床Vim核最外側部の手術. 機能的外科31:42-48(1992)

27) Parkinson Study Group:Impact of deprenyl and tocophenol treatment on Parkinson's disease in DATATOP subjects not reguiring levodopa. Ann Neurol 39:29-36 (1996)

28) Peterson DI, Price ML, Small CG, et al:Autopsy findings in a patient who had an adrenal-to-brain transplant for Parkinson's disease. Neurology 39:235-238(1989)

29) Roberts JW, Cor-Locatelli G, Bravi D, et al:Catechol-O-methyl transferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 44:2685-2688(1994)

30) Sibley DR, Monsma FJ Jr:Molecular biology of dopamin receptors. Trends Pharmacol Sci 13:61-68(1992)

31) Tasker RR, DeCarvalho GC, Li CS, et al:Does thalamotomy alter the course of Parkinson's disease? Adv Neurol 69:563-583(1996)

32) Tohgi H, Abe T, Kikuchi T, et al:The significance of 3-O-methyldopa concentrations in the cerebrospinal fiuid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Neurosci Lett 132:19-22(1991)

33) Weller M:NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons;Neuroprotective properties of amantadine and memantine. Brain Res 613:143-148(1993)

34) Xu M, Hu XT, Cooper DC, et al:Elimination of cocain-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine DI receptormutant mice. Cell 79:945-955(1994)

35) Yanagisawa N, Kanazawa I, Goto I, et al:Seven year follow-up study of bromocriptine therapy for Parkinson's disease. Eur Neurol 34:29-35(1994)

P.416 掲載の参考文献

1) Alvarado R, Contereras S, Segovia-Riquelme N, et al:Effects of serotonin uptake blockers and of 5-hydroxytryptophan on the voluntary consumption of ethanol, water and solid food by UehA and UehB rats. Alcohol 7:315-319(1990)

2) Altschler HL, Phillips PE, Feinhandler DA:Alteration of ethanol self-administration by naltrexone. Life Sci 26:679-688 (1980)

3) Andersen MP:Lack of bioequivalence between disulfiram formulations. Exemplified by a tablet/effervescent tablet study. Acta Psychiatr Scand 86:31-35 (1992)

4) 有川勝嘉, 長沼六一, 大島正親:家族から見たCyanamide Double Medication による飲酒嗜癖者の生活行動の変化. 精神医学14:447-455(1972)

5) Asmussen E, Hald J, Larsen V:The pharmacological action of acetaldehyde onthe human organism. Acta Pharmacol 4:311-320(1948)

6) Berger D, Weiner H:Effects of disulfiram and chloral hydrate on the metabolism of catecholamine in rat liver and brain. Biochem Pharmacol 26:741-747(1977)

7) Collins M, Nijm W, Borge G, et al:Dopamine related tetrahydroisoquinolines; Significant urinary excretion in alcoholics after alcohol consumption. Science 206:1184-1186 (1979)
pubmed

8) Conde-Salazar L, Guimaraens D, Romero L, et al:Allergic contact dermatitis tocyanamide(carbimide). Contact Dermatitis 7:329-330(1981)

9) DeMaster EG, Kaplan E, Shirota FN, et al:Metabolic activation of cyanamide by liver mitochondria, a requirement for the inhibition of aldehyde dehydrogenase enzymes. Biochem Biophys Res Commun 107:1333-1339(1982)

10) DeMaster EG, Shirota FN, Nagasawa HT:The metabolic activation of cyanamide to an inhibition of aldehyde dehydrogenase is catalyzed by catalase. Biochem Biophys Res Commun 122:358-365(1984)

11) Dietrich RA, Erwin V:Mechanism of the inhibition of aldehyde dehydrogenase in vivo by disulfiram and diethyld thiocarbamate. Mol Pharmacol 7:301-307(1971)

12) Dietrich RA, Troxell PA, Worth WS, et al:Inhibition of aldehyde dehydrogenase in brain and liver by cyanamide. Biochem Pharmacol 25:2733-2737(1976)

13) Dorus W, Ostrow DG, Anton R, et al:Lithium treatment of depressed and nondepressed alcoholics. JAMA 262:1646-1652(1989)

14) Eade NR:Mechanism of sympathomimetic action of aldehydes. J Pharmacol Exp Ther 127:29-34(1959)

15) Eisen H, Ginsberg AL:Disulfiram hepatoxicity. Ann Intern Med 83:673-675(1975)

16) Eneanya DI, Bianchine JR, Duran DO, et al:The actions and metabolic fate of disulfiram. Ann Rev Pharmacol Toxicol 21:575-596(1981)

17) Ewing JA, Rouse BA, Mueller RA, et al:Can dopamine beta-hydroxylase level spredict adverse reactions to disulfiram ?Alcohol Clin Exp Res 2:93-94(1978)

18) Fawcett J, Clark DC, Gibbons RD, et al:Evaluation of lithium therapy foralcoholism. J Clin Psychiatry 45:494-499(1984)

19) Fried R:Enzymatic oxidation of diethyldithiocarbamate by xanthine oxidase and colorimetric assay of diethyldithiocarbamate. Ann NY Acad Sci 273:212-218 (1976)
pubmed

20) Fuller RK, Branchey L, Brightwell DR, et al:Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA 256:1449-1455(1986)

21) Gardner-Thorpe C, Benjamin S:Peripheral neuropathy after disulfiram administration. J Neurol Neurosurg Psychiatry 34:253-259(1971)

22) Goldstein M:Inhibition of norepinephrine biosynthesis at the dopamine-β-hydroxylation stage. Pharmacol Rev 18:77-82(1966)

23) Goodwin DW:The use of disulfiram implantation in alcoholism. Br J Psychiatry 123:613-614 (1973)

24) Hald J, Jacobsen E, Larsen V:Formation of acetaldehyde in the organism inrelation to dosage of Antabuse(tetraethylthiuram disulfide)and alcohol concentration in blood. Acta Pharmacol 5:179-188(1949)

25) Hald J, Jacobsen E:A drug sensitizing the organism to ethyl alcohol. Lancet ii:1001-1003 (1948)

26) Hald J, Jacobsen E, Larsen V:The sensitizing effect of tetraethylthiuram disulfide(Antabuse)to ethyl alcohol. Acta Pharmacol Toxicol 4:285-296(1948)

27) Hald J, Jacobsen E:The formation of acetaldehyde in the organism after ingestion of Antabuse(tetraethylthiuram disulfide)and to alcohol. Acta Pharmacol Toxicol 4:305-310(1948)

28) Hotson JR, Langtson JW:Disulfiram-induced encephalopathy. Arch Neurol 33:141-142 (1976)

29) 石郷岡純:抗酒薬. 精神治療薬大系, 三浦貞則(監), 上島国利, 村崎光邦, 八木剛平(編), 第3巻, pp 268-281, 星和書店, 東京(1996)

30) Johnsen J, Morland J:Depot preparations of disulfiram;Experimental and clinical results. Acta Psychiatr Scand 86:27-30(1992)

31) Keefe EB, Smith F:Disulfiram hypersensitivity hepatitis. J Am Med Assoc 230:435-436 (1974)

32) Kingler D, Schmidbauer H:EEG changes in patients with Antabuse incompatibility. Soc Proc Austrian Swiss EEG Soc 9:193(1976)

33) Kiorboe E:Phenytoin intoxication during treatment with Antabuse(disul-firam). Epilepsia 7:246-249(1966)

34) Kitson TM:The disulfiramethanol reaction;A review. J Stud Alcohol 38:96-113 (1977)
pubmed

35) Kitson TM, Crow KE:Studies on possible mechanisms for the interaction between cyanamide and aldehyde dehydrogenase. Biochem Pharmacol 28:2551-2556 (1979)
pubmed

36) Knee SP, Razani J:An acute organic brain syndrome;A complication of disulfiram therapy. Am J Psychiatry 131:1281-1282(1974)

37) 小宮山徳太郎, 庄田秀志, 小片寛:シアナマイド・アルコール反応(cyanamidealcohol reaction)の臨床および生化学的研究. 精神医学24:609-620(1982)

38) 小山恒, 前田正人, 坂本龍ほか:Cyanamideによると考えられるground-glass inclusionsを多数認めた非B型慢性肝炎の1例. 肝臓25:252-256(1984)

39) Lake CR, Major LF, Ziegler MG, et al:Increased sympathetic nervous systemactivity in alcoholic patients treated with disulfiram. Am J Psychiatry 134:1411-1414 (1977)
pubmed

40) Liddon SC, Satran R:Disulfiram(Antabuse)psychosis. Am J Psychiatry 123:1284-1289 (1967)
pubmed

41) Lieber CS, DeCarli LM:Hepatic microsomal ethanol oxidizing system; In vitro characteristics and adaptive properties in vitro. J Biol Chem 245:2505-2515(1970)

42) Lieber CS:Mechanisms of ethanol-drug-nutrition interactions. Clin Toxicol 32:631-681 (1994)
pubmed

43) MacLeod LD:Acetaldehyde in relation to intoxication by ethyl alcohol. Q J Stud Alcohol 11:385-390(1950)

44) Marchner H, Tottmar OA:A comparative study on the effects of disulfiram, cyanamide and 1-aminocyclopropanol on the acetaldehyde metabolism in rats. Acta Pharmacol Toxicol 43:219-232(1978)

45) 松下幸生, 樋口進, 林田基:新しい治療薬naltrexoneの紹介. 精神科治療学11(8):827-831 (1996)

46) Mendelson JH:Recent Advances in Alcoholism Treatment in The United States. Jpn J Alcohol Drug Dependence 22:77-83(1987)

47) Merry J, Reynolds CM, Bailey J, et al:Prophylactic treatment of alcoholism by lithium carbonate;A controlled study. Lancet 1(7984):481-482(1976)

48) Meyrs RD, Borg S, Mossberg R:Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol 3:383-388 (1986)

49) 水尾仁志, 美馬聡昭:内科病棟における抗酒剤療法. アルコール医療研究3:306-309 (1986)

50) Moddel G, Bilbao JM, Payne D, et al:Disulfiram neuropathy. Arch Neurol 35:658-660 (1978) (20)

51) 森村茂樹:抗酒剤の作用機作. 精神経誌57:131-143(1955)

52) 向笠寛:酒客のcyanamideによる飲酒量抑制効果について. 精神医学2:23-28(1960)

53) 向笠寛, 原孝:アルコール中毒の治療-Cyanamide二重投与法の手技. 九州神精医13:150-156(1967)

54) 村岡英雄, 山田耕一, 樋口進ほか:アルコール依存症とその概念. 神経精神薬理6(10):671-679 (1984)

55) 村岡英雄:アルコール依存症の外来精神療法. 臨床精神医学16(6):847-852(1987)

56) 村岡英雄:アルコール依存症-A. A. , 断酒会. 臨床精神医学23(3):289-294(1994)

57) Narajo CA, Sellers EM, Sullivan JT, et al:The serotonin uptake inhibitor citralopram attenuates ethanol intake. Clin Pharmacol Ther 41:266-274(1987)

58) O'Malley SS, Jaffe AJ, Chang G, et al:Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 49:881-887(1992)

59) 折田正人, 吉田正己, 大滝倫子:シアナマイドによる薬疹. 皮膚臨床26:280-281(1984)

60) Paille FM, Guelfi JD, Perkins AC, et al:Double-blind randomized multicentretrial of acamprosate in maintaining abstinence from alcohol. Alcohol 30:239-247 (1995)
pubmed

61) Peachey JE:A review of the clinical use of disulfiram and calcium carbimide in alcoholism treatment. J Clin Psychopharmacol 1:368-375(1981)

62) Peachey JE, Sellers EM:The disulfiram and calcium carbimide acetaldehyde-mediated ethanol reactions. Pharmacol Ther 15:89-97(1981)

63) Peachey JE, Zilm D, Cappell H, et al:Comparative study of the disulfiram-ethanol reaction and the carbimide-ethanol reaction in nonalcoholic men. I. Effects of initial alcohol exposure. Clin Pharmacol Ther 29:271(1981)

64) Price TRP, Silverfarb PM:Disulfiram-induced convulsions without challenge by alcohol. J Study Alcohol 37:980-982(1976)

65) Prufionosa J, Obach R, Valles JM:Determination of cyanamide in plasma by high-performance liquid chromatography. J Chromatogr 377:253-260(1986)

66) Rainey JM Jr:Disulfiram toxicity and carbon disulfide poisoning. Am J psychiatry 134:371-378 (1977)
pubmed

67) Ranek C, Andreasen P:Disulfiram hepatoxicity. Br Med J 2(6079):94-96(1977)

68) Reid LD, Hunter GA:Morphine and naloxone modulate intake of ethanol. Alcohol 38:33-37(1984)

69) Reid LD, Delconte JD, Nichols ML, et al:Tests of opioid deficiency hypothesis of alcoholism. Alcohol 8:247-257(1991)

70) Reilly TM:Peripheral neuropathy associated with citrated calcium carbimide. Lancet i:911-912 (1976)
pubmed

71) Ronis MJJ, Huang J, Crouch J, et al:Cytochrome P450 CYP2EI induction during chronic alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats. J Pharmacol Exp Ther 264:944-950(1993)

72) Rothstein E:Warfarin effect enhanced by disulfiram(letter). J Am Med Assoc 206:1574-1575 (1968)

73) Schreiber SS, Briden K, Oratz M, et al:Ethanol, acetaldehyde and myocardial protein synthesis. J Clin Invest 51:2820-2826 (1972)
pubmed

74) Stockwell T, Edwards G:The impact of a new alcohol sensitizing agent(nitrefazole)on craving in severely dependent alcoholics. Br J Addict 79:403-409 (1984)
pubmed

75) Stromme JH:Metabolism of disulfiram and diethyldithiocarbonate in rats with demonstration of an in vivo ethanol induced inhibition of the glucuronic acid conjugation of the thiol. Biochem Pharmacol 14:393-410(1965)

76) Suokas A, Kupari M, Pettersson J, et al:The nitrefazole-ethanol interaction inman. Cardiovascular responses and the accumulation of acetaldehyde and cathecholamines. Alcohol Clin Exp Res 9:221-227(1985)

77) 鈴木康夫:アルコール症者の予後に関する多面的研究. 精神経誌84:243-261(1982)

78) 竹村道夫:抗酒剤. 精神科MOOK, 増刊1, pp 207-211, 金原出版, 東京(1994)

79) Thomsen P, Renicke V:Ground glass inclusion in liver cells in an alcoholic treated with cyanamide(pispan). Liver l:67-73(1981)

80) Thurman RG, Scholz R:The role of hydrogen peroxide and catalase in hepatic microsomal ethanol oxidation. Drug Metab Dispos 1:441-448(1993)

81) Tottmar O, Hellstrom E:Blood pressure response to ethanol in relation to acetaldehyde levels and dopamine-β-hydroxylase activity in rats pretreated with disulfiram, cyanamide and coprine. Acta Pharmacol Toxicol 45:272-281(1979)

82) Trachtenberg MC, Blum K:Alcohol and opioid peptides;Neuropharmacological rationale for physical craving of alcohol. Am J Drug Alcohol Abuse 13:365-372 (1987)
pubmed

83) Truitt EB, Walsh MJ:The role of acetaldehyde in the actions of ethanol. The Biology of Alcoholism, Kissin B, Begleiter H(ed), Vol 1 Biochemistry, pp 161-195, Plenum Press, New York(1971)

84) 薄葉光夫:石灰窒素によるアルコール中毒の治療. 精神経誌58:93-103(1956)

85) Voegtlin W, Broz W:The conditioned reflex treatment of chronic alcoholism, X. An analysis of 3125 admissions. Ann Intern Med 30:580-597(1949)

86) Volpicelli JR, Davis MA, Olgin JE:Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci 38:841-847(1986)

87) Volpicelli JR, Alterman AI, Hayashida M, et al:Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880(1992)

88) Volpicelli JR, Watson NT, King AC, et al:Effect of naltrexone on alcohol "High" in alcoholics. Am J Psychiatry 152:613-615(1995)

89) Wilson A, Davidson WJ, Blanchard R, et al:Disulfiram implantation, a placebo-controlled trial with two-year follow up. J Stud Alcohol 39:809-819(1978)

90) 吉場朗, 小室映士, 熊田博光ほか:シアナマイドによると思われる肝障害. 薬物性肝障害, 山本祐夫, 溝口靖紘(編), p272-277, 中外医学社, 東京(1980)

P.428 掲載の参考文献

1) Angrist B, Sudilovsky A:Central nervous system stimulants;Historical aspects and clinical effects. Handbook of Psychopharmacology, Iversen L, et al(ed), Vol 11, pp 99-165, Plenum Press, New York(1978)

2) Aoyama T, Sasaki T, Kotaki H, et al:Pharmacokinetics and pharmacodynamics of(+)-three-methylphenidate enantiomer in patients with hypersomnia. Clin Pharmacol Ther 55(3):270-276(1994)

3) Biel JH, Bopp BA:Amphetamines;Structure-activity relationships. Handbook of Psychopharmacology, Iverson L, et al(ed), Vol 11, pp 1-39, Plenum Press, New York(1978)

4) Billiard M, Besset A, Montplaisir J, et al:Modafinil;A double-blind multi-centric study. Sleep 17(Supp18):S107-112 (1994)

5) Bloom AS, Russell LJ, Weisskopf B, et al:Methylphenidate-induced delusional disorder in a child with attention deficit disorder with hyperactivity. J Am Acad Child Psychiatry 27(1):88-89 (1988)

6) Bradley C:The behavior of children receiving benzedrine. Am J Psychiatry 94:577-585 (1937)

7) Broughton RJ, Fleming JA, George CF, et al:Randomized, double-blind, Placebo-controlled crossover trial of modafinil in the treatment of excessive day-time sleepiness in narcolepsy. Neurology 49(2):444-451(1997)

8) Brown GR:The use of methylphenidate for cognitive decline associated with HIV disease. Int J Psychiatry Med 25(1):21-37(1995)

9) Cantwell DP:Attention deficit disorder;A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35(8):978-987(1996)

10) Chiarello RJ, Cole JO:The use of psychostimulants in general psychiatry;A reconsideration. Arch Gen Psychiatry 44(3):286-295(1987)

11) Crisostomo EA, Duncan PW, Propst M, et al:Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol 23(1):94-97(1988)

12) Daly DD, Yoss RE:The treatment of narcolepsy with methylphenypiperidylacetate;A preliminary report. Proc Staff Meet Mayo Clin 31:620-625(1956)

13) Elia J:Drug treatment for hyperactive children;Therapeutic guidelines. Drugs 46(5):863-871 (1993)
pubmed

14) Emptage RE, Semla TP:Depression in the medically in elderly;A focus on methylphenidate. Ann Pharmacother 30(2):151-157(1996)

15) Extein I:Methylphenidate induced choreoathetosis. Am J Psychiatry 135(2):252-253 (1978)
pubmed

16) Fernandez F, Adams F, Holmes VF, et al:Methylphenidate for depressive disorders in cancer patients. Psychosomatics 28(9):455-461(1987)

17) Fernandez F, Levy JK, Samley HR, et al:Effects of methylphenidate in HIV-related depression;A comparative trial with desipramine. Int J Psychiatry Med 25(1):53-67 (1995)
pubmed

18) Fawcett J, Kravitz HM, Zajecka JM, et al:CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 11(2):127-132(1991)

19) Friedmann N, Thomas J, Carr R, et al:Effect on growth in pemoline-treated children with attention deficit disorder. Am J Dis Child 135(4):329-332(1981)

20) Gadow KD, Sverd J, Sprafkin J, et al:Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 52(6):444-455 (1995)
pubmed

21) Gillberg C, Melander H, von Knorring AL, et al:Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms;A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 54(9):857-864(1997)

22) Greenhill LL, Stterberg S:Pharmacotherapy of disorders of adolescents. Psychiatr Clin North Am 16(4):793-814(1993)

23) Holmes VF:Medical use of psychostimulants;An overview. Int J Psychiatry Med 25(1):1-19(1995)

24) 本多裕, 高橋康郎:ナルコレプシー患者における精神賦活剤長期投与の効果と問題点. 精薬療基金研年報28:54-59(1997)

25) 飯島壽佐美:ナルコレプシー. 精神科MOOK, 島薗安雄ほか(編), No 21睡眠の病態, pp 220-232, 金原出版, 東京(1988)

26) Insel TR, Hamilton JA, Guttmacher LB, et al:D-Amphetamine in obsessive-compulsive disorder. Psychopharmacology 80(3):231-235(1980)

27) 石郷岡純:精神刺激薬. 精神治療薬大系, 上島国利ほか(編), 第3巻抗うつ薬, 抗躁薬, 抗てんかん薬, 抗パ薬, 漢方薬他, pp 251-267, 星和書店, 東京(1996)

28) Jacobsen A:The use of ritaline in psychotherapy of depressions of the aged. Psychiatr Q 32:474-483(1958)

29) Janowsky DS, el-Yousel MK, Davis JM, et al:Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 28(2):185-191 (1973)
pubmed

30) Joffe RT, Swinson RP, Levitt AJ:Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 11(4):237-241(1991)

31) Johnston C, Pelham WE, Hoza J:Psychostimulant rebound in attention deficit disordered boys. J Am Acad Child Adolesc Psychiatry 27(6):806-810(1988)

32) 加藤信:覚せい剤の薬理. 精神科MOOK, 島薗安雄ほか(編), No 3覚せい剤・有機溶剤中毒, pp 1-10, 金原出版, 東京(1982)

33) Klei RG:The role of methylphenidate in psychiatry. Arch Gen Psychiatry 52(6):429-433 (1995)

34) Kraus MF:Neuropsychiatric sequelae of stroke and traumatic brain injury;The role of psychostimulants. Int J Psychiatry Med 25(1):39-51(1995)

35) Lazarus LW, Winnemiller DR, Lingam VR, et al:Efficacy and side effects of methylphenidate for post stroke depression. J Clin Psychiatry 53(12):447-449(1992)

36) Lowe TL, Cohen DJ, Detlor J, et al:Stimulant medications precipitate Tourette's syndrome. JAMA 247(8):1168-1169(1982)

37) Lucas PB, Gardner DL, Wolkowitz OM, et al:Methylphenidate-induced cardiac arrhythmias. N Engl J Med 315(23):1485(1986)
pubmed

38) 町山幸輝, 町山るり子:中枢刺激薬. 精神科MOOK, 八木剛平(編), 増刊1 精神科領域における薬物療法, 金原出版, 東京(1989)

39) Masand PS, Tesar GE:Use of stimulants in the medically ill. Psychiatr Clin North Am 19(3):515-547(1996)

40) Mattes JA, Gittelman R:Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry 40(3):317-321(1983)

41) Myerson A:The effect of benzedrine sulfate on mood and fatigue in normal and neurotic persons. Arch Neurol Psychiatry 36:816-822(1936)

42) Mitler MM, Aldrich MS, Koob GF, et al:Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 17(4):352-371(1994)

43) Nausieda PA, Koller WC, Weiner WJ, et al:Pemoline-induced chorea. Neurology 31(3):356-360 (1981)
pubmed

44) Nehra A, Mullick F, Ishak KG, et al:Pemoline-associated hepatic injury. Gastroenterology 99(5):1517-1519(1990)

45) 日本医薬情報センター(編):日本医薬品集. 薬業時報社, 東京(1997)

46) 太田恵利子, 藤原豊, 久保信介ほか:メチルフェニデートの短期投与が有効であった抑制型うつ状態の5例. 精神科治療10(10):1163-1169(1995)

47) Olin J, Masand P:Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 37(1):57-62(1996)

48) Prinzmetal M, Bloomberg W:The use of benzedrine for the treatment of narcolepsy. JAMA 105:2015(1935)

49) Robertson MM, Eapen V:Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome. Clin Neuropharmacol 15(5):408-425(1992)

50) Sandor P:Clinical management of Tourette's syndrome and associated disorders. Can J Psychiatry 40(10):577-583 (1995)
pubmed

51) Shaywitz BA, Fletcher JM, Shaywitz SE:Attention-deficit/hyperactivity disorder. Adv Pediatr 44:331-367(1997)

52) Spier SA:Toxicity and abuse of prescribed stimulants. Int J Psychiatr Med 25(1):69-79 (1995)

53) 高橋康郎:中枢神経刺激剤. 現代精神医学大系, 懸田克躬(編), 第22巻B 精神薬理学II, pp 122-138, 中山書店, 東京(1979)

54) 高橋康郎:ナルコレプシー・特発性過眠症とその治療. 臨床精神医学24(7):885-895 (1995)

55) 高橋康郎:周期性傾眠症と睡眠酩酊. 精神科MOOK, 島薗安雄(編), Vol 21睡眠の病態, pp 233-247, 金原出版, 東京(1988)

56) Wharton RN, Perel JM, Dayton PG, et al:A potential clinical use for methyl-phenidate with tricyclic antidepressants. Am J Psychiatry 127(12):1619-1625(1971)

57) Warneke L:Psychostimulants in psychiatry. Can J Psychiatry 35(1):3-10(1990)

58) Wilens TE, Biederman J:The stimulants. Psychiatr Clin North Am 15(1):191-222 (1992)
pubmed

59) Woods SW, Tesar GE, Murray GB, et al:Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 47(1):12-15(1986)

60) Wheatley D:Amphetamines in general practice;Their use in depression and anxiety. Semin Psychiatry 1:163-173 (1969)

61) Wroblewski BA, Leary JN, Phelan AM, et al:Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 53(3):86-89 (1992)

P.443 掲載の参考文献

1) Aarons RD, Nies AS, Gal J, et al:Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest 65(5):949957 (1980)

2) Adler L, Angrist B, Peselow E, et al:Efficacy of propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 5(3):164-166(1985)

3) Adler L, Angrist B, Peselow E, et al:A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149:42-45(1986)

4) Adler L, Reiter S, Angrist B, et al:Pindolol and propranolol in neuroleptic-induced akathisia. Am J Psychiatry 144(9):1241-1242(1987)

5) Adler LA, Reiter S, Corwin J, et al:Differential effects of propranolol and benztropine in patients with neuroleptic-induced akathisia. Psychopharmacol Bull 23:519-521 (1987)

6) Adler L, Angrist B, Rotrosen J:Single day trials of metoprolol and propranolol in neuroleptic-induced akathisia. Biol Psychiatry 27(6):673-675 (1990)

7) Adler LA, Angrist B, Weinreb H, et al:Studies on the time course and efficacy of beta-blockers in neuroleptic-induced akathisia and the akathisia of idiopathic Parkinson's disease. Psychopharmacol Bull 27(2):107-111(1991)

8) Alpert M, Allan ER, Citrome L, et al:A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 26(3):367-371(1990)

9) Anonymous:Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Partyon Mild to Moderate Hypertension. Lancet 2(8246):539-543(1981)

10) Anonymous:Timolol-induced reduction in mortality and reinfarction inpatients surviving acute myocardial infarction. N Engl J Med 304(14):801-807(1981)

11) Anonymous:A randomized trial of propranolol in patients with acute myocardialinfarction. I. Mortality results. JAMA 247(12):1707-1714(1982)

12) Aoba A, Murasaki M, Kamijima K, et al:A double-blind, placebo-controlled assessment of carteolol in the treatment of neuroleptic-induced akathisia. 第5回日本臨床精神神経薬理学会シノプシス, 中沢洋一(編), pp 55-57, 第5回日本臨床精神神経薬理学会, 久留米(1995)

13) Atsmon A, Blum I, Wijsenbeek H, et al:The short-term effects of adrenergic blocking agents in a small group of psychotic patients. Preliminary clinical observations. Psychiatria Neurologia Neurochir 74(3):251-258(1970)

14) Berlant JL:One more look at propranolol for the treatment of refractoryschizophrenia. Schizophr Bull 13(4):705-714 (1987)

15) Bernadt MW, Silverstone T, Singleton W:Behavioural and subjective effects of beta-adrenergic blockade in phobic subjects. Br J Psychiatry 137:452-457(1980)

16) Bonn JA, Turner P:D-Propranolol and anxiety. Lancet i(7713):1355-1356(1971)

17) Bonn JA, Turner P, Hicks DC:Beta-adrenergic-receptor blockade with practololin treatment of anxiety. Lancet i(7755):814-815(1972)

18) Botschev C, Bondy B, Hofmann M, et al:Beta 2-receptor density on mononuclear blood cells in patients suffering from neuroleptic-induced akathisia(NIA). Biol Psychiatry 40(3):203-207(1996)

19) Brantigan CO, Brantigan TA, Joseph N:Effect of beta blockade and beta stimulation on stage fright. Am J Med 72(1):88-94(1982)

20) Bright RA, Everitt DE:Beta-blockers and depression;Evidence against an association. JAMA 267(13):1783-1787(1992)

21) Burrows GD, Davies B, Fail L:A placebo controlled trial of diazepam and oxprenolol for anxiety. Psychopharmacology 50(2):177-179(1976)

22) Coffey BJ:Anxiolytics for children and adolescents;Traditional and new drugs. J Child Adolesc Psychopharmacol 1:57-83(1990)

23) Costain DW, Green AR:Beta-adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. Br J pharmacol 64 (2):193-200 (1978)
pubmed

24) Cove-Smith JR, Kirk CA:CNS-related side-effects with metoprolol and atenolol. Eur J Clin Pharmacol 28(Suppl):69-72 (1985)

25) Cremona-Barbaro A:Propranolol and depression. Lancet i(8318):185(1983)

26) Currie D, Lewis RV, McDevitt DG, et al:Central effects of beta-adrenoceptorant agonists. I-Performance and subjective assessments of mood. Br J Clin Pharmacol 26(2):121-128(1988)

27) Drayer DE:Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy 7(4):87-91(1987)

28) Duch S, Duch C, Pasto L, et al:Changes in depressive status associated with topical beta-blockers. Int Ophthalmol 16(4-5):331-335(1992)

29) Duncan GE, Little KY, Koplas PA, et al:Beta-adrenergic receptor distribution in human and rat hippocampal formation;Marked species differences. Brain Res 561(1):84-92 (1991)
pubmed

30) Dupuis B, Catteau J, Dumon Jp, et al:Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 144(6):802-805 (1987)
pubmed

31) Eccleston D, Fairbairn AF, Hassanyeh F, et al:The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiatry 147:623-630 (1985)
pubmed

32) Elliott FA:Propranolol for the control of belligerent behavior following acute brain damage. Ann Neurology 1(5):489-491(1977)

33) Emorine L, Blin N, Strosberg AD:The human beta 3-adrenoceptor;The search for a physiological function. Trends Pharmacol Sci 15(1):3-7(1994)

34) File SE, Lister RG:A comparison of the effects of lorazepam with those of propranolol on experimentally-induced anxiety and performance. Br J Clin Pharmacol 19(4):445-451(1985)

35) Fleminger R:Visual hallucinations and illusions with propranolol. Br Med J l(6121):1182 (1978)

36) Fleming PD, Drachman DA:Propranolol, hallucinations, and sleep disturbance. Am J Psychiatry 139(4):540-541(1982)

37) Fraser HS, Carr AC:Propranolol psychosis. Br J Psychiatry 129:508-509(1976)

38) Gaby NS, Lefkowitz DS, Israel JR:Treatment of lithium tremor with metoprolol Am J Psychiatry 140(5):593-595(1983)

39) Gengo FM, Huntoon L, McHugh WB:Lipid-soluble and water-soluble beta-blockers;Comparison of the central nervous system depressant effect. Arch Intern Med 147(1):39-43(1987)

40) Gershon ES, Goldstein RE, Moss AJ, et al:Psychosis with ordinary doses of propranolol. Ann Intern Med 90(6):938-939(1979)

41) Gerstman BB, Jolson HM, Bauer M, et al:The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiology 49(7):809-815 (1996)

42) Gleiter CH, Nutt DJ:Chronic electroconvulsive shock and neurotransmitter receptors;An update. Life Sci 44(15):985-1006(1989)

43) Gleiter CH, Deckert J:Adverse CNS-effects of beta-adrenoceptor blockers. Pharmacopsychiatry 29(6):201-211(1996)

44) Glennon RA, Dukat M:Serotonin receptor subtypes. Psychopharmacology, Bloom FE, Kupfer DJ(ed), The fourthe generation of progress, pp 415-429, Raven Press, New York(1955)

45) Golden RN, Hoffman J, Falk D, et al:Psychoses associated with propranolol withdrawal. Biol Psychiatry 25(3):351-354(1989)

46) Gorman JM, Liebowitz MR, Fyer AJ, et al:Treatment of social phobia with atenolol. J Clin Psychopharmacol 5(5):298-301(1985)

47) Granville-Grossman KL, Turner P:The effect of propranolol on anxiety. Lancet i(7441)1788-790 (1966)

48) Greendyke RM, Schuster DB, Wooton JA, et al:Propranolol in the treatment of assaultive patients with organic brain disease. J Clin Psychopharmacol 4(5):282-285 (1984)
pubmed

49) Greendyke RM, Kanter DR, Schuster DB, et al:Propranolol treatment of assaultive patients with organic brain disease;A double-blind crossover, placebo-controlled study. J Nerv Ment Dis 174(5)290-294(1986)

50) Greedyke RM, Kanter DR:Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease;A double-blind study. J Clin Psychiatry 7(8):423-426 (1986)

51) Greendyke RM, Gulya A:Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital. J Clin Psychiatry 49(3):105-107 (1988)
pubmed

52) Greendyke RM, Berkner Jp, Webster JC:Treatment of behavioral problems with pindolol. Psychosomatics 30(2):161-165(1989)

53) Griffin SJ, Friedman MJ:Depressive symptoms in propranolol users. J Clin Psychiatry 47(9):453-457 (1986)
pubmed

54) Guze BH, Baxter LR Jr:The serotonin syndrome;Case responsive to propranolol. J Clin Psychopharmacol 6(2):119-120(1986)

55) Hallstrom C, Treasaden I, Edwards JG, et al:Diazepam, propranolol and their combination in the management of chronic anxiety. Br J Psychiatry 139:417-421 (1981)
pubmed

56) Hartley LR, Ungapen S, Davie I, et al:The effect of beta adrenergic blocking drugs on speakers performance and memory. Br J Psychiatry 142:512-517(1983)

57) Helson L, Duque L:Acute brain syndrome after propranolol. Lancet i(8055):98(1978)
pubmed

58) Hermesh H, Molcho A, Munitz H:Successful propranolol therapy for neuroleptic-induced akathisia resistant to anticholinergic and benzodiazepine drugs. Clin Neuropharmacol 11:369-372(1988)

59) Hinshelwood RD:Hallucinations and propranolol. BMJ 2(654):445(1969)

60) Horwitz RI, Gottlieb LD, Kraus ML:The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial. Arch Intern Med 149(5):1089-1093(1989)

61) 一宮洋介, 井上令一:点眼薬による精神症状, 精神科治療学11(2):147-150(1996)

62) 石崎高志:β-受容体遮断剤の臨床薬理学, 診断と治療11(47):2853-2865(1989)

63) James I, Savage I:Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians;A comparison with diazepam and placebo. Am Heart J 1018:1150-1155(1984)

64) James IM, Griffith DN, Pearson RM, et al:Effect of oxprenolol on stage-frightin musicians. Lancet ii(8045):952-954(1977)

65) Jefferson JW:Social phobia;A pharmacologic treatment overview. J Clin Psychiatry 56(Suppl 5):18-24 (1995)

66) Jenike MA:Treating the violent elderly patient with propranolol. Geriatrics 38(3):29-30, 34 (1983)
pubmed

67) Jouvent R, Baruch P, Simon P:Manic episode after propranolol withdrawal. Am J Psychiatry 143(12):1633(1986)
pubmed

68) 上村誠, 青葉安里, 山口登ほか:薬剤性アカシジアに対する塩酸カルテオロールの臨床効果. 聖マリアンナ医大誌20:51-59(1992)

69) Kathol RG, Noyes R Jr, Slymen DJ, et al:Propranolo川n chronic anxietydisorders;A controlled study. Arch Gen Psychiatry 37(12):1361-1365(1980)

70) 加藤博明, 遠藤征子, 遠藤秀雄ほか:向精神薬服用時の頻脈, 振戦, アカシジアに対するβ遮断薬Pindolol(Carvisken)の使用経験. 臨床精神医学5:531-538(1976)

71) Kellett JM, Metcalfe M, Bailey J, et al:Beta blockade in lithium tremor. J Neurol Neurosurg Psychiatry 38(7):719-721(1975)

72) Kellner R, Collins AC:The short-term antianxiety effects of propranolol HCI. J Clin Pharmacol 14(5-6):301-304(1974)

73) Kim A, Adler L, Angrist B, et al:Efficacy of low-dose metoprolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 9(4):294-296(1989)

74) Kirk L, Baastrup PC, Schou M:Propranolol and lithium-induced tremor. Lancet i(7755):839 (1972)
pubmed

75) Kirk L, Baastrup PC, Schou M:Propranolol treatment of lithium-inducedtremor. Lancet ii(7837):1086-1087 (1973)

76) Kramer MS, Gorkin RA, DiJohnson C, et al:Propranolol in the treatment of neuroleptic-induced akathisia(NIA)in schizophrenics;A double-blind, placebo-controlled study. Biol Psychiatry 24(7):823-827 (1988)
pubmed

77) Kraus ML, Gottlied LD, Horwitz RI, et al:Randomized clinical trial of atenololin patients with alcohol withdrawal. N Engl J Med 313(15):905-909(1985)

78) Kruse JM, Ereshefsky L, Scavone M:Treatment of lithium-induced tremor with nadolol. Clinical Pharmacy 3(3):299-301(1984)

79) Kruse P, Ladefoged J, Nielsen U, et al:Beta-blockade used in precision sports;effect on pistol shooting performance. J Appl Physiol 61(2):417-420(1986)

80) Kurland ML:Organic brain syndrome with propranolol. N Engl J Med 300(7):366 (1979)
pubmed

81) Lader MH, Tyrer PJ:Central and peripheral effects of propranolol and sotalolin normal human subjects. Br J Pharmacol 45(3):557-560(1972)

82) Lapierre YD:Control of lithium tremor with propranolol. CMAJ 114(7):619-620, 624 (1976)

83) Lid6n S, Gottfriess CG:Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians. Lancet ii(7879):529(1974)

84) Lipinski JF, Zubenko GS, Barreira P, et al:Propranolol in the treatment of neuroleptic-induced akathisia. Lancet ii(8351):685-686 (1983)

85) Lipinski JF Jr, Zubenko GS, Cohen BM, et al:Propranolol in the treatment ofneuroleptic-induced akathisia. Am J Psychiatry 141(3):412-415(1984)

86) Lockwood AH:Medical problems of musicians. N Engl J Med 320(4):221-227(1989)

87) Lynch MG, Whitson JT, Brown RH, et al:Topical beta-blocker therapy and central nervous system side effects;A preliminary study comparing betaxolol and timolol. Arch Ophthalmol 106(7):908-911(1988)

88) Mattes JA:Psychopharmacology of temper outbursts. A review. J Nerv Ment Dis 174(8):464-470(1986)

89) McGahan DJ, Wojslaw A, Prasad V, et al:Propranolol-induced psychosis. Drug Intelligence & Clinical Pharmacy 18(7-8):601-603(1984)

90) McMahon CD, Shaffer RN, Hoskins HD Jr, et al:Adverse effects experienced by patients taking timolol. Am J Ophthalmol 88(4):736-738(1979)

91) Meibach RC, Dunner D, Wilson LG, et al:Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety;A double-blind trial. J Clin Psychiatry 48(9):355-358 (1987)

92) Metzer WS, Paige SR, Newton JE:In efficacy of propranolol in attenuation of drug-induced parkinsonian tremor. Mov Disord 8(1):43-46(1993)

93) Munjack DJ, Rebal R, Shaner R, et al:Imipramine versus propranolol for the treatment of panic attacks;A pilot study. Compr Psychiatry 26(1):80-89(1985)

94) Munjack DJ, Crocker B, Cabe D, et al:Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 9(1):22-27(1989)

95) Myers DH, Campbell PL, Cocks NM, et al:A trial of propranolol in chronicschizophrenia. Br J Psychiatry 139:118-121 (1981)

96) Neftel KA, Adler RH, Kappeli L, et al:Stage fright in musicians;A model illustrating the effect of beta blockers. Psychosom Med 44(5):461-469(1982)

97) Nicholson AN, Wright NA, Zetlein MB, et al:Central effects of beta-adrenoceptorant agonists. II;Electroencephalogram and body sway. Br J Clin Pharmacol 26(2):129-141(1988)

98) Nolan BT:Acute suicidal depression associated with use of timolol. JAMA 247(11):1567 (1982)
pubmed

99) Noyes R Jr, Anderson DJ, Clancy J, et al:Diazepam and propranolol in panicdisorder and agoraphobia. Arch Gen Psychiatry 41(3):287-292(1984)

100) 小原克彦, 日和田邦男:降圧剤の位置付け-β遮断薬. 医薬ジャーナル33(2):633-641 (1997)

101) Pazos A, Probst A, Palacios JM:Serotonin receptors in the human brain-III;Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21(1):97-122 (1987)
pubmed

102) Peet M, Bethell MS, Coates A, et al:Propranolol in schizophrenia. I;Comparison of propranolol, chlorpromazine and placebo. Br J Psychiatry 139:105-111(1981)

103) Peet M, Middlemiss DN, Yates RA:Propranolol in schizophrenia. II;Clinical and biochemical aspects of combining propranolol with chlorpromazine. Br J sychiatry 139:112-117 (1981)

104) P6rez V, Gilaberte I, Faries D, et al:Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349(9065):1594-1597 (1997)

105) Petrie WM, Ban TA:Propranolol in organic agitation. Lancet i(8215):324(1981)
pubmed

106) Petrie WM, Maffucci RJ, Woosley RL:Propranolol and depression. Am J Psychiatry 139(1):92-94 (1982)
pubmed

107) Ramsay I, Greer S, Bagley C:Propranolol in neurotic and thyrotoxic anxiety. Br J Psychiatry 122(570):555-560 (1973)
pubmed

108) Ratey JJ, Sorgi P, Polakoff S:Nadolol as a treatment for akathisia. Am J Psychiatry 142(5):640-642 (1985)
pubmed

109) Ratey JJ, Mikkelsen EJ, Smith GB, et al:Beta-blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol 6(2):103-107(1986)

110) Ratey JJ, Bemporad J, Sorgi P, et al:Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord 17(3):439446 (1987)

111) Ratey JJ, Sorgi P, O'Driscoll GA, et al:Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients;A double-blind, placebo-controlled study. J Clin Psychiatry 53(2):41-46 (1992)
pubmed

112) Ravaris CL, Friedman MJ, Hauri PJ, et al:A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol 11(6):344-350 (1991)
pubmed

113) Reiter S, Adler L, Angrist B, et al:Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 7(4):279-280(1987)

114) Reznikoff GA, Manaker S, Rhodes CH, et al:Localization and quantification of beta-adrenergic receptors in human brain. Neurology 36(8):1067-1073(1986)

115) Rodriguez M, Carillon C, Coquerel A, et al:Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. Mol Brain Reg. 29(2):369-375(1995)

116) Rosenthal S, Ellison J:Propranolol withdrawal in psychosis. Am J psychiatry 147(4):534-535 (1990)
pubmed

117) 佐仲雅樹, 久山泰:離脱症候群-β遮断薬. 医薬ジャーナル32(3):23-27(1996)

118) Saul P, Jones BP, Edwards KG, et al:Randomized comparison of atenolol and placebo in the treatment of anxiety;A double-blind study. Eur J Clin Pharmacol 28(Suppl):109-110 (1985)

119) Shankle WR, Nielson KA, Cotman CW:Low-dose propranolol reduces aggression and agitation resembling that associated with orbit of rontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 9(4):233-237(1995)

120) Shehi M, Patterson WM:Treatment of panic attacks with alprazolam and propranolol Am J Psychiatry 141(7):900-901(1984)

121) Silver JM, Yudofsky SC, Kogan M, et al:Elevation of thioridazine plasmalevels by propranolol. Am J Psychiatry 143(10):1290-1292(1986)

122) Sorgi P, Ratey J, Knoedler D, et al:Depression during treatment with beta blockers;Results from a double-blind placebo-controlled study. J Neuropsy-chiatry Clin Neurosci 4(2):187-189(1992)

123) 田島治:β遮断薬. 精神科MOOK, 島薗安雄ほか(編), 増刊1精神科治療薬の主作用と副作用-向中枢神経薬 , pp 179-188, 金原出版, 東京(1989)

124) 高瀬正彌:治療法. 新臨床眼科全書, 市川宏ほか(編), 第9巻B 緑内障, pp 248-342, 金原出版, 東京(1987)

125) Turner P, Granville-Grossman KL:Effect of adrenergic receptor blockade of the tachycardia of thyrotoxicosis and anxiety state. Lancet ii(7426):1316-1318(1965)

126) Tyrer PJ, Lader MH:Effects of beta adrenergic blockade with sotalol in chronic anxiety. Clin Pharmacol Ther 14(3):418-426(1973)

127) Tyrer PJ, Lader MH:Response to propranolol and diazepam in somatic and psychic anxiety. BMJ 2(909):14-16(1974)

128) Waal HJ:Propranolol-induced depression. BMJ 2(543):50(1967)

129) Walle T, Fagan TC, Walle UK, et al:Food-induced increase in propranolol bioavailability;Relationship to protein and effects on metabolites. Clin Pharmacol Ther 30(6):790-795(1981)

130) Weiler PG, Mungas D, Bernick C:Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurology 1(4):226-230(1988)

131) Wheatley D:Comparative effects of propranolol and chlordiazepoxide in anxiety states. Br J Psychiatry 115(529):1411-1412 (1969)
pubmed

132) White WB, Riotte K:Propranolol and white rabbits. N Engl J Med 307(9):558559 (1982)

133) Williams DT, Mehl R, Yudofsky S, et al:The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Adolesc Psychiatry 21(2):129-135(1982)

134) Wilson RP, Spaeth GL, Poryzees E:The place of timolol in the practice of ophthalmology. Ophthalmology 87(5):451-454(1980)

135) Worner TM:Propranolol versus diazepam in the management of the alcohol withdrawal syndrome;Double-blind controlled trial. Am J Drug Alcohol Abuse 20(1):115-124 (1994)
pubmed

136) Yorkston NJ, Zaki SAI, Pitcher DR, et al:Propranolol as an adjunct to the treatment of schizophernia. Lancet ii(8038):575-578(1977)

137) 吉村裕之, 小川暢也:敵意と不安に関する薬理学的および動物習性学的研究adrenergic β-blockersの影響について. 薬物・精神・行動5:223-229(1985)

138) Yudofsky S, Williams D, Gorman J:Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiatry 138(2):218-220 (1981)
pubmed

139) Yudofsky SC, Silver JM, Hales RE:Treatment of aggressive disorder. Textbook of Psychopharmacology, Schatzberg AF, Nemeroff CB(ed), pp 735-751, American Psychiatric Press Inc, Washington DC(1995)

140) Zilm DH, Sellers EM, MacLeod SM, et al:Propranolol effect on tremor in alcoholic withdrawal. Ann Intern Med 83(2):234-236(1975)

141) Zubenko GS, Lipinski JF, Cohen BM, et al:Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 11(2):143-149(1984)

142) Zubenko GS, Cohen BM, Lipinski JFJr:Comparison of metoprolol and propranolol in(1984)the treatment of lithium tremor. Psychiatry Res 11(2)1163-164

P.460 掲載の参考文献

1) 原敬二郎:老人性痴呆. 今日の精神科漢方治療, 松橋敏夫(編), pp 205-227, 金剛出版, 東京(1990)

2) 井上裕之, 村岡英雄, 松下幸生ほか:向精神薬で生じる口渇に対する白虎加人参湯の臨床的検討. 新薬と臨床42(7):1511-1518(1993)

3) 岩崎真三, 福島伸一郎, 今井昌夫ほか:抗精神病薬服用に伴う排尿障害に対する猪苓湯の使用経験. 漢方医学20(5):153-158(1996)

4) 神庭重信, 木下徳久:精神分裂病における漢方. 現代東洋医学14(4):490-493(1993)

5) 菊谷豊彦:保険適用製剤による精神科疾患の漢方治療. 現代東洋医学14(4):530-538 (1993)

6) 杵淵彰:精神神経系総論漢方治療のABC. 日本医師会(編), pp 118-119, 医学書院, 東京(1992)

7) 杵淵彰:精神科の漢方治療概論. 現代東洋医学14(4):525-529(1993)

8) 松橋敏夫:急性精神病と躁病. 今日の精神科漢方治療, 松橋敏夫(編), pp 151-165, 金剛出版 , 東京(1990)

9) 松橋敏夫:柴朴湯が奏効した術後精神障害. 新薬と臨床39(7):1426-1428(1990)

10) 中根允文, 川口哲:「臨床医のための漢方治療」てんかん. 日医師会誌107(7):21-24 (1992)

11) 成田洋夫:精神神経科領域における漢方治療. 臨床精神医学16(11):1549-1555(1987)

12) 成田洋夫:「臨床医のための漢方治療」精神分裂病. 日医師会誌107(3):5-8(1992)

13) 斉藤文男, 石山哲, 小田桐正孝ほか:神経症およびうつ病に対する加味帰脾湯の効果. Prog Med 13(7):1456-1464(1993)

14) 関場香 , 占部清, 久保信夫ほか:更年期不定愁訴症候群への中医学的アプローチ . THE KAMPO 5(3):114-123(1987)

15) 丁宗鐵:漢方薬の薬理-漢方治療のABC. 日本医師会(編), pp 20-32, 医学書院, 東京(1992)

16) 寺沢捷年:脳血管性痴呆に対する釣藤散の臨床効果-プラセボを対照とした二重盲検試験. 長寿科学総合研究(平成7年)9:22-28(1996)

17) 寺沢捷年:和漢診療学. 医学書院, 東京(1990)

18) 筒井末春, 坪井康次, 中野弘一ほか:胃腸神経症に対する半夏厚朴湯, 加味逍遙散の効果-因子分析による検討. 医学と薬学12(6):1821-1828(1984)

19) 山田和男:漢方薬. 精神治療薬大系, 三浦貞則(監), 第3巻抗うつ薬, 抗躁薬, 抗てんかん薬, 抗パ薬, 漢方薬他, pp 284-309, 星和書店, 東京(1996)

20) 山田光胤:東洋医学における精神病治療史. 今日の精神科漢方治療, 松橋敏夫(編), pp 19-46, 金剛出版, 東京(1990)

21) 山脇成人, 横田則夫, 河相和昭ほか:うつ状態. 老化と疾患4(3):406-411(1991)

P.469 掲載の参考文献

1) Bansky G, Meier PJ, Riderer E, et al:Effects of the benzodiazepine antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 97(3):744-750 (1989)

2) Bonetti EP, Pieri L, Cumin R, et al:Benzodiazepine antagonist Ro15-1788; Neurological and behavioral effects. Psychopharmacology 78:8-18(1982)

3) Burr W, Sandham P, Judd A:A death after flumazenil. Br Med J 298:1713(1989)

4) Cadranel JF, Younsi MEI, Pidoux B, et al:Flumazenil therapy for hepatic encephalopathy in cirrhotic patients;A double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 7(4):325-329(1995)

5) Cheng SC, Brunner EA:Aproposed GABA mechanism of anaesthesia. Pharmacological Basis of Anaesthesiology;Clinical pharmacology of new analgesics and anaesthetics, Tiengo M, Cousins MJ(ed), p13-23, Raven Press, New York(1983)

6) Darragh A, Lanbe R, Kenny M, et al:Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro15-1788. Eur J Clin Pharmacol 24:569-570(1983)

7) Ferenci P, Grimm G, Meryn S, et al:A successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 96:240-243(1989)

8) Gee KW, Ehlert FJ, Yamamura HI:Differential effect of γ-aminobutyric acidon benzodiazepine receptor subtypes labeled by[3H]propyl β-carboline-3-carboxylate in rat brain. J Pharmacol Exp Ther 225:132-137(1983)

9) Grecksch G, Carvalho LP, Vanault P, et al:Conversions induced by submaximal dose of pentylenetetrazol in mice are antagonized by the benzodiazepine antagonist Ro15-1788. Life Sci 32(22):2579-2584 (1983)

10) Grimm G, Ferenci P, Katzenschlager R, et al:Improvement of hepatic encephalopaty treated with flumazenil. Lancet ii:1392-1394(1988)

11) Grimm G, Lenz K, Kleinberger G, et al:Ro15-1788 improves coma in 40ut of 5 patients with fulminant hepatic failure;Verification by long latency auditory and somatosensory evoked potentials(abstr). J Hepatol 4(Suppl 1):S21(1987)

12) 花岡一雄, 山村秀夫, 沼田克雄ほか:ベンゾジアゼピン拮抗薬フルマゼニル(Flumazenil)の臨床への応用-用法用量の検討. 麻酔39(9):1092-1100(1990)

13) 花岡一雄, 山村秀夫, 佐久間昭:ベンゾジアゼピン拮抗薬フルマゼニル(Flumazenil)の臨床効果の検討-多施設共同による二重盲検群間比較試験による検討. 医学のあゆみ155(4):263-273(1990)

14) Hunkeler W, Mohler H, Pieri L, et al:Selective antagonists of benzodiazepines. Nature 290:514-516(1981)

15) Kaijima M, Le Gal La Salle G, Rossier J:The partial benzodiazepine agonist properties of Ro15-1788 in pentylenetetrazol-induced seizure in cats. Eur J Pharmacol 93:113-115(1983)

16) Klepner CA, Lippa AS, Benson DI, et al:Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors. Pharmacol Biochem Behav 11:457-462 (1979)
pubmed

17) Lheureux P, Askenasi R:Efficacy of flumazenil in acute alcohol intoxication;Double blind placebo-controlled evaluation. Hum Exp Toxicol 10:235-239(1991)

18) Mohler H, Okada T:Benzodiazepine receptor;Demonstration in the central nervous system. Science 198:849-851(1977)

19) Mohler H, Richards JG:The benzodiazepine receptors;A pharmacological control element of brain. Eur J Anaesthesiol 2(Suppl):15-24(1988)

20) 百瀬隆, 伊東和人, 山田満ほか:NLA変法による全身麻酔に対するフルマゼニル(YM684)の拮抗作用の検討. 新薬と臨床39(6):1140-1151(1990)

21) Mullen KD, Martin JV, Mendelson WB, et al:Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy?Lancet i:457-459 (1988)
pubmed

22) 村崎光邦:抗不安薬の臨床用量依存. 精神経誌98(9):612-621(1996)

23) 村崎光邦:新しい精神科薬物治療の展開-新規向精神薬の開発を通して . 臨床精神薬理1:5-22(1998)

24) 小澤由紀子, 藤原明, 佐藤修一ほか:Flumazenilの一般薬理作用. 基礎と臨床24(8):3811-3826 (1990)

25) Pomier-Layrargues G, Giguere JF, Lavoie J, et al:Flumazenil in cirrhotic patients in hepatic coma;A randomized double-blind placebo-controlled crossovertrial. Hepatology 19(1):32-37(1994)

26) Scollo-Lavizzari G:First clinical investigation of benzodiazepine antagonist Ro15-1788 in comatose patients. Eur Neurol 22:7-11(1983)

27) Scollo-Lavizzari G:The anticonvulsant effect of benzodiazepine antagonist, Ro15-1788;An EEG study in 4 cases. Eur Neurol 23:1-6(1984)

28) Scollo-Lavizzari G, Steinmann E:Reversal of hepatic coma by benzodiazepine antagonist(Ro15-1788)(lett). Lancet i:1324-1325 (1985)

29) 関野久之, 中道昇, 神村秀隆ほか:YM 684(Flumazenil)の臨床第I相試験. 医学と薬学23(4):777-798(1990)

30) 新宮興, 村山隆紀, 森健次郎:ベンゾジアゼピン拮抗薬フルマゼニルの全身麻酔に及ぼす影響. 薬理と治療18(12):4813-4819(1990)

31) 新宮興, 玉井直, 本間勇:ベンゾジアゼピン拮抗薬. 呼吸12(6):743-747(1993)

32) 高木昌一, 森脇久隆, 中村俊之ほか:肝不全時の脳内神経伝達物質レセプターに対するベンゾジアゼピン投与の影響-γ-aminobutyric acid(GABA)結合能を指標として. 肝臓32(4):411-418(1991)

33) 融道男(監):ベンゾジアゼピン受容体. 臨床ハンドブック神経伝達物質受容体, pp 52-55, 最新医学社, 大阪(1995)

34) 山岸久子, 川口充:末梢臓器におけるベンゾジアゼピン受容体. 歯科学報93(8):819-828 (1993)

35) Woods SW, Charney DS, Silver JM, et al:Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil inpanic disorder. Psychiatry Res 36:115-127 (1990)

P.480 掲載の参考文献

1) Altschule MD, Siegal EP, Hennemann DH:Blood glutathione level in mental disease before and after treatment. Arch Neurol Psychiatry 67:64-68(1952)

2) 浅井信成, 千住隆男, 清水将之:大量甲状腺末とレセルピン併用が著効を奏した周期性精神病の一例. 臨床精神医学17:1193-1201(1988)

3) Benkert O, Gordon A, Martschke D:The comparison of thyrotropin releasing hormone, luteinizing hormone-releasing hormone and placebo in depressivepatients using a double-blind cross-over technique. Psychopharmacologia 40:191-198 (1974)
pubmed

4) Branconnier R, Cole JO, Gardos G:ACTH 4-10 in the amelioration of neuropsychological symptomatology associated with senile organic brain syndrome. Psychopharmacology 61:161-165(1979)

5) Carman JS, Wyatt RJ:Calcium;Bivalent cation in the bivalent psychoses. Biol Psychiatry 14:295-336 (1979)
pubmed

6) Cowdry RW, Wehr TA, Zis AP, et al:Thyroid abnormalities associated withrapid-cycling biporal illness. Arch Gen Psychiatry 40:414-420(1983)

7) Cullberg J:Mood changes and menstrual symptoms with different gestagenestrogen combinations. Acta Psychiatr Scand(Suppl)236:1(1972)
pubmed

8) Dalton K:Comparative trials of new oral progestogenic compounds in treatment of premenstrual syndrome. BMJ 2:1307(1959)
pubmed

9) Dalton K:Progesterone prophylaxis used successfully in post-natal depression. Practitioner 229:507-508 (1985)

10) Ehrensing RH, Kastin AJ:Melanocyte-stimulating hormone-release inhibiting hormone as an antidepressant. Arch Gen Psychiatry 30:63-65(1974)

11) Endr6czi E:Pavlovian conditioning and adaptive hormones. Hormones and Behavior, Levine S(ed), pp 173-208, Academic Press, New York(1972)

12) Felthous AR, Robinson DB, Conroy RW:Prevention of recurrent menstrual psychosis by an oral contraceptive. Am J Psychiatry 137:245-246(1980)

13) Frederiksen SO, d'Elia G, Bengtsson BO:ACTH 4-9 analogue(Org 2766)indepressed elderly patients. I. Effect on depressed mood. Acta Psychiatr Scand 72:341-348 (1985)
pubmed

14) Gjessing RR:Disturbances of somatic functions in catatonia with periodic course, and their compensation. J Ment Sci 84:608-621(1938)

15) Gold PW, Weingartner H, Ballenger JC:Effects of 1-desamino-8-arginine vaso-pressin on behaviour and cognition in primary affective disorder. Lancet ii:992994 (1979)

16) Gorelick DA, Catlin DH, Gerner RH:β-Endorphin studies in psychiatricpatients. Modern Problems of Pharmacopsychiatry, Emrich HM(ed), pp 236-245, S. Karger, Basel(1981)

17) Greengrass PM, Tonge SR:Some effects of acute and chronic administration of sex hormones on brain monoamine concentration. Br J Pharmacol 47:660-661(1973)

18) Hallonquist JD, Seeman MV, Lang M, et al:Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 33:207-209(1993)

19) Hatotani N, Ishida C, Yura R, et al:Psycho-physiological studies of a typical psychoses;Endocrinological aspect of periodic psychoses. Folia Psychiatr Neurol Jpn 16:248-292(1962)

20) Heal DJ, Atterwill CK:Repeated administration of triiodothyronine(T3)torats enhances nigrostriatal and mesolimbic dopaminergic behavioural responses. Neuropharmacology 21:159-162(1982)

21) 東村輝彦, 三好新之祐:大量の甲状腺ホルモンが効を奏した周期性緊張病の一例. 神経精神薬理3:749-752(1981)

22) 石井博, 中瀬尚幸, 野村純一:急性精神病およびストレス状態における肝エストロゲン代謝. Progress Medicine 6(4):887-890(1986)

23) Itil TM, Cora R, Akipinar S, et al:"Psychotropic" action of sex hormone;Computerized EEG in establishing the immediate CNS effects of steroid hormone. Curr Ther Res 16:1147-1170(1974)

24) Itil TM, Herrmann WM:Effects of hormones on computer-analized humanel ectroencephalogram. Psychopharmacology;A generation of progress, Lipton MA, Di Mascio A, Killam KF(ed), pp 729-743, Raven Press, New York(1978)

25) Kane FJ, Keeler M:The use of enovid in postpartum mental disorders. South Med J 58:1089-1092(1965)

26) Kerr GD, Day JB, Munday MR, et al:Dydrogesterone in the treatment of the premenstrual syndrome. Clin Trials 224:852(1980)

27) 北山功:躁うつ病の内分泌療法. 躁うつ病と神経内分泌, 日本生物学的精神医学会(編), pp 99-111, 学会出版センター, 東京(1993)

28) 北山功, 野村純一:周期性精神障害のホルモン療法. 精神科MOOK, 八木剛平(編), 増刊1精神科領域における薬物療法, pp 292-302, 金原出版, 東京(1989)

29) Kitayama I, Yamaguchi T, Harada M, et al:Periodic psychoses and hypothalamo-pituitary function. Mie Med J 34:127-138(1984)

30) Klaiber EL, Broverman DM, Vogel W, et al:Effects of estrogen therapy on plasma MAO activity and EEG driving responses of depressed women. Am J Psychiatry 128:1492-1498 (1972)

31) Klaiber EL, Broverman DM, Vogel W, et al:Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 36:550-554(1979)

32) Kline NS, Li CH, Lehmann HE, et al:β-Endorphin-induced changes in schizophrenic and depressed patients. Arch Gen Psychiatry 34:1111-1113(1977)

33) 越川法子, 辰沼利彦:中枢作用をもつホルモン剤. 精神科MOOK, 八木剛平(編), 増刊1 精神科領域における薬物療法, pp 189-200, 金原出版, 東京(1989)

34) Kral VA, Wigdor BT:Further studies on the androgen effect on senescentmemory function. Can Psychiatr Assoc J 6:345(1961)
pubmed

35) Krishna G, Hynie S, Brodie BB:Effects of thyroid hormones on adenyl cyclasein adipose tissue and on free fatty acid mobilization. Proc Natl Acad Sci USA 59:884-889 (1968)
pubmed

36) Ladsich W:lnfluence of progesterone on serotonin metabolism;A possible causal factor for mood changes. Psychoneuroendocrinology 2:257-266(1977)

37) Loosen PT:Hormones of the hypothalamic-pituitary-thyroid axis;A psychoneuro endocrine perspective. Pharmacopsychiatry 19:401-415(1986)

38) Morton JH:Premenstrual tension. Am J Obstet Gynecol 60:343-352(1950)

39) 西久保光弘:難治性うつ病に対する三環系抗うつ剤イミプラミンと甲状腺ホルモンの併用療法の奏効機序について. 三重医学26:309-317(1982)

40) 野村純一, 鳩谷龍, 久松憲二ほか:肝臓の物質代謝に対する中枢神経系の影響. 精神医学20:719-726(1978)

41) O'Connor M, Baker HW:Depomedroxy progesterone acetate as an adjunctive treatment in three aggressive schizophrenic patients. Acta Psychiatr Scand 67:399-403 (1983)
pubmed

42) Oppenheim G:Estrogen in the treatment of depression;Neuropharmacological mechanism. Biol Psychiatry 18:721-725(1983)

43) Paige KE:Effects of oral contraceptives on affective fluctuations associated with the menstrual cycle. Psychosom Med 33:515-537(1971)

44) Prange AJ Jr:Estrogen may well affect response to antidepressant. JAMA 219(2):143-144 (1972)

45) Prange AJ Jr, Wilson IC, Knox A, et al:Enhancement of imipramine by thyroid stimulating hormone;Clinical and theoretical implication. Am J psychiatry 127:191-199 (1970)
pubmed

46) Prange AJ Jr, Wilson IC, Lara PP, et al:Effect of thyrotropin-releasing hormone in depression. Lancet ii:999-1002(1972)

47) Prange AJ Jr, Wilson IC, Rabon AM, et al:Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 126:39-51(1969)

48) Rees L:The premenstrual tension syndrome and its treatment. BMJ 1:1014(1953)
pubmed

49) Reiss M:Psychoendocrinology. Grune & Stratton, New York(1958)

50) Richter CP:Hormones and rhythms in man and animals. Recent Prog Horm Res 13:105-159 (1957)
pubmed

51) Riecher-Rossler A, Hafner H, Stumbaum M, et al:Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20:203-214(1994)

52) Sampson GA:Premenstrual syndrome;A double blind controlled trial of progesterone and placebo. Br J Psychiatry 135:209 (1979)
pubmed

53) Stancer HC, Persad E:Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatry 39:311-312(1982)

54) Vogel W, Klaiber EL, Broverman DM:Roles of the gonadal steroid hormones in psychiatric depression in men and women. Prog Neuropsychopharmacology 2:487-503 (1978)

55) Vogel W, Klaiber EL, Broverman DM:A comparison of the antidepressant effects of a synthetic androgen(Mesterolone)and amitriptyline in depressedmen. J Clin Psychiatry 46:6-8(1985)

56) 山口隆久, 大工清志, 辻村良太郎ほか:精神疾患の甲状腺ホルモン療法. 精神経誌85:769-776 (1983)

57) Zohar J, Drummer D, Edelstein ED:Effect of lysine vasopressin in depressed patients on mood and 24-hour rhythm of growth hormone, cortisol, melatonin and prolactine. Psychoneuroendocrinology 10:273-279 (1985)
pubmed

P.495 掲載の参考文献

1) Basile AS, Harrison PM, Hughes RD, et al:Relationship between plasma benzodiazepine receptor ligand concentration and severity of hepatic encephalopathy. Hepatology 19:112-121(1994)

2) Bennet WM, Singer I, Coggins CJ:A guide to drug therapy in renal failure. JAMA 230:1544-1553(1974)

3) Blascheke TF:Protein binding and kinetics of drugs in liver disease. Clin Pharmacokinet 2:32-44(1997)

4) Boobis SW:Alteration of plasma albumin in relation to decreased drug bindingin uremia. Clin Pharmacol Ther 22:147-153(1977)

5) Branch RA, Morgan MH, James J, et al:Intravenous administration of diazepam in patients with chronic liver disease. Gut 17:975-983(1976)

6) Byerly MJ, DeVane CL:Pharmacokinetics of clozapine and risperidone;A review of recent literature. J Clin Psychopharmacol 16:177-187(1996)

7) Fabre J, Balant L:Renal failure, drug pharmacokinetics and drug action. Clin Pharmacokinet 1:99-120(1976)

8) Ferenci P, Kleinberger G, Schafer DF, et al:Serum levels of gamma-aminobutyric-acid like activity in acute and chronic hepatocellular disease. Lancet ii:811-814 (1983)

9) Greenblatt DJ, Murray TG, Audet PR, et al:Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency. Nephron 34:234-238(1983)

10) Grossman SH, Davis D, Kitchell BB, et al:Diazepam and lidocaine plasma protein binding renal disease. Clin Pharmacol Ther 31:350-357(1982)

11) Groth U, Prellwitz W, Jahnchen E:Estimation of pharmacokinetic parameters of lithium from saliva and urine. Clin Pharmacol Ther 16:490-498(1974)

12) Gyr K, Meier R:Flumazenil in the treatment of portal systemic encephalopathy;An overview. Intensive Care Med 17:S39-S42(1991)

13) 石郷岡純, 竹内尚子:向精神薬の体内動態. 精神治療薬大系, 上島国利, 村崎光邦, 八木剛平(編), 第1巻向精神薬の歴史・基礎・臨床, pp 169-236, 星和書店, 東京(1996)

14) 石郷岡純, 若田部博文, 村崎光邦ほか:新しいBenzisoxazole系抗精神病薬Risperidoneの第I相試験. 臨床評価19:93-163(1991)

15) 石崎高志:肝硬変における薬物動態. 内科MOOK 34, 肝硬変, pp 147-158, 金原出版, 東京(1987)

16) Janssen U, Walker S, Maier K, et al:Flumazenil disposition and elimination incirrhosis. Clin Pharmacol Ther 46:317-323(1989)

17) Jick H:Adverse drug effects in relation to renal function. Am J Med 62:514-517 (1977)
pubmed

18) Klotz U, Antonin KH, Brugel H, et al:Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clin Pharmacol Ther 21:430-436(1977)

19) Kutt H, Winters W, Sherman R:Diphenylhydantoin and phenobarbital toxicity. Arch Neurol 11:649-656(1964)

20) Maher JF:Pharmacological considerations for renal failure and dialysis. Replacement of Renal Failure by Dialysis, Maher JF(ed), pp 1018-1076, Klumer Academic Publishers, Dordrecht(1989)

21) Mannens G, Huang ML, Meuldermans W, et al:Absorption, metabolism, and excertion of risperidone in humans. Drug Metab Dispos 21:1134-1141(1993)

22) Mannens G, Meuldermans W, Snoek E, et al:Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 114:566-572(1994)

23) Maxwell JD, Carrella M, Parkes JD, et al:Plasma disapperance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci 43:143-151(1972)

24) Meier R, Gyr K:Treatment of hepatic encephalopathy(HE)with the benzodiazepine antagonist flumazenil;A pilot study. Eur J Anaesthesiol 2(Suppl):139146 (1988)

25) Misra PS, Lefeure A, Ishii H, et al:Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and rat. Am J Med 51:346-351(1971)

26) 美川郁夫:高度腎機能障害例におけるスルピリドの吸収排泄動態と泌尿器科領域における使用経験について. 新薬と臨床31:691-694(1982)

27) 美川郁夫, 西東康夫, 横山修:腎機能障害患者におけるTiaprideの血中動態および尿中排泄について. 基礎と臨床18:5357-5362(1984)

28) 水野佳子:SM-3997の血清タンパクとの結合. 新医薬品承認審査概要(SDA)8, 厚生省薬務局審査課(1996)

29) Morgan MH, Read AE:Antidepressant and liver disease. Gut 13:697-701(1972)

30) Mullen KD, Basile AS:Benzodiazepine-receptor antagonists and hepatic encephalopathy;Where do we stand? Gastroenterology 105:937-940(1993)

31) Mullen KD, Szanter KM, Kaminsky-Russ K:"Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 366:8183 (1990)

32) Murray TG, Chiang ST, Koepka HH, et al:Renal disease, age, and oxazepam kinetics. Clin Pharmacol Ther 30:805-809(1981)

33) 中野重行:腎不全におけるpharmacokinetics. 腎と透析19:25-32(1985)

34) Odar-Cederlof I, Vessman J, Alvan G, et al:Oxazepam disposition in uremicpatients. Acta Pharmacol Toxical 40(Suppl 1):52-62(1977)

35) 大田和夫:腎不全患者と薬剤の投与. 人工腎臓の実際 , pp 479-501, 南江堂, 東京(1993)

36) Reidenberg MM:The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med 62:466-470(1977)

37) Reidenberg MM:The biotransformation of drug in renal failure. Am J Med 62:482-485 (1977)
pubmed

38) Sandz M, Vandel S, Vandel B, et al:Metabolism of amitriptyline in patients with chronic renal failure. Eur J Clin Pharmacol 26:227-232(1984)

39) 佐藤喜一郎, 山角駿:腎不全・透析患者の向精神薬療法. 神経精神薬理6:507-515 (1984)

40) Seyffart G:Drugs in renal failure;Dosing guideline for frequently used in end stage renal disease and dialysis patients. Blood Purif 3:140-168 (1985)

41) Shull HJ, Wilkinson GR, Johnson R, et al:Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 84:420-425(1976)

42) Sonne J, Andreasen PB, Loft S, et al:Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology 11:951-956(1990)

43) 内山真, 一瀬邦弘, 田中邦明:高齢者に対する向精神薬使用上の問題点. 精神科治療学6:159-167(1991)

44) 若田部博文, 石郷岡純, 大谷義夫:血液透析におけるハロペリドール血中濃度について. 神奈川精神薬理1:10-13(1987)

45) Wilkinson GR, Shand DG:A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390(1975)

46) Yurdaydin C, Gu Z, Nowak G, et al:Benzodiazepine receptor ligands are elevated in an animal model of hepatic encephalopathy;Relationship between brain concentration and severity of encephalopathy. J Pharmacol Exp Ther265:565-571 (1993)

47) Zeneroli ML, Venturini I, Corisi L, et al:Benzodiazepine-like compounds in plasma of patients with fulminant hepatic failure. Scand J Gastroenterol 33:310-313 (1988)

P.510 掲載の参考文献

1) Aarskog D:Association between maternal intake of diazepam and oral clefts. Lancet ii(7941):921 (1975)

2) Abramovici A, Abramovici I, Kalman G, et al:Teratogenic effect of chlorimi-pramine in a young human embryo. Teratology 24:42A(1981)

3) Ananth J:Congenital malformations with psychopharmacologic agents. Compr Psychiatry 16:437-445 (1975)
pubmed

4) 有広忠雅:薬剤服用と妊娠. 臨床成人病15(5):78-80(1985)

5) Atthinarayanan P, Pierig SH, Nigam SK, et al:Chlordiazepoxide withdrawal in the neonate. Am J Obstet Gynecol 124:212-213(1976)

6) Ayd FJ Jr:Children born of mothers treated with chlorpromazine during pregnancy. Clin Med 71:1758-1763(1964)

7) Bader TF, Newman K:Amitriptyline in human breast milk and the nursing infant's serum. Am J Psychiatry 137:855-856(1980)

8) Banister P, Dafoe C, Smith E, et al:Possible teratogenicity of tricyclic antide-pressants. BMJ 1:838-839(1972)

9) Barson AJ:Malformed infant. BMJ 1:45(1972)

10) Batnum S:Possible effect of chlordiazepoxide on the fetus. Can Med Assoc J 100:351 (1969)

11) Ben Musa A, Smith CS:Neonatal effects of maternal clomipramine therapy. Arch Dis Child 54:405(1979)

12) Bjerkedal T, Czeizel A, Goujard J, et al:Sodium valproate and spina bifida. Lancet ii(8307):1096 (1982)

13) Bossi L:Fetal effects of anticonvulsants. Antiepileptic Drug Therapy in Pediatrics, Morselli PL, Pippenger CE, Penry JK(ed), pp 37-64, Raven Press, New York(1983)

14) Briggs GG:Drugs in Pregnancy and Lactation. 3rd ed(1990):佐藤孝道:妊婦と薬剤の基本的な知識. 実践妊婦と薬, 佐藤孝道, 加藤弘道(編), pp 3-13, 薬業時報社, 東京(1992)

15) Calabrese JR, Gulledge AD:Psychotropics during pregnancy and lactation;A review. Psychosomatics 26(5):413-426(1985)

16) Catz CS:Diazepam in breast milk. Drug Ther 3:72-73(1973)

17) Cooper SJ:Psychotropic drugs in pregnancy;Morphological and psychological adverse effects on offspring. J Biosoc Sci 10:321-334 (1978)
pubmed

18) Coyle I, Wayner MJ, Singer G:Behavioral teratogenesis;A critical evaluation. Pharmacol Biochem Behav 4:191(1976)
pubmed

19) Cree JE, Meyer J, Hailey DM:Diazepam in labour;Its metabolism and effecton the clinical condition and thermogenesis of the newborn. BMJ 4:251-255(1973)

20) Crombie DL, Pinsent RJ, Fleming DJ:Imipramine in pregnancy. BMJ 1:745(1972)

21) Crombie DL, Pinsent RJ, Fleming DJ, et al:Fetal effects of tranquilizers in pregnancy. N Engl J Med 293:198-199(1975)

22) Desmond MM, Schwanecke RP, Wilson GS, et al:Maternal barbiturate utilisation and neonatal withdrawal symptomatology. J Pediatr 80:190-197(1972)

23) Donaldson GL, Bury RG:Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy. Acta Paediatr Scand 71:335-338(1982)

24) Eggermont E, Raveschot J, Deneve V, et al:The adverse influence of imipramineon the adaptation of the newborn infant to extrauterine life. ActaPaediatr Belg 26:197-204 (1972)
pubmed

25) Falterman CG, Richardson CJ:Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 97:308-310(1980)

26) Freeman R:Limb deformities;Possible association with drugs. Med J Aust 1:606-607 (1972)
pubmed

27) Friis B, Sandemann H:Neonatal hypocalcemia after intrauterine exposure to anticonvulsant drugs. Arch Dis Child 52:239-247(1977)

28) 藤原妙子, 岡崎祐士:精神神経疾患合併妊娠の薬物療法. 周産期医学25(2):213-216 (1995)

29) 福島裕, 近藤毅:抗てんかん薬の副作用-催奇形性. 臨床精神薬理11(2):121-128 (1989)

30) Gillberg C:"Floppy infant syndrome" and maternal diazepam. Lancet ii(8031):244 (1977)

31) Goldfield M, Weinstein M:Lithium carbonate in obstetrics;Guidelines for clinical use. Am J Obstet Gynecol 116:15-22(1973)

32) Hall G:A case of phocomelia of the upper limbs. Med J Aust 1:449-450(1963)

33) Hammond JE, Toseland PA:Placental transfer of chlorpromazine. Case report. Arch Dis Child 45:139-140(1970)

34) Hanson JW, Oakley GP Jr:Haloperidol and limb deformity. JAMA 231(1):26(1975)
pubmed

35) Hartz SC, Heinonen OP, Shapiro S, et al:Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 292:726-728(1975)

36) Hauser LA:Pregnancy and psychiatric drugs. Psychopharmacology 26(8):817818 (1985)

37) Hill RM, Desmond MM, Kay JL:Extrapyramidal dysfunction in an infant of aschizophrenic mother. J Pediatr 69:589-595(1966)

38) 本多裕, 岡崎祐士:妊娠・出産と精神障害. 臨床精神医学6(4):483-491(1977)

39) 本多裕, 田中光芳:妊娠・産褥期の精神障害. 臨床精神医学10(1):21-28(1981)

40) Jones KL, Smith DW:Recognition of the fetal alcohol syndrome in early infancy. Lancet ii(7836):999-1001 (1973)

41) 梶谷喬:抗てんかん薬の催奇形性. 神経精神薬理3(4):297-305(1981)

42) Kallen B, Tandberg A:Lithium and pregnancy. Acta Psychiatr Scand 68:134-139 (1983)
pubmed

43) 兼子直:妊娠・出産とてんかん. てんかん学の進歩, 秋元波留夫, 山内俊雄(編), No 3, pp 189-201, 岩崎学術出版社, 東京(1996)

44) 兼子直:妊娠可能年齢にあるてんかん女性の治療. 精神経誌99(10):763-770(1997)

45) 兼子直, 安井規雄:妊娠, 出産に関する薬物療法. 精神科治療学13(増):209-213 (1998)

46) Kanto JH:Use of benzodiazepines during pregnancy, labour and lactation with particular reference to pharmacokinetic considerations. Drugs 23:354-38(1(1982)

47) 風祭元:胎児に対する精神神経用薬剤の影響. 周産期医学8(7):775-780(1978)

48) 風祭元, 池田久基:妊娠と薬剤向精神薬, 睡眠薬. 臨床医薬情報6(2):59-62(1987)

49) 木下潤:向精神薬の妊娠・出産・胎児への影響. 周産期医学4(10):935-945(1974)

50) 木下潤:妊産婦・胎児・新生児. 精神科MOOK, 八木剛平(編), 増刊No 1 精神科領域における薬物療法, pp 325-349, 金原出版, 東京(1989)

51) Kopelman AE, McCullar FW, Heggeness L:Limb malformations following maternal use of haloperidol. JAMA 231(1):62-64(1975)

52) Kris EB:Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 7:785-789(1965)

53) Kuenssberg EV, Knox JDE:Imipramine in pregnancy. BMJ 2:292(1972)

54) Levy L:Imipramine and fetal deformities. Can Mad Assoc J 106:1057-1058(1972)

55) Lewis WH, Suris OR:Treatment with lithium carbonate;Results in 35 cases. Tex Med 66:58-63(1970)
pubmed

56) Marchetti F, Romero M, Bonati M, et al:Use of psychotropic drugs during pregnancy;A report of the international cooperative drug use in pregnancy(DUP)study. Eur J Clin Pharmacol 45:495-501(1993)

57) Mazzi E:Possible neonatal diazepam withdrawal;A case report. Am J Obstet Gynecol 129:586-587(1977)

58) McBride WG:Limb deformities associated with iminodibenzyl hydrochloride. Med J Aust 1:492(1972)
pubmed

59) Milkovich L, van den Berg BJ:Effects of prenatal meprobamate and chlordiazepoxidehydrochloride on

60) 宮原明夫, 岡崎祐士:妊婦への向精神薬投与上の注意. 臨薬物治療9(4):103-109(1990)

61) Morrow AW:Limb deformities associated with iminodibenzyl hydrochloride. Med J Aust 1:658-659(1972)

62) 中島一憲, 守屋裕文, 正岡直樹ほか:妊婦の精神病に対する無けいれん性電撃治療の有効性と安全性について. 精神医学30(8):907-914(1988)

63) 中根允文:妊婦に対する向精神薬の使用. 臨床精神医学5(9):1171-1180(1976)

64) 中根允文:副作用-抗てんかん薬の妊婦および子どもへの影響. てんかん学, 秋元波留夫, 山内俊雄(編), pp 337-350, 岩崎学術出版社, 東京(1984)

65) Nelson BK:Evidence for behavioral teratogenicity in humans. J Appl Toxicol 11:33-37 (1991)
pubmed

66) Nora JJ, Nora AH, Toews WH:Lithium, Ebstein's anomaly, and other congenital heart defects. Lancet ii(7880):594-595 (1974)

67) Nurnberg HG, Prudic J:Guidelines for treatment of psychosis during pregnancy. Hosp Community Psychiatry 35(1):67-71(1984)

68) O'Brien TE:Excretion of drugs in human milk. Am J Hosp Pharm 31:844-854(1974)

69) 岡野禎治, 野村純一:産褥精神病-その概念と今日的意義について. 精神科治療学9(2):148-156 (1994)

70) 岡崎祐士:個別指導における基本技術と心がまえ-妊婦の精神障害とその対策. 周産期医学10(8):1209-1214(1980)

71) 岡崎祐士, 本多裕:精神障害の既往のある妊産婦の産褥期における再発予防プログラム. 助産婦誌39:776-778(1985)

72) 岡崎祐士:妊娠期および産後の精神障害の病態と予防・治療. 精神科MOOK, 原田憲一(編), No 11身体疾患と精神科障害. pp 148-161, 金原出版, 東京(1985)

73) 大熊輝雄, 高橋良, 中根允文ほか:抗てんかん薬の催奇形性について. 神経の進歩23(6):1247-1263(1979)

74) O'Leary JL, O'Leary JA:Nonthalidomide ectromelia, report of a case. Obstet Gynecol 23:17-20 (1964)
pubmed

75) Park JM, Sridaromont S, Ledbetter EO, et al:Ebstein's anomaly of the tricuspid valve associated with prenatal exposure to lithium carbonate. Am J Dis Child 134:703-704 (1980)
pubmed

76) Pastuszak A, Schick-Boschetto B, Zuber C, et al:Pregnancy outcome following first-trimester exposure to fluoxetine(Prozac). JAMA 269(17):2246-2248(1993)

77) Patrick MJ, Tilstone WJ, Reavey P:Diazepam and breast-feeding. Lancet i(7749):542-543 (1972)
pubmed

78) Rachelefsky GS, Flynt JW Jr, Ebbin AJ, et al:Possible teratogenicity of tricyclic antidepressants. Lancet i(7755):838-839 (1972)

79) Rane A, Tomson G, Bjarke B:Effects of maternal lithium therapy in a new born infant. J Pediatr 93:296-297 (1978)

80) Rementeria JL, Bhatt K:Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 90:123 (1977)
pubmed

81) Robinson GE, Stewart DE, Flak E:The rational use of psychotropic drugs in pregnancy and postpartum. Can J psychiatry 31:183-190 (1986)
pubmed

82) Rosenberg L, Mitchell A, Parsells J, et al:Lack of relation of oral cleft todiazepam use during pregnancy. N Engl J Med 309:1282-1285(1983)

83) Rumeau-Rouquette C, Goujard J, Huel G:Possible teratogenic effects of phenothiazines in human beings. Teratology 15:57-64(1976)

84) Safra MJ, Oakley GP Jr:Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet ii(7933):478-480(1975)
pubmed

85) 佐藤孝道:妊婦と薬剤の基本的な知識. 実践妊婦と薬, 佐藤孝道, 加藤弘道(編), pp 3-13, 薬業時報社, 東京(1992)

86) Saxen I, Saxen L:Association between maternal intake of diazepam and oral clefts. Lancet ii(7933):498 (1975)

87) Scanlan FJ:The use of thioridazine(Melleril)during the first trimester. Med J Aust 1:1271-1272(1972)

88) Schou M, Amdisen A, Jensen E, et al:Occurrence of goiter during lithium treatment. BMJ 3:710-713(1968)

89) Schou M, Goldfield MD, Weinstein MR, et al:Lithium and pregnancy. I. Preport from the register of lithium babies. BMJ 2:135-136(1973)

90) Schou M, Amdisen A:Lithium and pregnancy. III. Lithium ingestion by children breast-feed by women on lithium treatment. BMJ 2:138(1973)

91) Schou M:What happened later to the lithium babies? A follow-up study of children born without malformation. Acta Psychiatr Scand 54:193-197(1976)

92) 島悟:妊娠・出産・授乳に対する影響. 精神治療薬大系, 三浦貞則(監), 上島国利, 村崎光邦, 八木剛平(編), 第5巻向精神薬の副作用とその対策 , pp 322340, 星和書店, 東京(1997)

93) 清水章子, 北脇雅之, 千葉健:精神分裂病患者の妊娠中の再発例について-臨床上の問題点をめぐって. 臨床精神医学13(7):861-867(1984)

94) Sim M:Imipramine and pregnancy. BMJ 1:45(1972)

95) Sjoqvist F, Berfor PG, Borga O, et al:Plasma disappearance of nortriptyline in a new born infant following placental transfer from an intoxicated mother;Evidence for drug metabolism. J Pediatr 80:496-500(1972)

96) Slone D, Siskind V, Heinonen OP, et al:Antenatal exposure to the phenothiazinesin relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128:486-488(1977)

97) Sobel DE:Infant mortality and malformations in children of schizophrenic women. Psychiatr Q 35:60-64(1961)

98) Sovner R, Orsulak PJ:Excretion of imipramine and desipramine in human breast milk. Am J Psychiatry 136:451-452(1979)

99) Stochers JK, Wilson DW, Royston N:Lithium toxicity in the new born. BMJ 3:233-234 (1973)

100) 須賀良一, 三浦まゆみ, 八幡剛喜ほか:妊娠中の分裂病者への向精神薬使用について. 精神医学28(1):101-103(1986)

101) 竹村道夫, 和田周太, 淵野和子:ClomipramineとDesmethyl clomipramineの乳汁中への分泌. 精神医学24(7):749-753(1982)

102) Tamer A, McKey R, Arias D, et al:Phenothiazine-induced extrapyramidal dysfunction in the neonate. J Pediatr 75:479-480 (1969)
pubmed

103) 田中光芳, 本多裕, 岡崎祐士:女子精神障害者の妊娠・出産期における増悪・再発の追跡調査. 臨床精神医学9(9):929-936(1980)

104) 田中光芳, 本多裕:母体に投与した薬剤の新生児に及ぼす影響-向精神薬. 周産期医学11(10):1425-1429(1981)

105) 田中雄三, 土屋均, 浜崎豊ほか:向精神薬服用中の女子精神疾患患者の出産について. 精神医学31(3):297-306(1989)

106) van Creveld S:Nouveaux aspects de la maladie hemorragique du nouveaung. Arch Fr Pediatr 15:721-724(1958)

107) Vince DJ:Congenital malformations following phenothiazine administration during pregnancy. Can Med Assoc J 100:223(1969)
pubmed

108) Weinstein MR, Goldfield MD:Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 132:529-531(1975)

109) Wertelecki W, Purvissmith SG, Blackburn WR:A mitriptyline-perphenazine maternal over-dose and birth defect. Teratology 21:74A(1980)

110) Wilson JG:Environmental effects on development. Teratology, Pathophysiology of Gestation, Assali NS(ed), Vol 2, p 269, Academic Press, New York(1972)

111) Wilson JG:Present status of drugs as teratogens in man. Teratology 7:3-16 (1972)

112) Woody JN, London WL, Wilbanks GD:Lithium toxicity in the newborn. Pediatrics 47:94-96 (1971)
pubmed

113) 山下晋:妊婦・授乳婦への薬物投与時の注意(改訂4版). 医薬ジャーナル社, 大阪(1998)

114) 八幡剛喜, 鈴木孝明, 湯沢秀夫ほか:精神分裂病合併妊娠・分娩の臨床統計. 臨婦産39(1):47-51(1985)

115) Zackai EH, Mellman WJ, Niederren B, et al:The fetal trimethadione syndrome. J Pediatr 87:280(1975)

P.526 掲載の参考文献

1) Castleden CM, George CF, Marcer D, et al:Increased sensitivity to nitrazepamin old age. BMJ 1:10-12(1977)
pubmed

2) Chiu TH, Tietz EI, Rosenberg HC:Benzodiazepine. Toxicology of CNS Depressants, Ho IK(ed), pp 1-22, CRC Press, Florida(1987)

3) Cook PJ, Flanagan R, James IM:Diazepam tolerance;Effect of age, regular sedation, and alcohol. BMJ 289:351-353(1984)

4) Dawling S, Crome P:Clinical pharmacokinetic consideration in the elderly. Unupdate. Clin Pharmacokinet 17:236-263(1989)

5) Dillon N, Chung S, Kelly J, et al:Age and beta adreno receptor mediated function. Clin Pharmacol Ther 27:769-772(1980)

6) Drachman DA:Memory and cognitive function in man;Does the cholinergic system have a specific role? Neurology 27:783-790(1977)

7) Eap CB, Cuendet C, Baumann P:Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. Arch Pharmacol 337:220-224 (1988)

8) Farde L, Wiesel FA, Halldin C, et al:Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic durgs. Arch Gen Psychiatry 44:71-76 (1988)

9) Flood JF, Smith GG, Cherkin A:Memory retention;Potentiation of cholinergic drug contributions in mice. Neurobiol Aging 4:37-43(1983)

10) Foote SL, Aston-Jones GS:Pharmacology and physiology of central noradrenergic systems. Psychopharmacology;The fourth generation of progress, Bloom FE, Kupfer DJ(ed), pp 335-345, Raven Press, New York(1995)

11) Gerber JG:Drugs usage in the elderly. Clinical Internal Medicine in the Aged, Schrier RW(ed), Saunders, Philadelphia(1982)

12) Henann NE, Carpenter DU, Janda SM:Famotidine-associated mental confusion in elderly patients. Drug Intell Clin Pharm 22:976-978(1988)

13) Hollister L:General principles of treating the elderly with drugs. Clinical Pharmacology and the Aged Patients, Jarvic L(ed), pp 1-9, Raven Press, New York(1981)

14) Kapur S, Remington G, Zipursky R, et al:The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms;APET study. Life Sci 57:103-107 (1995)

15) Kitani K:Drugs and ageing liver. Life Chem Rep 6:143-230(1988)

16) Learoyd BW:Psychotropic drug and elderly patient. Med J Aust 1:131-133(1972)

17) Mark LC, Sheldon HP, Ronald LM:Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Geriatric Psychiatry 20:205-218 (1997)

18) Mark TK, Peter C:Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet 33:302-312(1997)

19) McBride PA, Brown RP, DeMeo M, et al:The relationship of 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behavior. Biol Psychiatr 35:295-308 (1994)

20) Miyamoto M, Narumi S, Nagaoka A, et al:Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesion. J Paharmacol Exp Ther 249:825-835(1989)

21) Morgan DG, May PC, Finch CE:Dopamine and serotonin systems in human and rodent brain;Effects of age and neurodegenerative disease. Am Geriatr Soc 35:334-345 (1987)
pubmed

22) Pandey GN, Pandey SC, Dwivedi Y, et al:Platelet serotonin-2A receptors;A potential biological marker for suicidal behavior. Am J Psychiatry 152:850-855(1995)

23) Polc P, Bonetti EP, Schaffner R, et al:A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist RO15-1788, benzodiazepine tranquilizers, β-carbolines and phenobarbitone. Naunyn-Schmiedebergs Arch Pharmacol 321:260-264(1982)

24) Pollock BG, Perel JM, Reynolds CF III:Pharmacodynamic issues relevant togeriatric psychopharmacology. J Geriatr Psychiatry Neurol 31221-228(1990)

25) Preskorn SH, Jerkovich GS:Central nervous system toxicity of tricyclic antidepressants;Phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 10:88-95(1990)

26) Roberts J, Tumer N:Age and diet effects on drug action. Pharmacol Ther 37:111-149 (1988)
pubmed

27) Saura J, Andr6s N, Andrade C, et al:Biphasic and region-specific MAO-Bresponse to aging in normal human brain. Neurobiol Aging 18:497-507(1997)

28) Severson JA, Marcusson J, Winblad B, et al:Age-correlated loss of dopaminergic binding sites in human basal ganglia. J Neurochem 39:1623-1631(1982)

29) Shimada T, Yamazaki H, Mimura M, et al:Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals;Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423(1994)

30) Spigset O, Mj6rndal T:Seroton in 5-HT, A receptor binding in platelets from healthy subjects as studied by[3H]-lysergic acid diethylamide([3H]-LSD);Intra-and interindividual variability. Neuropsycho Pharmacology 16:285. 293(1997)

31) Sunderland T:Neurotransmission in the aging central nervous system. Clinical Geriatric Psychopharmacology, 2nd ed, Salzman C(ed), pp 41-59, Williams & Wilkins, Baltimore(1992)

32) Swift CG, Swift MR, Hamley J, et al:Side-effect 'tolerance' in elderly long-term recipients of benzodiazepine hypnotics. Age Ageing 13:335-343(1987)

33) Swift CG:Pharmacodynamics;Changes in homeostatic mechanisms, receptor and target organ sensitivity in the elderly. B M Bull 46:36-52(1990)

34) 朝長正徳:老年期における青斑核の変化について. 日老医誌16:545-549(1979)

35) Tumer N, Scarpace PJ, Lowenthal DT:Geriatric pharmacology;Basic and clinical considerations. Ann Rev Pharmacol Toxicol 32:271-302(1992)

36) Volkow ND, Wang GJ, Joanna S, et al:Measuring age-related changes in dopamine D2 receptors with 11C-raclopride and 18F-N-methylspiroperidol. Psychiatr Res Neuroimaging 67:11-16(1996)

P.543 掲載の参考文献

1) Akiskal HS, Bital AH, Puzantian VR, et al:The nosological status of neurotic depression. Arch Gen Psychiatry 35:756-766(1978)

2) Asperger H:Autistische Psychopathen im Kinderalter. Arch Psychiatr Nerven kr 117:76-136(1944)-詫摩武元(訳):小児の自閉的精神病質. 児精医誌34:180-197, 282-301 (1993)

3) Bernstein GA, Borchard CM:Anxiety disorders of childhood and adolescence;A critical review. J Am Acad Child Adolesc Psychiatry 30:519-532(1991)

4) Bradley C:The behavior of children receiving benzedrine. Am J Psychiatry 94:577-585 (1937)

5) Cohen HJ, Biel HJ, Crain LS, et al:Medication for children with an attention deficit disorder. Pediatrics 80:56-59 (1987)

6) Conners CK:The teacher rating scale for use in drug studies with children. Am J Psychiatry 126:884-888 (1969)
pubmed

7) Cooper JR, Bloom FE, Roth RH:The Biochemical Basis of Neuropharmacology. 3rd ed, Oxford University Press, New York(1977)

8) Dauel RK:Treatment of attention problems with stimulant medication. J Pediatrics 113:68-71 (1988)

9) Drug Prescribing in Renal Failure:Dosing Guideline for Adult. 3rd ed, the American College of Physicians, Philadelphia(1994)-臨牀透析編集委員会川口良人, 浅野泰, 佐藤喜一郎ほか:鎮静薬, 睡眠導入薬, 向精神薬;腎不全時の薬物使用-適正投与法のガイドライン. 臨牀透析(4月特別増刊号)(1998)

10) 藤川英昭, 小林隆児, 古賀靖彦ほか:大学入学後に精神病的破綻をきたし, 抑うつ, 自殺企図を示した19歳のAsperger症候群の1例. 児精医誌28:217-225(1987)

11) Graae F, Milner J, Rizzotto L, et al:Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:372-376(1994)

12) Garfankel BD, Nolan EE, Sverd J, et al:Tricyclic antidepressant and methyl-phenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 22:318-348(1983)

13) Gittelman R, Mannuzza S:Hyperactive boys almost grown up, III;Methyl-phenidate effects on ultimate height. Arch Gen Psychiatry 45:1131-1134(1988)

14) Gross M:Case report-improvement with L-dopa in a hyperkinetic child. Dis Nervous System 38:556-559(1977)

15) Gualtieri CT, Evans RW:Motor Performance in hyperactive children treated with imipramine. Percept Mot Skills 66:763-769(1988)

16) Hasen CR, Cohen DJ:Multimodality approach in treatment of attention deficit disorders. Pediatr Clin North Am 31:499-513(1984)

17) Hechman L:Adolescent outcome of hyperactive children treated with stimulant in childhood;A review. Psychopharmacol Bull 21:178-191(1985)

18) 帆足英一:遺尿症・遺糞症. 精神科治療学10(臨時特大号):285-286(1995)

19) 本城秀次:小児期に特異的に発症する情緒障害 . 精神科治療学10(臨時特大号):271-273 (1995)

20) 石川知子:行為障害. 精神科治療学10(臨時特大号):268-270(1995)

21) Kaplan HI, Sadock BJ, Grebb JA:Kaplan and Sadock's Synopsis of Psychiatry. 7th ed, William's and Wilkins, Baltimore(1994)-井上令一, 四宮滋子(監訳):カプラン臨床精神医学テキスト DSM-IV. 診断基準の臨床への展開 , 医学書院MYW, 東京(1996)

22) Klein RG:Prognosis of attention deficit disorder and its management in adolescence. Pediatr Rev 8:216-222 (1987)
pubmed

23) 小林隆児:自閉症-その多彩な臨床症状をどのように理解できるか. 臨床精神医学22:575-581 (1993)

24) Levine MD, Brooks R, Shonkoff JP:A Pediatric Approach to Learing Disorders. John Wiley & Sons, New York(1980)

25) Lipsitz JD, Martin LY, Mannuzza S, et al:Childhood separation anxiety disorder in patients with adult anxiety disorder. Am J Psychiatry 51:927-929(1994)

26) Lowe TL, Cohen DJ, Detlor J, et al:Stimulant medication precipitate Tourette's syndrome. JAMA 247:1168-1169(1982)

27) McGee R, Share DL:Attention deficit disorder-Hyperactivity and academic failure;Which comes first and what should be treated? J Am Acad Child Adolesc Psychiatry 27:318-325(1988)

28) 中根晃:多動症症候群. 精神科治療学10(臨時特大号):264-267(1995)

29) 小倉清:小児期の恐怖症性不安障害, 社会性不安障害. 精神科治療学10(臨時特大号):274-275(1995)

30) 太田昌孝:多動症候群の神経心理学. 発達の心理学と医学1:161-176(1990)

31) 太田昌孝, 清水康男, 原仁:小児の行動異常の薬物療法. 神経精神薬理6:135-144 (1998)

32) Raskin LA, Shaywitz SE, Shaywitz BA, et al:Neurochemical correlates of attention deficit disorder. Pediatr Clin North Am 31:387-396(1984)

33) Sandberg S:Hyperkinetic and attention deficit disorder. Br J Psychiatry 169:1017 (1996)

34) 佐藤喜一郎:夜尿症の治療<その1>-クロミプラミンの治療効果と夜尿症児の諸特性との関連について. 薬理と治療11:209-232(1983)

35) 佐藤喜一郎:チック. 小児科診療50:2142-2146(1987)

36) 佐藤喜一郎:中枢神経の異常に対する薬剤-透析患者への薬剤. 臨牀透析11(特別増刊号):86-119(1995)

37) Shaywitz SA, Yager RD, Klopper JH:Selective brain dopamine depletion indeveloping rats;An experimental models of minimal brain dysfunction. Science 191:305-308 (1976)

38) Shaywitz SE, Shaywitz BA:Diagnosis and management of attention deficit disorder;A pediatric perspective. Pediatr Clin North Am 31:429-457(1984)

39) 白瀧貞昭:チック障害. 精神科治療学10(臨時特大号):282-284(1995)

40) 上野和彦:学習障害. 児童心理学の進歩, 1986年度版, pp 183-207, 金子書房, 東京(1986)

41) 山崎晃資:小児期の神経症的発症と行動異常. 向精神薬治療ハンドブック, 改訂3版, 風祭元(編), pp 152-165, 南江堂, 東京(印刷中)

42) 山崎晃資:精神遅滞, 自閉症. 向精神薬治療ハンドブック, 改訂3版, 風祭元(編), pp 167-176, 南江堂, 東京(印刷中)

43) Werry JS:An overview of pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 21:3-9(1982)

44) Zametkin A, Rapoport J:Neurobiology of attention deficit disorder with hyper-activity;Where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 26:676-686 (1987)

P.561 掲載の参考文献

1) 青葉安里:老人における向精神薬の薬物動態学的特徴. 精神科治療学10(7):765770 (1995)

2) 青葉安里, 上村誠:抗精神病薬の薬物相互作用. 臨床精神医学26(2):155-163(1997)

3) Arana GW, Epstein S, Molloy M, et al:Carbamazepine-induced reduction of plasma alprazolam concentrations;A clinical case report. J Clin Psychiatry 49(11):448-449 (1988)
pubmed

4) Bailey DG, Arnold JMO, Spence JD:Grape fruit juice and drugs;How significant is the interactions? Clin Pharmacokinet 26(2):91-98(1994)

5) Bertilsson L, Alm C, De Las Carreras C, et al:Debrisoquine hydroxylation polymorphism and personality. Lancet i:555(1989)
pubmed

6) Bertilsson L, Dahl M-L:Polymorphic drug oxidation;Relevance to the treatment of psychiatric disorders. CNS Drugs 5(3):200-223(1996)

7) Bertschy G, Vandel S, Vandel B, et al:Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol 40:119-120(1991)

8) Bouchard RH, Pourcher E, Vincent P:Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146(10):1352-1353(1989)

9) Brosen K, Skjelbo E, Rasmussen BB, et al:Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacology 45(6):1211-1214(1993)

10) Centorrino F, Baldessarini RJ, Kando J, et al:Serum concentrations of clozapine and its major metabolites;Effects of cotreatment with fluoxetine orvalproate. Am J Psychiatry 151(1):123-125(1994)

11) 千葉寛:薬物代謝に関しての薬物間相互作用の基礎知識. 治療76(9):2214-2220 (1994)

12) Crewe HK, Lennard MS, Tucker GT, et al:The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6(CYP2D6)activity in human liver microsomes. Br J Clin Pharmacol 34:262-265(1992)

13) De Vane CL:Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 55(Suppl 12):38-45 (1994)

14) Glue P, Banfield C:Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacology 11:97-114(1996)

15) Goff DC, Baldessarini RJ:Drug interactions with antipsychotic agents. J Clin Psychopharmacol 13(1):57-67(1993)

16) Goff DC, Midha KK, Sarid-Segal O, et al:A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 117:417-423 (1995)
pubmed

17) Gram LF, Fredricson-Overo K:Drug interaction;Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. BMJ 1:463-465(1972)

18) Greenblatt DJ:Basic pharmacokinetic principles and their application to psychotropic drugs. J Clin Psychiatry 54(Suppl 9):8-13 (1993)

19) Greenblatt DJ, Preskorn SH, Cotreau MM, et al:Fluoxetine impairs clearance of alprazolam but not clonazepam. Clin Pharmacol Ther 52(5):479-485(1992)
pubmed

20) Greenblatt DJ, von Moltke LL, Harmatz JS, et al:Interaction of triazolam and ketoconazole. Lancet 345:191 (1995)
pubmed

21) Grimsley SR, Jann MW, Carter JG, et al:Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 50(1):10-15 (1991)
pubmed

22) Gugler R, Jensen JC:Omeprazole inhibits oxidative drug metabolism;Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gas-troenterology 89(6):1235-1241 (1985)

23) Hanner M, Moebius FF, Flandorfer A, et al:Purification, molecular cloning, and expression of the mammalian sigma-1 binding site, Proc Natl Acad Sci USA 93:8072-8077 (1996)

24) Harris RA, Allan AM:Alcohol intoxication;Ion channels and genetics. FASEB J 3:1689-1695(1989)

25) Heiman EM:Cardiac toxicity with thioridazine-tricyclic antidepressant combination. J Nerv Ment Dis 165(2):139-143(1977)

26) 樋口輝彦:アルコールと向精神薬の相互作用-薬物動態および薬力学的観点より. 精神科治療学10(7):771-778(1995)

27) Inaba T, Jurima M, Mahon WA, et al:In vitro inhibition studies of two isozymes of human liver cytochrome P-450;Mephenytoin phydroxylase and sparteine monooxygenase. Drug Metab Dispos 13(4):443-448(1985)

28) 石崎高志:チトクロムP450(cytochromes P450)の遺伝的多型性と向精神薬の代謝. 臨床精神医学26(2):137-152(1997)

29) Jalil P:Toxic reaction following the combined administration of fluoxetine and phenytoin;Two case reports. J Neurol Neurosurg Psychiatry 55:412-413(1992)

30) Janicak PG:The relevance of clinical pharmacokinetics and therapeutic drug monitoring;Anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 54(Suppl 9):35-41 (1993)

31) Jerling M, Lindstrom L, Bondesson U, et al:Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine;Evidence from a therapeutic drug monitoring service. Ther Drug Monit 16(4):368-374(1994)

32) Kapur S, Remington G:Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153(4):466-476(1996)

33) Kidron R, Averbuch I, Klein E, et al:Carbamazepine-induced reduction of bloodlevels of haloperidol in chronic schizophrenia. Biol Psychiatry 20:219-222(1985)

34) Klein M, Musacchio JM:Effects of cytochrome P-450 ligands on the binding of [3H] dextromethorphan and sigma ligands to guineapig brain. Sigma Receptors, Itzhak Y(ed), pp 243-262, Acad Press, London(1994)

35) Kudriakova TB, Sirota LA, Rozova GI, et al:Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 33:611-615(1992)

36) Lai AA, Levy RH, Cutler RE:Time-course interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 24(3):316-323(1978)

37) Leinonen E, Lillsunde P, Laukkanen V, et al:Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychophar-macol 11(5):313-318(1991)

38) Lemoine A, Gautier JC, Azoulay D, et al:Major pathways of imipramine metabolism is catalyzed by cytochromes P-4501A2 and P-4503A4 in human liver. Mol Pharmacol 43:827-832(1993)

39) Lin KM, Poland RE, Lau JK, et al:Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 8(3):195-201(1988)

40) LLerena A, Alm C, Dahl M-L, et al:Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14(2):92-97(1992)

41) LLerena A, Dahl M-L, Ekqvist B, et al:Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype;Increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14(3):261-264(1992)

42) LLerena A, Edman G, Cobaleda J, et al:Relationship between personality and debrisoquine hydroxylation capacity;Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87:23-28 (1993)
pubmed

43) Muly EC, Mcdonald W, Steffens D, et al:Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry 150(10):1565(1993)
pubmed

44) 村崎光邦:抗不安薬, 睡眠薬. 精神治療薬大系, 三浦貞則(監), 第4巻, 星和書店, 東京(1997)

45) Nakamura K, Goto F, Ray WA, et al:Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38(4):402-408(1985)

46) Nanda RN, Johnoson RH, Keogh HJ, et al:Treatment of epilepsy with clonazepam and its effect on the other anticonvulsants. J Neurol Neurosurg Psychiatry 40:538-543 (1977)

47) Nelson JC:Combined treatment strategies in psychiatry. J Clin Psychiatry 54(Suppl 9):42-49 (1993)

48) Nemeroff CB, De Vane CL, Pollock BG:Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153(3):311-320(1996)

49) Niznik HB, Tyndale RF, Sallee FR, et al:The dopamine transporter and cytochrome P45011Dl(debrisoquine 4-hydroxylase)in brain;Resolution and identification of two distinct[3H]GBR-12935 binding proteins. Arch Biochem Biophys 276(2):424-432 (1990)
pubmed

50) Olkkola KT, Aranko A, Luurila H, et al:A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53(3):298-305(1993)

51) Olkkola KT, Backman JT, Neuvonen PJ:Midazolam should be avoided inpatients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55(5):481-485(1994)

52) Pourbaix S, Desager Jp, Hulhoven R, et al:Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolamand triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicology23(8):447-451 (1985)

53) Preskorn SH:Pharmacokinetics of psychotropic agents;Why and how they are relevant to treatment. J Clin Psychiatry 54(Suppl 9):3-7(1993)

54) Preskorn SH:Pharmacokinetics of antidepressants;Why and how they are relevant to treatment. J Clin Psychiatry 54(Suppl 9):14-34(1993)

55) Rivera-Calimlim L:Problems in therapeutic blood monitoring of chlorpromazine. Ther Drug Monit 4(1):41-49(1982)

56) Rudorfer MV:Pharmacokinetics of psychotropic drugs in special populations. J Clin Psychiatry 54(Suppl 9):50-54 (1993)

57) 坂井俊之, 上島国利:抗うつ薬の薬物相互作用. 臨床精神医学26(2):165-177(1997)

58) Sellers EM, Busto U:Benzodiazepines and ethanol;Assessment of the effects and consequences of psychotropic drug interactions. J Clin Psychopharmacol 2(4):249-262 (1982)
pubmed

59) Spina E, Ancione M, Di Rosa AE, et al:Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 42:347-348(1992)

60) Spina E, Caputi AP:Pharmacogenetic aspects in the metabolism of psychotropic drugs;Pharmacokinetic and clinical implications. Pharmacol Res 29(2):121-137 (1994)

61) Spina E, Perucca E:Newer and older antidepressants;A comparative review of drug interactions. CNS Drugs 2(6):479-497(1994)

62) Sternbach H:The serotonin syndrome. Am J Psychiatry 148(6):705-713(1991)

63) Stoehr GP, Kroboth PD, Juhl RP, et al:Effect of oral contraceptives on triazolam, temazepam, alprazolam and lorazepam kinetics. Clin Pharmacol Ther 36(5):683-690 (1984)
pubmed

64) Syvalahti EKG, Lindberg R, Kallio J, et al:Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22:89-92(1986)

65) Vahre A, Olkkola KT, Neuvonen PJ:Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56(6):601-607(1994)
pubmed

66) von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al:Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole;A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268(3):1278-1283(1994)

67) von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al:Inhibitors of alprazolam metabolism in vitro;Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31(1994)

68) von Moltke LL, Greenblatt DJ, Harmatz JS, et al:Cytochromes in psychopharmacology. J Clin Psychopharmacol 14(1):1-4(1994)

69) Watanabe M, Rominger D, Hurt SD, et al:[3H]1-(cyclopropylmethyl)-4-〔2-(4-fluorophenyl)-2-oxoethyl〕piperidine HBr(DuP734);A selective ligand forsigma receptors in mouse brain in vivo. J Pharmacol Exp Ther 266(3):1541-1548 (1993)

70) Wood AJJ, Zhou H:Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 20(5):350-373(1991)

71) 山本秀子, 山本敏文, 渡辺雅幸:シグマ受容体(δreceptors). 精神科治療学12(8):987-989 (1997)

P.577 掲載の参考文献

1) Bauer LA, Davis R, Wilensky A, et al:Valproic acid clearance;Unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 37:697-700 (1985)

2) Black I, Parker L, Axelrod J:A daily rhythm in the rate of depletion of brain norepinephrine by reserpine. Biochem Pharmacol 18:2688-2691(1969)

3) Bruguerolle B, Bouvenot G, Bartolin R:Temporal and sex related variations of lorazepam kinetics. Annual Review of Chronopharmacology, Reinberg A, Smolensky M, Labrecque G(ed), Vol 1, pp 21-25, Pergamon Press, Oxford(1984)

4) Campbell A, Baldessarini RJ:Circadian changes in behavioral effects of haloperidol in rats. Psychopharmacology 77:150-155(1982)

5) Campbell A, Herschel M, Sommer B, et al:Circadian changes in distribution and effects of haloperidol in the rat. Neuropharmacology 21:663-669(1982)

6) Chamberlain J, Hill HM, Ings RMJ, et al:Diurnal variation of clobazamkinetics in man. Br J Clin Pharmacol 11:436-437(1981)

7) Currie PJ, Coscina DV:Diurnal variations in the feeding response to 8-OH-DPAT injected into the dorsal or median raphe, Neuroreport 4:1105-1107(1993)
pubmed

8) Davis WM:Day-night periodicity in pentobarbital response of mice and the in Huence of socio-psychological condition. Experientia 18:235-237 (1962)
pubmed

9) Ferrari E, Bossolo PA, Bono G, et al:Chronobiological approach to the treatment of cluster headache by lithium carbonate. Annual Review of Chronopharmacology, Reinberg A, Smolensky M, Labrecque G(ed), Vol 1, pp 407-410, Pergamon Press, Oxford(1984)

10) Frankel JP, Pirtosek Z, Kempster PA, et al:Diurnal differences in response to oral levodopa. J Neurol Neurosurg Psychiatry 53:948-950(1990)

11) Friedman AH, Walker CA:Rat brain amines, blood histamine and glucose levels in relationship to circadian changes in sleep induced by pentobarbitone sodium. J Physiol 202:133-146(1969)

12) Halbreich U, Asnis GM, Halpern F, et al:Diurnal growth hormone responses to dextroamphetamine in normal young men and post-menopausal women. Psychoneuroendocrinology 5:339-344 (1980)
pubmed

13) Halbreich U, Sachar EJ, Asnis GM, et al:Diurnal cortisol responses to dextroamphetamine in normal subjects. Psychoneuroendocrinology 6:223-229(1981)

14) Hashiguchi M, Fujimura A, Ohashi K, et al:Diurnal effect on caffeine clearance. J Clin Pharmacol 32:184-187(1992)

15) Hawkins R, Kripke DF, Janowsky DS:Circadian rhythm of lithium toxicity in mice. Psychopharmacology 56:113-114(1978)

16) Henauer S, Lombrozo L, Hollister LE:Circadian variations of lorazepam-induced neurologic deficits. Life Sci 35:2193-2197 (1984)
pubmed

17) Jori A, Di Salle E, Santini V:Daily rhythmic variation and liver drug metabolismin rats. Biochem Pharmacol 20:2965-2969(1971)

18) Kuribara H, Tadokoro S:Circadian variation in methamphetamine and apomorphine-induced increase in ambulatory activity in mice. Pharmacol Biochem Behav 17:1251-1256 (1982)
pubmed

19) Lemmer B, Holle L:Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. Chronobiol Int 8:176-185 (1991)
pubmed

20) Levy RH, Lockard JS, Patel IH, et al:Time-dependent kinetics III;Diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys. J Pharm Sci 66:1154-1156(1977)

21) Lu J-Q, Nagayama H:Circadian rhythm in the response of central 5-HT1A receptor to 8-OH-DPAT in rats. Psychopharmacology 123:42-45(1996)

22) Lu J-Q, Nagayama H:Circadian rhythm in the function of central 5-HT1A receptors is endogenous in nature. Cell Mol Life Sci 53:224-226(1997)

23) Lu J-Q, Nagayama H:Circadian rhythm in the hypothermic response to serotonin 1A receptor agonist 8-OH-DPAT in rats. Chronobiol Int 14:267-273(1997)

24) Margules DL, Lewis MJ, Dragovich JA, et al:Hypothalamic norepinephrine;Circadian rhythms and the control of feeding behavior. Science 178:640-643(1972)

25) Mason R:Circadian variation in sensitivity of suprachiasmatic and lateral geniculate neurones to 5-hydroxytryptamine in the rat. J Physiol 377:1-13(1986)

26) Monteleone P, Bortolotti F, Oreazzo C, et al:Differences between morning and afternoon hormonal responses to D-fenfluramine in healthy humans. Psychoneuroendocrinology 22:79-87 (1997)

27) Morris RW:Street drug interactions with ethyl alcohol circadian and lunarlethality rhythms. Life Sci 27:2577-2581(1980)

28) Moser PC, Redfern PH:Lack of variation over 24-hours in responses to stimulation of 5-HTI receptors in the mouse brain. Chronobiol Int 2:235-238(1985)

29) Moser PC, Redfern PH:Circadian variation in behavioural responses to central 5-HT receptor stimulation in the mouse. Psychopharmacology 86:223-227(1985)

30) Moser PC, Redfern PH:Circadian rhythms in behaviours mediated by 5-HTreceptor stimulation in the rat. Annual Review of Chronopharmacology, Reinberg A, Smolensky M, Labrecque G(ed), Vol 3, pp 13-16, Pergamon Press, Oxford (1986)

31) Mueller O:Circadian rhythmicity in response to barbiturates. Chronobiology, Scheving LE(ed), pp 187-190, Igakushoin, Tokyo(1974)

32) 永山治男:時間薬理学と治療. 朝倉書店, 東京(1985)

33) Nagayama H:Chronopharmacology of psychotropic drugs;Circadian rhythmsin drug effects and its implications to rhythms in tha brain. Pharmacol Ther 59:31-54 (1993)

34) 永山治男:疾患と時間治療学-精神疾患. 医学と薬学38:697-705(1997)

35) Nagayama H, Lu J-Q:Circadian rhythm in the responsiveness of central 5-HT2A receptors to DOI in rats. Psychopharmacology 127:113-116(1996)

36) Nagayama H, Lu J-Q:Circadian rhythm in the response to intrace rebroventricular administration of 8-OH-DPAT. Brain Res 756:92-96(1997)

37) Nagayama H, Nagano K, Ikezaki A, et al:Double-blind study of the chronopharmacotherapy of depression. Chronobiol Int 8:203-209(1991)

38) Nagayama H, Takagi A, Nakamura E, et al:Circadian susceptibility rhythm toapomorphine in the brain. Commun Psychopharmacol 2:301-310(1978)

39) Nagayama H, Takagi A, Sakurai Y, et al:Chronopharmacological study of neuroleptics. II;Circadian susceptibility rhythm to chlorpromazine. Psychopharmacology 58:49-53(1978)

40) Nagayama H, Takagi A, Sakurai Y, et al:Chronopharmacological study of neuroleptics. III;Circadian rhythm of brain susceptibility to haloperidol. Psychopharmacology 63:131-135(1979)

41) Nagayama H, Takagi A, Takahashi R:Circadian susceptibility rhythm tohaloperidol under constant conditions. Experientia 43:625-626 (1987)
pubmed

42) Nagayama H, Takagi A, Tateishi T, et al:Circadian susceptibility rhythm to neuroleptics;Tetrabenazine. Psychopharmacology 55:61-66(1977)

43) Nagayama H, Takagi A, Yoshimoto S, et al:Circadian rhythm of brain susceptibility to haloperidol during chronic administration. Pharmacol Biochem Behav 16:311-314 (1982)
pubmed

44) Nair V:Circadian rhythm in drug action;A pharmacologic, biochemical, and electronmicroscopic study. Chronobiology, Scheving LE(ed), pp 182-186, Igakushoin, Tokyo(1974)

45) Nakano S, Hara C, Ogawa N:Circadian rhythm of apomorphine-induced stereotypyin rats. Clin Pharmacol Ther 12:459-461(1980)

46) Nakano S, Hollister LE:No circadian effect on nortriptyline kinetics in man. Clin Pharmacol Ther 23:199-203(1978)

47) Nakano S, Hollister LE:Chronopharmacology of amitriptyline. Clin Pharmacol Ther 33:453-459(1983)

48) Nakano S, Watanabe H, Nagai K, et al:Circadian stage-dependent changes indiazepam kinetics. Clin Pharmacol Ther 36:271-277(1984)

49) Nathan RS, Perel J, Stiller R, et al:Chronopharmacology of haloperidol inschizophrenic patients. Annual Review of Chronopharmacology, Reinberg A, Smolensky M, Labrecque G(ed), Vol 3, pp 455-458, Pergamon Press, Oxford(1986)

50) Nathan RS, Perel JM, Hanin I, et al:Effect of benztropine on plasma haloperidol chronopharmacology and blood choline levels in man. Annual Review of Chronopharmacology, Reinberg A, Smolensky M, Labrecque G(ed), Vol 1, pp45-48, Pergamon Press, Oxford(1984)

51) Nelson W, Halberg F:An evaluation of time-dependent changes in susceptibility of mice to pentobarbital injection. Neuropharmacology 12:509-524(1973)

52) Ohdo S, Nakano S, Ogawa N:Chronopharmacokinetics of valproic acid following constantrate administration in mice. Chronobiol Int 8:35-43(1991)

53) Ohdo S, Nakano S, Ogawa N:Circadian changes of valproate kinetics depending on meal condition in humans. J Clin Pharmacol 32:822-826(1992)

54) Ohdo S, Ogawa N, Nakano S, et al:Infiuence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J pharmacol Exp Ther 278:74-81(1996)

55) Ohdo S, Watanabe H, Ogawa N, et al:Circadian rhythm of embryotoxicity induced by sodium valproate in mice. Eur J Pharmacol 293:281-285(1995)

56) Olesen OV, Thomsen K:Diurnal variations in serum lithium and renal lithium clearance in rats given lithium as a single small dose or as multiple high doses. Acta Pharmacol Toxicol Copenh 57:171-175(1985)
pubmed

57) Owasoyo JO, Walker CA, Whitworth UG:Diurnal variation in the dopamine level of rat brain areas; Effect of sodium phenobarbital. Life Sci 25:119-122(1979)

58) Pauly JE, Scheving LE:Temporal variation in the susceptibility of white rats to pentobarbital sodium and tremorine. Int J Neuropharmacol 3:651-658(1964)

59) Philipp M, Marneros A:Chronobiology and its implications for pharmacotherapy of endogenous depression. Pharmacopsychiatry 11:235-240(1978)

60) Planeta CS, DeLucia R, Aizenstein ML, et al:Daily variation in plasma concentration of fencamfamine and striatal dopamine receptors in rats. Braz J Med Biol Res 27:737-741 (1994)
pubmed

61) Ross FH, Grag NL, Sermons AL, et al:Chronotoxicity of antidepressant and psychomotor stimulants in mice. XIII International Conference Proceedings, Halberg F, Scheving LE, Powell EW, et al(ed), pp 125-130, Il Ponte, Milano(1981)

62) Ross FH, Sermons AL, Owasoyo JO, et al:Circadian variation of diazepam acute toxicity in mice. Experientia 37:72-73(1981)

63) Rutkowska A, Piekoszewski W, Brandys J:Circadian changes in the elimination of amitriptyline in rats. Pol J Pharmacol Pharm 44:671-677(1992)

64) Scheving LE, Vedral DF, Pauly JE:A circadian susceptibility rhythm in rats to pentobarbital sodium. Anat Rec 160:741-749(1968)

65) Scheving LE, Vedral DF, Pauly JE:Daily circadian rhythm in rats to damphetamine sulphate;Effect of blinding and continuous illumination on therhythm. Nature 219:621-622(1968)

66) Sermon AL, Ross FH, Walker CA:Twenty-four toxicity rhythms of sedative hypnotic drugs in mice. Arch Toxicol 45:9-14(1980)

67) Shappell SA, Kearns GL, Valentine JL, et al:Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man. J Clin Pharmacol 36:1051-1063(1996)

68) Shito T, Ando T, Okamoto T, et al:Chronopharmacokinetics and chronotoxicity of lithium in mice eating normal and low-sodium diets. Chronobiol Int 9:114-123 (1992)
pubmed

69) Singleton C, Marsden CA:Circadian variation in the head twitch response produced by 5-methoxy-n1, n1-demethyltryptamine and p-chloramphetamine in the mouse. Psychopharmacology 74:173-176(1981)

70) Smith DF:Diurnal variations of lithium clearance in the rat. Int Pharmacopsychiatry 8:99-103 (1973)
pubmed

71) Smith RB, Kroboth PD, Phillips JP:Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. J Clin Pharmacol 26:120-124(1986)

72) Sothern RB, Halberg F, Nelson W:Strain-difference in circadian murine chronotolerance to the antidepressant drug nomifensine. Chronobiologia 6:397404 (1979)

73) Urba-Holmgren R, Holmgren B, Aguiar M:Circadian variation in an amphetamine induced motor response. Pharmacol Biochem Behav 7:571-572(1977)

74) Usher RW, Beasley CMJ, Bosomworth JC:Efficacy and safety of morning versus evening fluoxetine administration. J Clin Psychiatry 52:134-136(1991)

75) Vesell ES:Genetic and environmental factors affecting hexobarbital metabolism in mice. Ann NY Acad Sci 151:900-912(1968)

76) Walker CA:Implications of biological rhythms in brain amine concentrations and drug toxicity. Chronobiology, Scheving LE (ed), pp 205-208, Igakushoin, Tokyo(1974)

77) Walker CA, Owasoyo JO:The influence of serotonin, GABA and D, L-DOPA onthe circadian rhythm in the toxicity of picrotoxin, pentylenetetrazol and phenobarbital in mice. Int J Chronobiol 2:125-130(1974)

78) Weiss GF, Rogacki N, Gueg A, et al:Effect of hypothalamic and peripheral fluoxetine injection on natural patterns of macronutrient intake in the rat. Psychopharmacology 105:467-476(1991)

79) Williams RL, Soliman KFA, Mizinga KM:Circadian variation in tolerance tothe hypothermic action of CNS drugs. Pharmacol Biochem Behav 46:283-288(1993)

80) Wolfe GW, Bousquet WF, Schnell RC:Circadian variations in response toamphetamine and chlorpromazine in the rat. Commun Psychopharmacol 1:29-37 (1977)
pubmed

はじめての方へ

個人／法人会員登録のご案内